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Abstract
The work presented in this thesis describes the development of a method to investigate 
az-mediated responses in the tail and first order mesenteric resistance arteries of the 
mouse. Furthermore, responses mediated by ai-adrenoceptors have been studied and, 
in part, subtyped in these vessels. These aims were achieved by using a combination of 
subtype selective ligands and transgenic technology.
rtz-adrenoceptors, expressed in the tail artery, mediate contractile responses that at 37^C 
are susceptible to profound, persistent desensitisation. In the absence of a fully 
functional olind receptor pool, contractions are affected by the way in which an agonist 
is administered. At 22^C, the a 2 -mediated response is significantly potentiated, a 
response that does not rely on the a 2 A/o subtype, but is critically dependent on previous 
exposure to an ai-selective agonist.
In mesenteric resistance arteries, a 2 -adrenoceptors, proposed to exist on the 
endothelium, mediate vasodilatations. Responses depend on more than one a 2 -subtype, 
and are mediated by nitric oxide, and possibly EDUF.
In the tail artery, aiA-adi*enoceptors mediate contraction with little, if any, contribution 
from the aiB-subtype, and increasing age has little effect on the responses gained. Like 
the tail artery, the aiA-receptor subtype is the major receptor mediating contraction of 
mesenteric arteries. However, in the absence of the aiB-adrenoceptor, a small, but 
significant contraction, mediated by the am-adrenoceptor is uncovered.
The use of subtype selective ligands and transgenic mice, has clarified the function of 
« 2  and ai-adrenoceptors in two mouse blood vessels, and allowed partial subtyping of 
the response. Alone, neither technique would have provided such clarity.
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Summary
Chapter three
1. A m ethod (sh ow n  to b e  e ffec tiv e  in the rat tail artery) has b een  applied and  
adapted for su ccessfu l study o f  U K 1 4 304-m ed ia ted  contractions in the m ou se  
tail artery, w here a contractile function  has been  estab lished , and in part, 
subtyped to a2A/D-adrenoceptors.
2. The effects of elevated vascular tone and nitric oxide synthase inhibition have 
been studied in detail, to determine suitable conditions for further 
phai'macological analysis of responses mediated by a 2 -adrenoceptors in the 
mouse tail artery.
3. Low levels of tone and/or inhibition of nitric oxide release enhance sensitivity
and increase the size of the response gained. In terms of size and sensitivity the
most advantageous conditions are high elevation of vascular tone with U46619 
to levels comparable to 50 % of the noradrenaline response.
4. All o f  the protocols tested  w ere carried out in the WT and D79N, for partial 
subtyping o f  the response. T he s izes  o f  responses gained  w ere sign ifican tly  
sm aller in the D79N. T his ind icates that at 37^C, and under th ese  cond itions, the 
0C2A/D-adrenoceptor is  in v o lv ed  in  contraction o f  the m urine tail artery.
Chapter four
1. UK-mediated contractions are susceptible to profound, persistent desensitisation 
and the study of responses in the tail artery is complicated by the development 
of rhythmic contractions. In the absence of a fully functional population of 
ct2 A/D-adrenoceptors the UK response is dependent on the method in which the 
agonist is administered, evidenced by enhanced responses in the D79N when 
UK14304 is administered non-cumulatively.
14
2. Rhythmic contractions develop in the mouse tail artery to a variety of exogenous 
agonists, an effect which is abolished by low concentrations (without causing a 
significant reduction in maximum) of nifedipine, an L type calcium channel 
antagonist
3. Desensitisation of the UK response is receptor specific and is alleviated by 
reducing the time that receptors are exposed to agonist or construction of non- 
cumulative response curves.
4. The desensitisation caused by UK is reversed by rauwolscine, representing a 
unique response that may reflect a “switching on” of a response, or the 
inhibition of receptor internalisation, therefore permitting a further response.
5. The non-cumulative UK response in the WT and D79N is competitively 
antagonised by rauwolscine, but unaffected by prazosin. This indicates that the 
UK-mediated contractions, results from selective stimulation of vascular 0 C2 - 
adrenoceptors (even at the highest agonist concentrations tested).
Chapter five
1. T he contractile response to UK in the m ou se tail artery has been  assessed  at tw o  
tem peratures, 22°C and 37°C; responses are o f  com parable s ize  and sen sitiv ity  in  
the WT and D79N at both tem peratures. H ow ever, previous exp osu re to  
phenylephrine leads to  a potentiation  in contractility  at 22°C. Partial subtyping  
o f  the resp on se (w ith  the D79N) ind icates that the a 2A/D-adrenoceptor is not 
in v o lv ed  in the enhanced  response.
2. The phenylephrine response is unaffected by a reduction in temperature, but 
significantly potentiated in the D79N at 22°C. This represents a unique 
phenotype, which may be due to upregulation of ai-mediated contractions in the 
absence of a functional Œ2 A/D response.
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3. Contractions to the agonists, phenylephrine, noradrenaline and 5HT were 
studied in WT and D79N mice. Phenylephrine (i.e. oci) and 5HT-mediated 
contractions are comparable in both strains, indicating no change in function of 
these receptors at 37^C. The noradrenaline response at 37*^ C is significantly 
smaller in the D79N tail artery than the WT. This suggests that at 37°C the 
azA/D-adrenoceptor is involved in mediating contractions to this non-selective 
agonist.
Chapter six
1. UK causes concentration-related vasodilatations in first order mesenteric 
resistance arteries from WT and D79N mice, which appear to involve two %- 
receptor subtypes, and depend on the release of nitric oxide, and possibly EDHF.
2. Rauwolscine antagonises the UK-mediated response in the WT, but at high 
agonist concentrations the effect is overcome. This data provides evidence that 
the vasodilator response is receptor specific and is most probably mediated by 
Œz-adrenoceptors located on the endothelium.
3. The UK-response is inhibited by L-NAME (1 x 10"^M), but the effects are 
suimountable, indicating the involvement of another endothelial derived 
relaxing factor. Elevated levels of K’*’ (15 and 30mM) cause concentration 
dependent reductions in UK-mediated relaxations, indicating the involvement of 
EDHF in the relaxant response (inconclusive without the use of prostaglandin 
inhibitors and nitric oxide scavengers).
Chapter seven
1. T he e ffects  o f  prazosin  (at 4  and 16-m onths) and subtype se lec tiv e  antagonists 
w ere studied in the m o u se  tail artery. T he A-adrenoceptor appears to be the
16
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major subtype leading to contraction, while the ais-adrenoceptor plays little, if 
any, role in the development of contractile responses, in young and old mice.
2. Nifedipine prevents the development of rhythmic contractions in the mouse tail
artery, and causes a significant reduction in the phenylephrine response in the 
WT and am KO at both age points. The reduction in maximum is more 
pronounced at four-months in the KO, an unexplained phenotype, which may 
indicate a greater dependency on extracellular calcium in the absence of 
functional am-adrenoceptors.
3. Prazosin competitively antagonises phenylephrine-induced contractions in the 
WT and am  KO tail artery and, at both age points, causes a significant reduction 
in maximal responses at high antagonist concentrations.
4. At both age points, the pAz value for prazosin is slightly lower in the am  KO 
than the WT, and at 16-months the slope of the Schild regression plots shifts 
from unity, which is indicative of non-competitive antagonism.
5. Alone, prazosin provides little information on the subtype (s) involved in the 
contractile response in the mouse tail artery, but combined with the use of 
subtype selective antagonists provides clarity on the role of each receptor in 
contraction.
Chapter eight
1. It has been established that like the tail artery, the aiA-adrenoceptor is the 
principal contractile receptor in first order mesenteric resistance aiteries. 
However, in the absence of functional am -adrenoceptors, a unique, contractile 
function, mediated by the am-subtype has been uncovered.
2. Responses have been studied at 4 and 16-months, and are clarified in arteries 
from older animals. In the am  KO a 5MeU resistant component of contractions
':5:
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is obvious, and is notably absent in the otm KO. BMY7378 abolishes the 5MeU 
resistant component of the contractile response, leaving a response that is 
comparable to that of the a w  KO.
3. This data provides evidence that, at least in the am  KO, the aio-adrenoceptor 
plays a small, but significant, role in contraction of first order mesenteric arteries 
of the mouse.
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Chapter one
Introduction and literature review
19
General Introduction
Adrenoceptors were first described over fifty years ago. The function of each 
adrenoceptor has been studied extensively, and the role they play in regulating a diverse 
array of physiological functions has been highlighted. With the advent of transgenic 
technology in the last five years, physiological/pharmacological research has been
normal ‘wild type’ control (C57/BL6c/129Sv), am  knockout, am  knockout, and the 
D79N (azA/D mutant).
is still desirable, and can have advantages over the use of knockout mice. The main
provided with a new tool that enables the study of individual receptor subtypes. I have 
used a combination of classical pharmacology combined with the use of transgenic mice 
to study the function of adrenoceptors in two murine blood vessels, the tail and first 
order mesenteric resistance arteries. The murine strains that I have used include a
Many of the recent advances in the treatment of cardiovascular disease have come from 
intensive research on animal models of human disease. Over the last few years there 
has been an explosion in the study of murine models of human disorders for a number 
of reasons. The availability and cost of mice makes them extremely desirable to work 
with. More importantly, advances in molecular biological techniques have provided us 
with mice harbouring mutated, upregulated, constitutively active or deleted receptors.
Transgenic mice are currently being used in the field of cardiovascular biology in an 
attempt to delineate the role of individual receptor subtypes and to determine what role, 
if any, adrenoceptors play in the development and progression of cardiovascular
disease. The availability of these transgenic mice in part obviates the need for subtype 
selective antagonists, the lack of which has hampered the clarification of receptor- 
mediated responses for many years. However, the use of subtype selective antagonists
I
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reason for this is that antagonists exclude the possibility that compensatory mechanisms 
lead to a change in phenotype, which cannot always be excluded when using 
transgenics.
On the basis of size the murine tail artery and first order mesenteric branch can be 
defined as resistance arteries; that is they have a diameter of less than 400pm.
However, this definition arose from studies carried out on human resistance vessels, and 
there are a far greater number of vessels that therefore fall into this category in the 
mouse than in human species. Due to this, murine arteries having a diameter less than 
400pm, are described as distributing vessels, as their role in the maintenance of 
peripheral blood pressure is as yet unclear.
The first objective of this work was to develop a protocol, suitable for the study of 
responses mediated by postjunctional az-adrenoceptors in the mouse tail artery. 
Following successful completion of this objective, I then used the D79N (azA/o mutant) 
mouse to classify the responses gained. Having established the response in the murine 
tail artery, I then applied the same principal to the study of az-mediated responses in 
first order mesenteric resistance arteries. Again, I had the intention of determining what 
role the azA/o-adrenoceptor contributes to responses by use of the D79N mouse.
In relation to responses mediated by vascular a%-adrenoceptors, this work has two aims. 
Firstly to determine the contribution of the a ie -adrenoceptor to contractile responses in 
the mouse tail artery. Given the magnitude of this task, I studied the effect of prazosin 
on phenylephrine-induced contractions while colleagues in our laboratory determined 
the effect of subtype-selective ligands. In addition to responses in the tail artery I also
21
set out to study the responses mediated by ai-adrenoceptor subtypes, known not to be 
the major receptor leading to contractions of mesenteric resistance arteries. To achieve 
this aim, I took advantage of the availability of two strains of mice cairying deletions of 
the aiB and aiD-receptor subtypes, combined with the use of subtype selective 
antagonists.
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already elucidated in the rat.
choice has been successfully altered, embryonic 129Sv stem cells are injected into 
blastocysts from C57BL/6 mice [Picciotto & Wickman, 1998]. During production of 
the F2 generation, the genetic material of both species is mixed, segregated, and 
randomly selected. To counteract this, mice from the F2 generation are then
1.0 Transgenic Mice: A new pharmacological tool
1.0.1 Genetically altered mice
Transgenics can be defined as those animals caiTying a segment of exogenous genetic 
information. To date, transgenic mice have provided us with considerable insight into 
the functions of a variety of receptors, including, adrenoceptors. One of the main 
advantages of using gene-tai'geted animals, is that it simplifies the interpretation of 
results, and makes the assignment of functions to a given receptor subtype(s) under 
complex physiological conditions far easier. In addition to this, gene targeting also 
overcomes the problems associated with the use of non-selective ligands.
Until the development of transgenic technology, the rat was the major rodent species 
used to delineate the role of adrenoceptor subtype (s) in vascular biology, in a variety of
tissue types. Unfortunately, manipulation of genes is far easier in the mouse than the
'rat, so the focus of many research laboratories has now shifted. The disadvantage of 
changing the species, in which responses are studied, is that many experiments have to 
be repeated to determine if functional responses are similar in the mouse to those
Tai'geted gene disruption was first developed in the mid to late 1980s [Thompson et al, 
1989]. The most common method for generating gene-targeted mice is to use 129Sv 
cell lines to knockout, overexpress, or mutate a gene of interest. Once the gene of
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backcrossed seven times. In doing so, the progeny have a genetic makeup which is 99 
% identical. This reduces the level of heterogeneity within the transgenic mouse 
colony. Backcrosses into the 129Sv murine strain are possible, but are rarely canied 
out because of the unreliable reproductive cycle of this mouse. Controlling the 
heterogeneity of transgenics is imperative, especially when interpreting experimental 
results. It has also been suggested that inbreeding to maintain the genetics within a 
strain should be avoided [Banbury Conference, 1997].
1.0.2 Overexpressing a gene of interest
Genes can be overexpressed in many different animal species, including the rat. 
However, in the majority of studies mice ai’e favoured, because of the wealth of 
experience that now exists in manipulation the murine genome. Once a gene of interest 
has been identified, it is cloned, and inserted into the genome of a target animal, or, if 
prefeiTed a cell line. When the inserted DNA segment has been stably transfected and 
incorporated into the recipient genome, animals can be genotyped and bred. The 
progeny of successful transfections are frequently used to determine the role of the 
overexpressed receptor/gene product and/or to determine the signalling pathways
cXzA/D-adrenoceptor is removed from the murine germline by insertion of a premature 
stop codon. When Western blot analysis confirms that the gene has been successfully
utilised when a receptor becomes active.
1.0.3 Deleting a germline receptor
Several murine models carrying gene directed knockouts of adrenoceptor subtypes have
1recently become available. One example of this is the (XzA/o knockout mouse. The
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removed, embryonic stem cell clones carrying the deletion are transferred into 
pseudopregnant females and mice are bred as described previously.
1.0.4 A cautionarv note
Compensatory changes resulting from the up, or down regulation of other structurally 
related receptor subtypes or activation of alternative signalling pathways cannot always 
be excluded as the reasons for an altered response or unusual phenotype. Studies using 
transgenic mice most at risk of phenotypic changes appear to be behavioural studies, as 
contradictory results can occur, even within the same breeding batch [Crabbe et al, 
1999]. To prevent inconsistencies, reproducibility of results is key. Data from different 
groups should be monitored very closely, so that real changes can be inteipreted as 
receptor specific, and not be attributed to compensatory mechanisms that result from the 
lack of a functional receptor.
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1.1.0 tti-adrenoceptor pharmacology
1.1.1 Discovery
Almost one hundred years ago, it became apparent that hormones and endogenous 
neurotransmitters caused more than one physiological response. Proposed to be the 
result of stimulating more than one receptor belonging to the same subclass. For 
example, adrenaline, isolated from the adrenal glands given in vivo caused 
vasoconstriction, followed by vasodilatation [Rang et al, 1995 (Churchill Livingstone)]. 
Some time later, Ahlquist first proposed the subdivision of adrenoceptors based on the
rank order of potency for noradrenaline, adrenaline and the synthetic beta agonist, 
isoprenaline [Ahlquist, 1948]. Subdivisions of the |3-adrenoceptor subclass were
■f
suggested some time later when differential responses resulting from the stimulation of 
p-adrenoceptors were described. Stimulation of P-adrenoceptors expressed in the heart 
causes positive inotropic effects, while activation of p-adrenoceptors expressed in the 
vasculature causes vasodilatation. These responses were attributed to the activation of 
different p-adrenoceptor subtypes. I?
McGrath and co workers first described heterogeneity within the (%i-adrenoceptor 
subclass in 1982. Their findings were based on the discovery that phenylethanolamine 
agonists produce a biphasic response curve. They discovered that a portion of the 
contractile response in the rat anococcygeus was resistant to antagonism with prazosin.
The prazosin resistant component of contraction persisted even when prazosin was 
combined with an ai-antagonist [McGrath et al, 1982]. In vitro experiments on the 
rabbit basilar artery and the rat anococcygeus then led McGrath and co workers to 
conclude that more than one ai-subtype existed, and that ai-adrenoceptors should be 
sub-divided into aia and otiy.
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Non-phenylethanolamine agonists are unresponsive in the rabbit basilar aitery, but 
produce a monophasic curve in the rat anococcygeus. Low concentrations of 
phenylephrine appear to stimulate aia-adrenoceptors, while aib-adrenoceptors mediate 
contractions at higher drug concentrations. At that time, a lack of suitable antagonists 
to distinguish between low and high affinity binding sites prevented further analysis.
Flavahan and Vanhoutte used an alternative method to classify ai-adrenoceptors, and 
described responses mediated by ai-adrenoceptors according to their potency for 
prazosin and yohimbine. They proposed that there were two ai-subtypes, each having 
different affinities for prazosin. Stimulation of the high affinity site, named the am, 
yields a pA% value greater than 9.0 for prazosin, and a pAg greater than 6.4 for 
yohimbine. Low affinity receptors, termed am-adrenoceptors, have reduced affinity for 
both prazosin and yohimbine [Flavahan & Vanhoutte, 1986].
Radioligand binding studies are a useful pharmacological tool, because they provide 
information on the number, molecular character and physiological function of receptors 
[Wood et al, 1979]. Due to the vast amount of information generated by these 
experiments, this technique has been used extensively to enhance our understanding of 
adrenoceptor functions and to define subtype selective responses.
Saturation binding experiments revealed two distinct binding sites based on the affinity 
of phentolamine and prazosin. Phentolamine and prazosin have different affinities for 
each binding site. Conclusive evidence that more than one a% receptor exists, came 
from studies using the subtype selective antagonist WB4101 [^H] in binding studies on
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the rat brain, ai-adrenoceptor-mediated responses were then described on the basis of 
the potency of WB4101 to antagonise responses. Receptors were described as WB4101 
sensitive aiA, and prazosin sensitive aiB-adrenoceptors [Morrow and Creese, 1986]. 
However, pharmacological subclassification was not widely accepted until 1994 when 
studies using selective a i and (Xg ligands were completed [Bylund et al, 1994].
CEC is an alkylating analogue of clonidine that has been used to distinguish between 
different ai-adrenoceptor subtypes. CEC reduces the number of available a i binding 
sites by alkylating plasma membrane bound a-adrenoceptors. Given this, a i- 
adrenoceptors were then subdivided, on their susceptibility to antagonism with CEC, 
because studies suggested that this drug could distinguish responses mediated by the 
aiB-adrenoceptor from those resulting from stimulation of the cciA-teceptor-subtype 
[Elhawary et al, 1992, Guarino et al, 1996].
To date, all of the -adrenoceptors cloned, have high affinity for prazosin and fit with 
the classification proposed by Flavahan and Vanhoutte, of the high affinity am  
[Flavahan & Vanhoutte, 1986]. However, to date no receptor subtype has been cloned 
that fits the description of the low affinity-binding site, the am  receptor [Docherty,
1998]. Ford and colleagues explained these findings by proposing that the am- 
adrenoceptor may represent an energetically favourable conformation of the am- 
adrenoceptor [Ford et al, 1998]. In recent years evidence in support of this hypothesis 
has grown.
'
Current classifications have led to the identification of nine adrenoceptor subtypes. The 
a-subclass these include the am , am, am , 0 C2 a/d, oLib , gli/c, in addition to the uncloned.
;
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illusive aiL. P-adrenoceptors have been subdivided into Pi, p% and Ps and a forth 
subtype, the P4 -adrenoceptor has been proposed to exist [Guimai'aes & Moura, 2001].
1.1.2 Expression of ai-adrenoceptors
The three ai-adrenoceptor subtypes expressed in humans, are encoded by separate 
genes on chromosomes 8 , 5 and 20, which correspond to the am , am and am  subtypes 
respectively [Hieble et al, 1995]. In humans and in animal species, alpha adrenoceptors 
control a plethora of physiological functions; including vasoconstriction, regulation of 
vascular growth, blood pressure regulation, heart rate, cognitive functions, metabolism, 
water and metabolite balance [Kunos & Ishac, 1987] and lipolysis. The physiological
.
importance of ai-adrenoceptors becomes clear in potentially life threatening situations, 
such as shock and haemorrhage. In these situations, stimulation of ai-adrenoceptor- 
mediated contractions can function to save life, when the sympathetic nervous system 
regulates blood vessel contraction to maintain blood flow, and can maintain pressure 
even when a twenty percent loss of a patient’s blood volume has occuned [Little &
Kirkman, 1997].
The existence of multiple receptor subtypes in arteries, veins and tissues, makes the 
study of subtype specific responses complex. In addition to the complexity of the 
situation where more than one ai-adrenoceptor is expressed in a given tissue or blood 
vessel, the major adrenoceptor subtype responsible for vascular contractions varies 
depending on the species studied and the vessel type [Docherty et al, 1998]. Having said 
this, there are a few tissues that contain a pure population of ai-adrenoceptors. Two
;
examples of this are the rat liver and spleen. Radioligand binding studies show that 
both of these tissues contain a pure population of am-adrenoceptors [Hieble et al,
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1995]. In the liver ai-adrenoceptors control a range of essential physiological functions 
including gluconeogenesis, fatty acid metabolism and protein release [Garcia-Sainz et 
al, 1999]. Human livers express predominantly am-adrenoceptors [Price et al, 1994]; 
while the major subtype expressed in animal models varies between species.
The major ai-adienoceptor subtype mediating catecholamine-induced responses in 
human arteries, depends on the vascular bed studied and on the age of a patient [Rudner 
et al, 1999]. Contractions in human resistance arteries result from dual activation of a% 
and ai-adrenoceptors [Parkinson et al, 1992]. When the ai-adrenoceptor is the 
dominant contractile receptor, analysis has been carried out to determine which ai 
subtype predominates (in essence, the response has been subtyped). Measuring 
mRNA/protein levels have shown that the aia-adrenoceptor is the most widely 
expressed ai-receptor subtype. The aia subtype is found in vascular, pulmonary, renal, 
splanchnic and coronary aiteries. In the venous circulation all three ai-adrenoceptor 
subtypes are expressed to comparable levels [Rudner et al, 1999].
I
Agonist-induced changes in a^-adrenoceptor expression levels 
Human embryonic kidney (HEK 293) cells have been used to study agonist-mediated 
changes in the expression of ai-adrenoceptors. Noradrenaline-induced changes in 
receptor expression have been studied in this cell line. Prolonged exposure to 
noradrenaline has no effect on the expression of the am  subtype, but increases 
expression of the am, while causing downregulation of am-adrenoceptors. The effect 
of noradrenaline on the expression of all three a r  adrenoceptor subtypes is time- 
dependent. Inhibiting protein kinase C with calphostin C prevents am  downregulation,
■H':
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but is ineffective in halting increased expression of am-adrenoceptors. The Ca^^- 
ATPase inhibitor thapsigargin, blocks enhanced am  expression [Lei et al, 2002]. To 
conclude, in HEK 293 cells prolonged exposure to noradrenaline has differential effects 
on the expression of ai-adrenoceptors. Noradrenaline-induced changes in the 
expression of am  and am-adrenoceptor appear to result from utilisation of different 
signalling cascades [Lei et al, 2002].
1.1.3 Subtvpe specific responses 
ai_A Adrenoceptors
The ai A-adrenoceptor was originally termed the a ic  subtype, but was later renamed.
The initial confusion in nomenclature aiose from studies where the cloned am  receptor 
failed to localise its mRN A in tissues already subtyped as am  [Piascik & Perez, 2001]. 
Subtype selective agonists that bind aiA-adrenoceptors with high affinity are 
oxymetazoline and methoxamine. Antagonists that selectively bind to the am - 
adrenoceptor are 5-methylurapadil, WB4101 and niguldipine. The am-adrenoceptor is 
distinguished from the am  by having a lower affinity for all of these compounds. 
[Piascik et al, 1997]
am  knockout mice aie slightly hypotensive, having a ten percent reduction in resting 
blood pressure; in addition agonists selective for the am  receptor do not cause pressor 
responses in the am  knockout mouse. However, phenylephrine still causes an elevation 
in blood pressure, which is slightly attenuated compared with controls [Rokosh & 
Simpson, 2001]. This confirms the hypothesis that the am-adrenoceptor mediates
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pressor responses in the mouse, and that other (Xi-receptor subtypes are involved in the 
control of blood pressure regulation.
The gene promoter for the rat a i a-adrenergic receptor has recently been cloned and 
characterised, and found to contain multiple transcription initiation sites. Gel shift 
analysis confirms that hypoxic conditions can cause a shift in the promoter sequence 
and directly activate transcription [Michelotti et al, 2003], illustrating that 
pathophysiological conditions can affect expression of the am-adrenoceptor at the 
transcriptional level.
Responses mediated bv ai a and/or an^^-adrenoceptors
Stimulation of am-adrenoceptors causes contraction of smooth muscle cells in the 
lower urinary tract [Marshall et al, 1995]. Contrary to this, other studies suggest that 
the aiL-adrenoceptor is the major contractile subtype in the urinary tract [Ford et al, 
1996a]. The existence of the am-adrenoceptor relies upon pharmacological analysis, 
and it has been suggested that the am  represents a low affinity state of the am- 
adrenoceptor. If this were the case, it would account for the variability in experimental 
data, and will help explain why attempts to isolate the am  receptor using molecular 
techniques have been unsuccessful. The identification of a number of cDNA splice 
valiants of the am-adrenoceptor supports the hypothesis that the am-adrenoceptor 
represents an energetically favourable conformation of the am-subtype. These variants 
have been termed the am-i, am - 2  and am-s- Each splice variant has a different amino 
acid sequence and a variable carboxy terminal chain length [Chang et al, 1998]. The 
function of each splice variant is currently under investigation.
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The rank order of potency of three ai-agonists has been deteimined in canine 
subcutaneous resistance arteries, and found to be A61603> noradrenaline> 
phenylephrine. This is consistent with the predominance of the am  subtype-mediating 
contraction of cutaneous arteries in the dog [Argyle & McGrath, 2000]. However, the 
potency of the antagonist’s prazosin and HV723 are low, indicating the presence of the 
a i L-adrenoceptor.
,-i
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Noradrenaline-induced contractions of cutaneous canine vessels are insensitive to 
antagonism with low concentrations of CEC, while high concentrations, reduce the 
contractile maximum without affecting sensitivity. Taken together the affinity and 
potency order of ligands in canine cutaneous arteries suggest that the am/otiL- 
adrenoceptors mediate contractile responses [Argyle & McGrath, 2000].
aiR Adrenoceptors
The role of the am-adrenoceptor in the control of arterial blood pressure and blood flow 
has been poorly defined. This is partly due to a lack of suitable subtype selective 
ligands. A limitation, which has now been overcome by the creation of transgenic mice 
harbouring mutated, overexpressed and deleted am-adrenoceptors.
!
In vitro studies on rabbit resistance arteries suggest that the am-adrenoceptor may be 
involved in the development of vascular contractions. Cutaneous resistance arteries 
contract in response to phenylephrine, noradrenaline and the am-selective agonist, 
A61603. The higher binding affinity of A61603 indicates that the am-adrenoceptor is 
the dominant subtype mediating contraction in this artery, while the involvement of the
I
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aiB -adrenoceptor is secondary. H o w ev er  antagonist affin ities refute the data gained  
w ith  the three agon ists [Sm ith  et al, 1997].
Incubating cutaneous rabbit arteries with CEC prior to constructing a noradrenaline 
response curve leads of a significant reduction in the maximum response, without 
affecting tissue sensitivity. Prazosin and WB4101 are both potent antagonists of 
receptor-mediated contractions in rabbit cutaneous arteries [Smith et al, 1997]; The pA2  
values determined suggest a prazosin-sensitive receptor-binding site. However Schild 
regression analysis for both of these antagonists have slopes that are different from 
unity, indicative of two site binding. Detailed analysis of the agonist affinities and '
antagonist potency suggests that the am-adrenoceptor mediates contractile responses in 
addition to the am, which plays a secondary contractile role in contraction of rabbit 
cutaneous resistance arteries [Smith et al, 1997].
Mice carrying a homozygous deletion of the am-adrenoceptor have normal baseline 
blood pressure, and contractile responses to non-selective ai-agonists are only slightly 
attenuated [Cavalli et al, 1997]. This led to the conclusion that the contribution the am- 
adrenoceptor makes to the control of peripheral blood pressure can be considered as 
minor. This hypothesis is supported by other literature [Chen et al, 1995, Hrometz et al,
1999].
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Contrary to this, mice lacking functional am-adrenoceptors have been found to be 
hypotensive at rest [Cavalli et al, 1997]. So one would expect that mice overexpressing 
the am-adrenoceptor would be hypertensive at rest. However this is not the case, in fact
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they have a slight, but significant reduction in systemic blood pressure [Zuscik et al, 
2001].
In an attempt to clarify what, if any, cardiovascular functions are controlled by the am- 
adrenoceptor, Zuscik and co-workers produced a mouse overexpressing the am- 
adrenoceptor. The am receptor was overexpressed with its isogenic promoter, so that 
overactivity of the am-adrenoceptor only occurs in tissues that normally express this 
receptor subtype. Two am  mutations were employed; they were single and triple 
mutants of the hamster am  - adrenoceptor. Both of these mutations cause am- 
adrenoceptors to couple constitutively to the Gq/phospholipase C pathway, which leads 
to protein kinase C and IP3 release [Zuscik et al, 2001]. By definition, these receptors 
can be referred to as constitutively active. I
7
T ransgenics w ith  altered a m receptors: e ffec ts  on caid iovasculai' function  
O verexpressing  a%-adrenoceptors cau ses hypertrophy o f  cultured cardiac m yocytes, an 
e ffec t that has been  attributed to the a iA -adrenoceptor [K now lton  et al, 1991]. In vivo, 
overexp ression  o f  the am -adrenoceptor cau ses cardiac hypertrophy; confirm ed  by  
echocardiographic analysis and an increased  heart to b od y  w eigh t ratio [Z uscik  et al,
2001], while other vital organs are unaffected. Basal heart rate is decreased in mice 
overexpressing the am-adrenoceptor, which may result from altered electrical 
conductance in purkinje fibers of the murine heart. This seems likely, because am- 
adrenoceptors regulate contractility of purkinje fibers [Balzo et al, 1990].
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Phenylephrine causes concentration-related contractions of myograph mounted murine 
blood vessels. Overexpressing the am-adrenoceptor has no effect on the phenylephrine 
response when compared with control blood vessels. This poses the question of how 
then, does overexpression of the am-adrenoceptor lead to hypotension? It may be that ' A
"■'1overexpressing the am-adrenoceptor causes a decrease in sympathetic nerve activity.
■ ' Î
This hypothesis is supported by experiments that show a fifty percent reduction in 
circulating catecholamines in mice overexpressing the am-adrenoceptor. Therefore, 
hypotension that occurs in mice overexpressing the am  receptor subtype probably 
results from autonomic dysfunction, caused by the neurodegeneration that occurs when 
expression of the am-adrenoceptor is altered [Zuscik et al, 2001]. This data indicates 
that the reduction in resting blood pressure that occurs when the am-adrenoceptor is 
overexpressed is not attributable to direct effects on peripheral blood vessels. Again, 
this suggests that the am-adrenoceptor is not a major contributor to blood pressure 
regulation in the mouse.
1
Cardiac myocytes overexpressing am-adrenoceptors have been studied in order to 
elucidate the second messenger cascades activated by this adrenoceptor subtype. i
Stimulation of am-receptors, expressed in cai'diac myocytes, leads to the activation of 
SRE/c-fos luciferase genes and MAPK signalling cascades [McWhinney et al, 2000]. It 
appears that the activation of both am and am-adrenoceptors in these cells may be 
required for the development of cardiac hypertiophy, as each subtype appears to lead to 
a different physiological response by activating alternative signalling pathways 
[McWhinney et al, 2000].
__
is specific for the am-adrenoceptor.
Mice overexpressing am-adrenoceptors develop myocardial hypertrophy, evidenced by 
an increase in the size of the ventricular septum and thickening of the ventricular wall. 
In addition, other more generalised abnormalities appear, such as a reduction in heart 
rate and reduced cardiac output. In vivo, intravenous administration of phenylephrine 
causes a reduction in pressor responses; and at rest, mice overexpressing the am- 
adrenoceptor are hypotensive [Zuscik et al, 2001]. In vivo, experiments in pithed mice 
confirm that phenylephrine-induced pressor effects result from activation of either the 
am or am-adrenoceptor [McCaffeity et al, 1999].
Plasma levels of the catecholamines, adrenaline and noradrenaline are reduced in mice
overexpressing the am-adrenoceptor. In addition to causing an alteration in 
catecholamine levels, cortisol levels are also significantly lower, indicative of a 
generalised reduction in sympathetic outflow [Zuscik et al, 2001].
Saturation curves constructed from radioligand binding experiments show that 
tamsulosin labels significantly fewer am-adrenoceptors than does prazosin in rat- 1  
fibroblasts and homogenised rat liver. However, noradrenaline displacement curves are 
similar for tamsulosin and prazosin, which indicates that the reduced receptor labelling
Tamsulosin is used clinically because it does not have dramatic effects on blood 
pressure, unlike most other ai-antagonists. It has been proposed that this may be 
explained by the lower affinity of tamsulosin for the am-adrenoceptor. However, this 
seems unlikely given that the am-adrenoceptor seems to play only a minor role in the
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functional population of am-adrenoceptors has been shown, in vitro, in the rat aorta.
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control of blood pressure regulation, and given that mice lacking functional am 
receptors are only slightly hypotensive [Cavalli et al, 1997].
Role of the a tn-adrenoceptor in normal brain functions
Overexpressing the am-adrenoceptor, in vivo, causes a progressive neurodegenerative 
condition that has been likened to Shy-Drager syndrome [Zuscik et al, 2000].
Neurodegeneration caused by overexpression and constitutive activity of the am-
'
adrenoceptor is granulovascular in nature. In early development the pathology is 
restricted to areas of the brain expressing native am-adrenoceptors. However, 
increasing age causes the neuronal damage to spread and encompass the entire murine 
brain. Physiologically, these neuronal abnormalities cause a Parkinsonian like 
dysfunction of the hindlimbs. Mice harbouring these mutated receptors also develop 
severe grand mal seizures and dysplasia of the cerebral cortex [Zuscik et al, 2000].
Mice have a dense sympathetic innervation in the cerebral circulation, but in humans 
innervation patterns are much more diffuse; reflected by a reduction in the number of 
ai-adrenoceptors found in the human brain [Bevan et al, 1998a]. Given this, it may be 
somewhat hasty to suggest that dysfunction of a%-adrenoceptors in the CNS of the 
mouse will manifest in similar disorders in humans.
t  g
am  Adrenoceptors
When the am-adrenoceptor was first cloned, it was termed the aiA, but after further 
pharmacological analysis, the nomenclature of a%-adrenoceptor subtypes was revised to 
bring them into line with functional studies [Hieble et al, 1995]. The presence of a
I.
Vasoconstrictor responses in the rat aorta are antagonised by BMY7378; a selective am  
antagonist [Saussy et al, 1994].
Although all three ai-adrenoceptor subtypes are expressed in a wide variety of vascular 
beds, one subtype usually dominates vascular contraction. In rodent animal models, the 
am-adrenoceptor has been found to mediate contractions of large, conduit arteries 
[Piascik et al, 1997]. In addition to the large calibre blood vessels, the am  subtype is 
also responsible for contracting femoral, iliac and superior mesenteric arteries in the rat 
[Hrometz et al, 1999]. am  knockout mice have normal baseline resting blood pressure, 
but phenylephrine-induced pressor responses are attenuated [Chalothorn et al, 2003].
In the absence of extracellular calcium, noradrenaline causes small transient 
contractions of the rat aorta, by stimulating am-adrenoceptors located on vascular 
smooth muscle cells. However, potassium chloride (KCl)-induced contractions are 
completely abolished in calcium free conditions. This illustrates that noradrenaline- 
mediated contractions of the rat aorta depend on intra and extracellular calcium, unlike 
KCl-mediated responses, which rely solely on extracellular calcium. Hypoxia has no 
effect on transient contractions induced by noradrenaline in calcium free conditions 
[Marriott & Marshall, 1989]. This may reflect a protective mechanism, whereby large 
conduit arteries can maintain some level of contraction when oxygen and calcium levels 
are low.
1.1.4 Cellular location of ai -adienocentors
Molecular cloning techniques have permitted the au-adrenoceptor to be removed and 
replaced with the LacZ gene. This gene encodes P galactosidase production, and
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perm its v isu a lisa tion  o f  otiA-receptor sites in situ. The presence o f  p ga lactosidase  
confirm s that the aiA -adrenoceptor is exp ressed  w id e ly  in  resistance arteries and  
arterioles and that the a i  a-adrenoceptor is  required for the m aintenance o f  arterial b lood  
pressure. Furtherm ore, that functional aiA -adrenoceptors are not exp ressed  in the  
m ou se  aorta [R okosh  &  S im p son , 2002].
Confocal microscopy combined with the use of vital cellular dyes, allows Ca^^ waves to 
be recorded, monitored, and visualised within a living cell after receptor stimulation. 
hTespective of their pre or postjunctional location, (Xi-adrenoceptors can be found on the 
surface of cells, or bound to intracellular organelles. In unstimulated, stably transfected 
rat- 1  fibroblasts, am-adrenoceptors are found in close association with the plasma 
membrane. Stimulation of these plasma membrane-bound receptors with selective 
agonists causes internalisation and association of the agonist-bound receptors with 
arrestin molecules [Chalothorn et al, 2002]. In sharp contrast to the cellular location of 
aiB-adrenoceptors, which are found primarily on the cell surface, unstimulated aio- 
adrenoceptors are bound to intracellular organelles.
Exposing rat-1 fibroblasts to prazosin, now known to be an inverse agonist, causes a 
redistribution of intracellular am-adrenoceptors. The agonist bound am-adrenoceptors 
translocate, and can then be found in close association with the plasma membrane.
These findings suggest that unstimulated am-receptors expressed in rat-1 fibroblasts 
may be constitutively active [McCune et al, 2000]. In vitro experiments support this 
hypothesis, and suggest that constitutively active am-receptors may exist in the rat tail 
artery [Gisbert et al, 2000]. Recently data has been presented that suggests native am  
receptors may be constitutively active, in vivo, in the rat aorta [Gisbert et al, 2000], a
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finding that may explain their intracellular location, as activated receptors are recycled 
in a cell.
The am-adrenoceptor is the principal ai-subtype causing contraction of the murine 
carotid artery, where BMY7378 abolishes phenylephrine-induced contractions 
[Deighan et al, 2000]. The presence of functional am-adrenoceptors has also been
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ai-adrenoceptor antagonists inhibit receptor activity because they compete with 
endogenous agonists for access to receptor-binding sites. The access of a drug to a 
receptor-binding site is critical in determining what effect agonist/antagonists can 
produce. If a receptor is sequestered within the intracellular milieu, the lipophilicity of a 
drug determines whether binding occurs, and not the ligand’s affinity for the receptor. 
These additional considerations have only been highlighted in recent years and should 
be given serious consideration when new subtype-selective compounds are being 
developed.
QAPB has been used in flow cytometry experiments to determine the cellular 
distribution of a%-adrenoceptor subtypes within a cell [Sugawara et al, 2002]. am- 
adrenoceptors are exclusively located on the cell suiface, while the a ^  subtype is more 
widely distributed, but predominantly found on intracellular organelles. When a 
receptor is localised to intracellular sites, the affinity that a drug has for this receptor 
becomes secondary and the antagonist’s lipophilicity determines whether binding 
occurs [Sugawara et al, 2002]. This may explain the inconsistencies observed when 
CEC has been used to study functional responses-mediated by the am-adrenoceptor, 
because it appears that the drug only alkylates membrane-bound receptors.
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shown in the rat iliac artery and aorta, where BMY7378 antagonises (with high affinity) 
phenylephrine-induced contractions of these arteries. Under normal physiological 
conditions, agonist-induced stimulation of am-adrenoceptors fails to contract caudal 
and renal arteries. Although expression of the am-adrenoceptor has been confirmed in 
both of these arteries, the low affinity of BMY7378 for phenylephrine-induced 
contractions in rat caudal and renal arteries suggests little, if any, contractile function 
for the am-subtype [Piascik et al, 1995]. This indicates that the major a%-subtype 
contributing to contraction of these vessels is a subtype other than the am-adrenoceptor.
__The location of ai-adrenoceptors within a cell has been studied in HEK 293 cells, and 
the majority of unstimulated am-adrenoceptors are sequestered on intracellular binding 
sites [Chalothorn et al, 2002]. Phenylephrine has no effect on the cellular distribution 
of am-adrenoceptors expressed in cultured cells, but does lead to the phosphorylation of 
ERKl and ERK2, as does aiA and am  receptor stimulation [Chalothorn et al, 2002].
A gon ist-m ed iated  internalization  o f  a i  A-adrenoceptors is s ign ifican tly  slow er than that
of the am-adrenoceptor [Chalothorn et al, 2002]. Once activated, stimulation of a%A-
adrenoceptors w ith  se lec tiv e  agonists cau ses rapid internalisation o f  agon ist bound
.receptors, which is preceded by an increase in ERKl and ERK2 activity. Internalisation 
of aiA and am-adrenoceptors depends upon the availability of arrestin and dynamin 
molecules within the cell [Chalothorn et al, 2002].
Fluorescent, lipophilic ligands negate the need for specific antibodies for G protein 
coupled receptors, and overcome the problems associated with access to receptor
binding sites. Fluorescent ligands can be used in live cell preparations as well as fixed
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blood vessels segments. This makes them useful tools for the study of receptor activity 
[MacKenzie et al, 2000]. Approximately forty percent of the a r  adrenoceptors 
expressed in cultured human smooth muscle cells, are located on intracellular binding 
sites [MacKenzie et al, 2000]. QAPB, also know as BODIPY-prazosin is a fluorescent 
form of the classical a r  antagonist, prazosin. QAPB has high affinity for a r  
adrenoceptors expressed in human smooth muscle cells, and competes with prazosin in 
radioligand binding experiments. Given this, the cellular location of a%-adrenoceptors 
should be considered when designing ligands for these receptors, as a high proportion of 
functional receptors are sequestered on internal surfaces in vascular cells.
1 .1 . 5  a i-adrenoceptors: a role in development
a r  adrenoceptors may be important in the development and maturation of sexual 
function in the rat. Male rats aged 40, 60 and 120 days, were studied to investigate the 
role of a r  adrenoceptors in sexual development. This study has shown that expression 
levels of a r  adrenoceptors change with increasing age, and altered expression levels are 
accompanied by an increase in testosterone levels. Increased levels of reproductive 
hormones are accompanied by an overall increase in body and epididymal weight. The 
presence of all three a r  adrenoceptor subtypes was confirmed in the reproductive 
system of rats at each age point [Queiroz et al, 2002].
Displacement curves earned out on homogenised caput and cauda epididymis, show 
that although all three a r  adrenoceptor subtypes are expressed, the aiA-adrenoceptor is 
the major subtype expressed in the epididymis of 40 day old, sexually immature rats 
[Queiroz et al, 2002]. The predominance of this ai-subtype in the epididymis of
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sexually Immature rats, suggests that the aiA-adrenoceptor may play a role in sexual 
development.
Furthermore, in vitro experiments have shown that (Xi-antagonists decrease ejaculatory 
capacity in the rat, which leads to a reduction in sperm quality. So (Xi-adrenoceptors are 
expressed in, and mediate a variety of functional responses in the rat reproductive 
system, and appear to contribute to the development and maintenance of fertility 
[Ratnasooriya & Wadsworth, 1990]. In addition to the rat, the guinea pig epididymis 
also contains a mixed population of a i and a^-adrenoceptors, which when stimulated 
with selective ligands participate in vasoconstrictor responses [Haynes & Hill, 1996].
Studies canied out to determine where adrenoceptors are expressed, provide valuable 
information. However, caution should be exercised when interpreting data, as the 
presence of mRNA for a given subtype is not always indicative of functional receptors 
[Hi’ometz et al, 1999].
1 . 1 . 6  %  adrenoceptors and vascular contraction
a i-s e le c t iv e  agon ists cau se  contractions b y  stim ulating receptors that are located  on  
vascular sm ooth  m u scle  ce lls , in  a w id e  variety  o f  vascular beds. S tim ulation  o f  Œia 
and aiD"adrenoceptors w ith  se lec tiv e  agon ists, leads to contractile resp on ses in  a 
num ber o f  m urine arteries. T he (Xiu-adrenoceptor is the m ajor subtype lead ing to  
contraction o f  the m urine aorta, carotid and superior m esenteric artery [D aly  et al, 
2 0 0 2 ]. W h ile  the a iA -adrenoceptor m ediates contraction o f  the caudal, and first order 
m esenteric b lood  v e sse ls  [D aly  et al, 2 0 0 2 ]. T he aiB -adrenoceptor is exp ressed  in a
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number of peripheral vessels, but the use of subtype selective ligands and transgenic 
mice has shown that the aiB-adrenoceptor plays only a minor role in contraction.
Stimulation of adrenergic receptors with selective ligands causes an increase in calcium 
wave activity in vasculai* tissues [Ruehlmann et al, 2000]. Mitochondrial inhibitors 
decrease the contractile force generated by stimulation of vascular ai-adrenoceptors in 
the rat tail artery by 50-80%, but calcium concentrations are unaffected [Sward et al,
2002]. Confocal microscopy has shown that mitochondrial inhibitors reduce a i- 
adrenoceptor-mediated calcium wave activity [Sward et al, 2002]. This is not 
surprising, given that it has already been shown that stimulation of adrenergic receptors 
causes an increase in calcium cuiTents in vascular tissue [Peng et al, 2001]. In addition 
to a reduction in ai-mediated contractions, inhibition of myosin phosphatase with 
calyculin decreases relaxant responses in the rat tail aitery by thirty percent [Sward et 
al, 2 0 0 2 ].
In a num ber o f  tissu es, stim ulation  o f  the aiA -adrenoceptor leads to sm ooth  m u scle  ce ll  
contraction. In the rat, preparations that contract fo llo w in g  stim ulation  o f  the (%iA- 
adrenoceptor in clu d e the renal and tail artery [V illa lo b o s-M o lin a  &  IbaiTa, 1996] and  
vas deferens. In the rat vas deferens, stim ulation  o f  the (XiA-adrenoceptor activates tw o  
ca lc iu m  pathw ays, firstly , by releasin g  Ca^ "^  from  intracellular stores and secon d ly , by  
op en in g  vo ltage  operated Ca^^ channels on the p lasm a m em brane o f  stim ulated  ce lls  
[Burt et al, 1998].
A61603 is a potent selective agonist at aiA-adrenoceptors. Ligand binding studies show 
that this compound has a thirty-five fold greater potency for the compaied with aib
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and aid binding sites. The greater affinity of A61603 for the aiA-adrenoceptor has also 
been demonstrated in vitro in the rat vas deferens and in canine prostate strips, both of 
which have previously been subtyped as aiA- Enhanced potency for one adrenoceptor 
subtype provides a useful method for studying subtype specific responses in arterial and 
venous beds in a variety of different animal species [Knepper et al, 1995].
WB4101 and 5MeU selectively antagonise agonist-mediated and electrically evoked 
changes in pupil diameter in the rat eye [Yu & Koss, 2002]. Selective antagonism with 
WB4101 and 5MeU confirms that the major adrenoceptor subtype leading to 
contraction of smooth muscle cells suiTounding the rat eye results from stimulation of 
the aiA subtype.
Major and minor contractile roles for -adrenoceptors
Contractions of the rat caudal aitery appear to be mediated by more than one a i- 
adrenoceptor subtype. Noradrenaline-induced contractions in this artery are 
concentration-dependent, and are antagonised by prazosin in a competitive manner, 
indicated by a Schild regression slope of 1. The ai-selective antagonist RS17053 shifts 
noradrenaline-mediated contractions to give a biphasic response curve. Following CEC 
treatment and RS 17053, noradrenaline concentration response curves are monophasic. 
BMY7378 is an am-selective antagonist, and in spite of the presence of mRNA for the 
aiD receptor in the rat tail artery, BMY7378 has little effect on noradrenaline-mediated 
contractions [Piascik et al, 1995]. Therefore, it appears that the major contractile 
receptor in the rat caudal artery is the aiA-adrenoceptor, with a minor, but significant 
contractile response being mediated by CEC sensitive am-adrenoceptors [Lachnit et al.
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1997]. The potency order of agonists in the rat caudal artery is similar to that found in 
the isolated rat kidney, which is predominantly aiA [Blue et al, 1995].
Contractions of the guinea pig cauda epididymis are mediated by a-adrenoceptors. 
Phenylephrine-induced contractions are concentration-dependent, and are antagonised 
by CEC, but only in the presence of the a^-antagonist, idazoxan [Haynes & Hill, 1996]. 
Interestingly, contractile responses to phenylephrine are enhanced by the presence of the 
ai-selective agonist, xylazine. When mounted tissues are incubated with xylazine prior 
to construction of a phenylephrine response, the concentration curve is shifted to the 
left. This indicates that sensitivity has been enhanced. Analysis of functional responses 
in the cauda epididymis reveals that a mixed population of and (%2 -adrenoceptors
exist, and stimulation of both subclasses leads to contractile responses. Activation of 
adrenoceptors enhances calcium influx, which explains the potentiating effect of 
xylazine on phenylephrine-induced responses [Haynes & Hill, 1996]. Due to the 
obvious problems associated with gaining tissue samples from healthy human subjects, 
the literature documenting the functional responses in reproductive organs is limited.
All three ai-adrenoceptor subtypes aie expressed in human prostate tissue [Walden et 
al, 1999], where they mediate smooth muscle cell contraction. Phenylephrine causes 
contraction of cultured human pro static stromal cells, which results in a significant 
shortening in cell length. Phenylephrine-induced contractions of cultured stromal cells 
are inhibited by L-type calcium channel antagonists, and PKC inhibitors [Preston & 
Haynes, 2003].
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1.1.7 Relaxations mediated bv ai-agonists
a 2 -adrenoceptors mediate relaxant responses in a number of arteries, the mechanisms of 
which have been studied widely. Until recently, oti-adrenoceptors were generally 
considered to carry out only contractile functions. However, research now suggests that 
stimulation of (%i-adrenoceptors can lead to relaxant responses in rat pulmonary arteries 
by causing the release of nitric oxide [Boer et al, 1999],
Furthermore, phenylephrine and noradrenaline appear to mediate two distinct vascular 
responses in pressurised rat mesenteric beds. The first is a small but significant 
relaxation. The second is a sustained concentration-dependent contraction. Relaxant 
responses occur at low agonist concentrations, and lead to a significant drop in
perfusion pressure. To determine if this response depends on a functional endothelium 
denuded and normal vessels were studied. Removal of the endothelium was achieved 
by perfusing the vessel lumen with distilled water, a method proposed to mimic 
mechanical damage caused by rubbing [Bolton et al, 1984]. The lack of a functional 
endothelial surface prevents phenylephrine and noradrenaline-induced relaxant effects, 
while contractile responses are unaffected. Therefore, the relaxant responses mediated 
by ai-adrenoceptors appear to result from stimulation of endothelial receptors.
The cellular signalling pathways leading to ai-adrenoceptor-mediated relaxations of rat 
mesenteric arteries involve calcium, evidenced by the antagonising effect of Ca 
ATPase inhibitors and phospholipase C blocking drugs. Furthermore, blockade of aiD 
and cciB-mediated responses with BMY7378 and CEC attenuates the relaxant response, 
while inhibiting the UiA-adrenoceptor with selective ligands has no effect on 
noradrenaline and phenylephrine-induced relaxations [Filippi et al, 2001].
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Cultured bovine endothelial cells were used to study the mechanisms involved in oti- 
mediated relaxant responses in greater detail. Phenylephrine causes a significant rise in 
inositol monophosphate levels in cultured endothelial cells and BMY7378 antagonises 
phenylephrine-induced increases in cNOS activity [Filippi et al, 2001]. Taken together, 
this data indicates that postjunctional ai-adrenoceptors can be stimulated, and cause
1.1.8 Smooth muscle cell hvnertrophv
Circulating levels of catecholamines are elevated in hypertensive patients and in
development of cardiovascular disease. In addition to contractile responses, the 
catecholamines noradi'enaline and adrenaline have effects on cell growth and 
proliferation via stimulation of ai-adrenoceptors [Chen et al, 1995]. In cultured rat
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small, but significant relaxant responses, which are followed by sustained contractile
responses in resistance arteries of the rat. Relaxations depend on a functional 
endothelium and have been proposed to result from stimulation of am-adrenoceptors.
individuals under extreme stress. Hypertension and stress are known risk factors for the
cardiac myocytes, the regulation of transcription factors that control cell growth and
'
size, are affected by stimulation of a%A-adrenoceptors [Knowlton et al, 1993]. In 
contrast, prolonged stimulation of am  and am-adrenoceptors with selective agonists, 
leads to an increase in a  actin; which is an important component involved in the 
development of vascular contraction [Chen et al, 1995]. Furthermore, overexpressing 
the aiB-adrenoceptor in vivo leads to cardiac hypertrophy. This data supports the 
hypothesis that am-adrenoceptors regulate growth of cardiac and vascular tissue, both 
of which are altered in hypertension.
I
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Treating isolated cardiac myocytes, from neonatal rats with ai-selective agonists leads 
to an elevation in aiA mRNA/protein levels. Enhanced levels of the aia-adrenoceptor 
are accompanied by a decrease in the expression of am and am-adrenoceptors [Rudner 
et al, 1999]. Altered a-adrenoceptor expression in cardiac myocytes has been proposed 
to contribute to the development of myocardial hypertrophy [Rokosh et al, 1996]. In 
addition to catecholamines, hormones can also affect the expression of a i- 
adi'enoceptors. Insulin causes an upregulation of aia-adrenoceptors expressed in 
vascular smooth muscle cells isolated from the rat [Hu et al, 1996]. Whether these 
processes are at work in vivo, will be more difficult to prove.
1.1.9 Regulation of cellular growth
In addition to mediating vascular contractions, ai-adrenoceptors also regulate the 
growth of vascular smooth muscle cells. In am knockout mice there is a reduction in the 
total number of adventitial cells in the mouse tail artery. This suggests that the am- 
adrenoceptor plays an active role in the maintenance of vascular growth [Daly et al. 
Unpublished observation], am  and am-adrenoceptors are proposed to play an active 
role in the control of vascular growth, and are known regulators of MAPK activity. By 
acting as regulators of ERK activity the am-adrenoceptor can regulate the growth of 
aortic smooth muscle cells in the rat [Xin et al, 1997]. By activating different signalling 
pathways in smooth muscle cells the am  receptor subtype functions primarily, to 
control vasculai" growth [McWhinney et al, 2000].
So what other mechanisms control growth? The presence of caveolin has been used as 
a marker for cell growth. Cholesterol and glycosphingolipids are found in caveloae 
which form small invaginations in the plasma membrane of cells. Caveolin is a mai'ker
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for the presence of caveolae, which inhibits the release of vascular growth factors 
[Couet et al, 1997]. Caveolin expression levels are down regulated in rapidly dividing 
cells and are significantly attenuated in developing tumours [Fujita et al, 2001].
Isolated cardiac cells become hypertrophic after prolonged exposure to catecholamines; 
an effect that is proposed to result from the activation of (%i-adrenoceptor signalling 
cascades [Ishikawa & Homey, 1997]. So how do signalling molecules do this? One 
possibility is that they interact with, and alter caveolin levels; allowing vascular growth 
to proceed unchecked.
Caveolin and ai signalling molecules are found in close association in rat cardiac tissue.
To determine if these factors contribute to the development of cardiac hypertrophy, their
; :
expression levels were studied in cardiac tissue from the rat [Fujita et al, 2001]. The 
distribution of ai-adrenoceptors in the plasma membrane of cells has previously been 
considered as random. That is until now. Fujita and co workers have shown that a i- 
adrenoceptors can be found in discrete areas of the cell membrane, closely associated 
with caveolin.
Caveolin-3 controls cellular growth; expression of caveolin-3 is significantly lower in 
cardiac tissue from spontaneously hypertensive rats compared with normotensive
::controls at one and three months of age. However, the expression of caveolin-3 is 
unaltered at three months of age compared with that at one month. This suggests that 
caveolin is not involved in the progression of hypertension in developing rats, but may 
be involved in the early stages of the disease [Fujita et al, 2001]. The interaction
between caveolin and ai-adrenoceptor expression levels is poorly understood and 
requires further investigation.
1.1.10 Age related changes in vascular structure and function 
The structure and function of blood vessels is altered with increasing age. Vascular 
changes occuning with age may be the result of altered receptor expression or be due to 
functional changes in the existing receptor population. For example, it is well 
documented that p-adrenoceptor function is altered with age. Relaxant responses 
mediated by P-adrenoceptors are attenuated with increasing age, while noradrenaline 
mediated contractions are enhanced [Marin et al, 1991]. In addition to changes 
occurring in p and ot]-adrenoceptors, az-mediated contractions are also significantly 
attenuated in old animals [Marin, 1995].
Age has been established as an independent risk factor for the development of 
cardiovascular disease. In developed countries the population has a greatly increased 
life expectancy; so this area of research generates a tremendous amount of interest, and 
funding. The phenotype of vascular smooth muscle cells changes with age, from a 
contractile to a synthetic phenotype. Such changes probably result from altered 
signalling pathways and or reduced responsiveness to smooth muscle cell inhibitors 
[Lundberg & Crow, 1999].
Age-related changes in ai-adrenoceptor expression levels are vessel specific. Indeed 
arteries from patients over sixty-five years old have a two-fold increased expression of 
adrenoceptors in mammary arteries. The principal ai-adrenoceptor subtype mediating 
contraction of mammary arteries from young adults has been found to be the ociA
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subtype. In later life, ai-adrenoceptor expression levels shift from aiA toward the am 
[Rudner et at, 1999]. Whether similar shifts occur in other vascular beds is as yet 
unknown.
Resistance arteries are important regulators of peripheral blood pressure. Therefore, 
any change in the expression levels and or the function of adrenoceptors in these arterial 
beds could have profound affects on blood pressure regulation, am-mediated 
contractions of resistance arteries are significantly enhanced with increasing age 
[Rudner et al, 1999]. If the increase in the expression of the am-adrenoceptor reflects a 
functional population of receptors involved in contraction this may, in part, account for 
the rise in blood pressure that accompanies advancing age.
1.1.11 Excitatorv responses in brain motomeurons
Noradrenergic neurons project into all areas of the central nervous system and aie 
instrumental in the control of motor, sensory, cognitive, emotional and autonomic 
functions [Aston-Jones et al, 1988, Friedman et al, 1991]. Stimulation of postjunctional
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High levels of fat and a cholesterol rich diet cause lipid rich plaques to form in large 
calibre arteries in humans. Plaque formation is unaffected by age, but progression of 
the condition is age-dependent. A developing plaque becomes fibrous, ulcerated, and 
calcium rich. Calcification makes the plaque unstable and it is at this stage that a fatal 
thrombotic lesion can occur [Robert, 1999]. Ageing is associated with a breakdown in 
regulatory functions at the receptor level [Xia et al, 1998]. Altered adrenoceptor 
expression may contribute to plaque instability. The mechanisms whereby this occurs 
are unclear.
kinases (GRK’S) [Ferguson et al, 1997]. The role of protein kinases C in receptor 
desensitisation is poorly defined. It appears that the GRK activated by protein kinase C 
is critical in determining whether desensitisation occurs and that GRK2 and GRK3 are 
involved, while GRK4 and GRK5 do not participate in agonist-induced receptor 
desensitisation [Diviani et al, 1995].
a i -adrenoceptors regulates spinal motorneurone activity. The subtypes involved in 
these responses have only recently been defined [Wada et al, 1997].
aiB mRNA has been detected in eighty-five percent of rat motomeurons. The 
remaining ai-adrenoceptor subtypes namely, aiA and am  are also expressed, but their
'
expression levels are lower than the am  and appear to be more random [Volgin et al,
2001]. Thus, data indicates that the major ai-adrenoceptor subtype regulating the 
function of spinal motomeurones appears to be the am-adrenoceptor.
1.1.12 Regulation of receptor function 
Binding of tritiated prazosin to cultured cells is significantly reduced when cells are pre- 
treated with adrenaline and noradrenaline. The reduction in available binding sites 
suggests catecholamine-induced receptor internalisation; a process that requires protein 
kinase C. When receptors are sequestered to the internal environment of a cell, 
prazosin, a hydrophobic ligand has no access, but lipophilic ligands are free to cross the 
plasma membrane and bind receptors [Cowlen & Toews, 1988].
Receptor desensitisation, which manifests as reduced responsiveness to applied 
agonists, occurs when susceptible receptors are phosphorylation by G protein receptor
I
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1.1.13 Quantitative pharmacology in single cell preparations 
Detailed pharmacological experiments have been carried out in single cells; to 
determine if quantitative pharmacology can be performed in cell lines and/or dissociated 
cells [Pediani et al, 2 0 0 0 ].
In cultured cells, phenylephrine mobilises intracellular calcium stores and causes 
voltage-gated calcium channels to open, recruiting extracellular calcium for contraction.
In rat-1 fibroblasts the aiA-selective agonist, A61603 was found to be 141 times more 
potent than phenylephrine at inducing the mobilisation of calcium currents. The
■antagonist potency order in this cell line was determined as 
WB4101>prazosin>BMY7378, and the antagonism produced by WB4101 and prazosin 
was insurmountable. The selectivity of A61603 and the antagonist potency order 
confirm that the use of this cell line provides an alternative method whereby aiA- 
mediated responses can be analysed pharmacologically. In addition to potency and 
affinity estimates the responses gained were reproducible, quantifiable, and could be 
measured over real time [Pediani et al, 2000]. The data gained from these experiments 
provides evidence that single cell systems are useful tools for the assessment of 
adrenoceptor-medi ated responses.
1.1.14 Phannacologv of constitutivelv active a i adrenoceptors 
Before a receptor can be defined as constitutively active it must fulfil three criteria. 
These are an increased affinity for agonist, no change in antagonist potency, and 
enhanced basal levels of second messengers. Mutations of the third cytoplasmic loop of 
the aia and the aib-subtypes cause these receptors to become constitutively active 
[McWhinney et al, 2000].
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Constitutively active receptors induce signal transduction in the absence of exogenous 
agonists. This feature distinguishes constitutively active from wild type receptors.
Experimentally, constitutive activity can be induced, by overexpressing the native 
receptor to ninety percent of normal expression levels. The advantage of this is that the 
signalling pathways activated by a constitutively active receptor can be studied in 
greater detail than normal physiological conditions permit [McWhinney et al, 2000].
Constitutively active receptors and inverse agonists are relatively new concepts, and 
have only recently been introduced to the study of receptor activity. Constitutive 
receptor/G protein coupling leads to persistent receptor cycling from the membrane to 
intracellular organelles, then back to the plasma membrane. Recent studies using a ?!
variety of antagonists have shown that these blocking drugs can shift the equilibrium of 
constitutively active receptors. Surprisingly, this shows that not only do antagonists 
have affinity for receptors, but they also have efficacy, and do not as previously $
assumed, act merely as blocking agents that prevent endogenous and exogenous agonist 
from binding. Prazosin acts as an inverse agonist in CHO cells expressing 
constitutively active ocia-adrenoceptors [Zhu et al, 2000].
Overexpression the aia adrenoceptor in cardiac myocytes leads to the receptor 
becoming constitutively active; the net result of which is, phosphatidylinositol 
hydrolysis and ANF-luciferase gene expression, and recruitment of the germ line 
promoters SPl and SRE. Therefore, by overexpressing the a%a-adrenoceptor in caidiac 
myocytes, pathways activated by the a% A-adrenoceptor have been identified, which may 
be involved in cardiac cell growth [McWhinney et al, 2000].
1.1.15 Œi-adrenoceptors can induce rhythmic arterial contractions 
Upon stimulation with agonists, susceptible arteries develop rhythmic activity in vitro, 
and may do so in vivo. The development of regular variations in tone is termed 
vasomotion [Peng et al, 2001]. Vasomotion is a common physiological phenomenon 
and is of pathophysiological importance [Griffith and Edwards, 1997]. Adrenoceptor 
agonists have been shown to induce rhythmic contractions in the rat mesenteric artery 
and in the mouse tail artery [McBride et al, unpublished observation].
Low concentration of the endogenous agonist, noradrenaline, cause Ca^ "^  waves to 
develop, a process that requires an intact endothelium or a cGMP donor drug [Peng et 
al, 2001]. Contrary to this, in other studies removal of the endothelium can actually 
enhance vasomotion [Griffith and Edwards, 1997]. Therefore the role of the 
endothelium in the development of rhythmic contractility is unclear.
Regardless of endothelial function, vasomotion only develops when a sufficient number 
of smooth muscle cells are recruited and become active at the same time. This happens 
when intracellular calcium is released from the sarcoplasmic reticulum. In order for 
contractions to become rhythmic, a sufficient number of vascular smooth muscle cells 
must be recruited to contract. Cell to cell communication, probably occurs via gap 
junctions, which promote synchronised calcium release in a number of vascular smooth 
muscle cells. The flux of positive ions changes the membrane potential and smooth 
muscle cell contraction ensues, in a synchronised, rhythmic manner [Peng et al, 2001].
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The development of vasomotion is not unique to arteries, and has also been studied in 
veins. Repetitive, asynchronous calcium waves can be induced by phenylephrine in the 
rabbit inferior vena cava. Stimulation of oci-adrenoceptors in this blood vessel recruits 
smooth muscle cells that contract in an all-or-nothing manner. The more cells 
participating in the contraction, the greater the force generated [Ruehlmann et al, 2000]. 
Although the development of rhythmic contractions is fascinating and attracts a great 
deal of interest, unwanted rhythmic activity can hamper the study of subtype specific 
responses in susceptible arterial beds, a factor which is highlighted in chapter four and 
seven of this thesis.
1.1.16 ai-adrenoceptors and hypertension
Patients with essential hypertension often have an increased vascular load and 
frequently have elevated levels of circulating catecholamines in their blood stream 
[Cottone et al, 1998]. Peripheral blood vessels from these patients and vessels isolated 
from hypertensive animals exhibit similai’ pathogenic alterations. A common functional 
alteration in blood vessels from hypertensives is that they develop supersensitivity to 
exogenous agonists. Increased sensitivity to contractile agents may reflect a generalised 
reduction in the number of available receptors, whereby the remaining population 
become supersensitive. Regardless of the way in which receptors become supersensitive 
to exogenous agonists, this represents a mechanism, which may contribute to the 
maintenance of high blood pressure in vivo.
Rats that spontaneously develop hypertension (SHR) and rodents with renal-induced 
hypertension are useful animal models for the study of the development and progression 
of hypertension. Both of these animal models exhibit altered adrenoceptor-mediated
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responses. In the SHR, the aorta and carotid display a significant upregulation of am - 
adrenoceptors [Michael et al, 1993]. Hypersensitivity to exogenous agonists is common 
in hypertension, and may be mediated by the am-adrenoceptor because this receptor 
subtype has been shown to be upregulated in blood vessels from hypertensive animals.
A variety of murine blood vessels contract in response to stimulation of am- 
adrenoceptors. These include, mesenteric and femoral arteries, and the carotid and aorta 
[Kenny et al, 1995, Daly et al, 2002], which all contract when am-adrenoceptors are 
stimulated. Contractions of downstream resistance arteries, such as rat mesenteric 
vessels have been attributed to stimulation of the ajL-adrenoceptor [Van der Graff et al, 
1996a], but appear to be the result of stimulating aiA-adrenoceptors [Daly et al, 2002]. 
Considered together, data from the rat and mouse provides strong evidence that suggests 
the am  subtype is involved in the maintenance of peripheral resistance. In young rats
the am-adrenoceptor plays only a minor role in vasoconstriction. However, in vitro 
experiments on mature animals show a shift toward am-mediated vasoconstrictions, 
indicative of a change in the major subtype leading to vascular contractions [IbaiTa et al, 
1997]. Furthermore, radioligand-binding studies confirmed that there is an alteration in 
the expression of ai-adrenoceptors in the kidneys of rats with renal-induced 
hypertension; and am-adrenoceptor subtypes mediate vasoconstriction in the rat 
myocardium, aorta, and vas deferens [Deng et al, 1996, Want et al, 1997] and mouse 
aorta.
The SHR animal model has been used to study the role of the am-adrenoceptor in 
hypertension. In vitro experiments on isolated blood vessels from the SHR have been
.
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conducted before and after the onset of clinical symptoms. BMY7378, blocks (Xr 
adrenoceptor-mediated contractions in the SHR but has no effect on control animals. 
Furthermore, in older animals BMY7378 shifts the phenylephrine response curve to the 
right. This data indicates that the am-adrenoceptor mediates vascular contractions 
before the onset of clinical symptoms, and in rats with established hypertension 
[Villalobos-Molina et al, 1999].
The am-adrenoceptor appears to play a dual role in hypertension, firstly, in the 
development of the disease, evidenced by the abundance of this receptor in young 
spontaneously hypertensive rats. Secondly, am-adrenoceptors appear to be involved in 
the maintenance of hypertension because mature rats show a significant upregulation in 
am-adrenoceptor-mediated responses.
1.1.17 Benign prostatic hvnemlasia
Elderly men are commonly afflicted by a condition known as benign prostatic 
hyperplasia, a disorder of the lower urinary tract that leads to obstruction of urine 
outflow; which severely affects a patient’s quality of life. Surgical intervention to 
rectify the obstruction is highly successful. However the stress of surgery, which 
involves general anaestheisa and transurethral resectioning often leads to morbidity 
[Garcia-Sainz et al, 1999].
a i -adrenoceptor expression levels are altered in prostatic hypeiplasia. Given this, it has 
been proposed that drugs that selectively inhibit ai-mediated contractions in the lower 
urinary tract may obviate the need for surgical intervention. The aiA and am- 
adrenoceptors are the major adrenoceptor subtypes-mediating contraction in the human
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prostate. Therefore, ligands that selectively block aiA and am-mediated responses offer 
potential benefits over non-selective compounds. Tamsulosin has been used as a 
successful treatment for benign prostatic hyperplasia for several years, not least because 
the drug-induced reductions in blood pressure are slight in comparison to those 
produced by other ai-blockers.
1.1.18 Drug treatments that target ai-adrenoceptors
A great deal of research has gone into the development of antagonists that are 
stmcturally related to prazosin, in an attempt to develop high affinity subtype-selective 
antagonists. Prazosin is a quinazoline-bearing compound. Substitution of the 
piperazine ring has shown that the quinazoline moiety is essential for the activity and 
selectivity of prazosin. The selectivity and activity of prazosin-like compounds depends 
on the length of their alkaline chain [Melchiorre et al, 2000]. If a cyclopentane ring is 
used to replace the carbon chain that separates the amine and phenoxy group, this 
enhances affinity for ai-adrenoceptors compared to 5HTi a receptors.
Antagonism of ai-receptors causes vasodilatation of veins and arteries because 
endogenous ai-agonists are prevented from binding available receptors. Inhibiting the
effects of endogenous ai-agonists can be advantageous, but chronic administration of 
a%-antagonists frequently leads to compensatory increases in catecholamine release
;
[Izzo et al, 1981]. One side effect of an increase in sympathetic tone and elevated 
catecholamine release is postural hypertension, a condition that is chaiacterised by 
dizziness upon standing. This often leaves patients agitated and doubtful about the 
consequences of using medication with such severe side effects.
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Non-selective ai-antagonists are effective antihypertensives in clinical conditions. 
However, there is an increased incidence of heart failure with these drug treatments,
Urapadil was originally marketed as an alternative drug therapy to prazosin. However, 
urapadil causes peripheral vasodilatation and increases muscle sympathetic activity, like 
prazosin. It has since been hypothesised that all drugs causing peripheral vasodilation 
will eventually cause compensatory increases in sympathetic nerve activity, thus their 
use is still contraindicated [Grassie et al, 2000].
of blood pressure, than the aiA and aiB-receptor subtypes.
Prazosin antagonises ai-mediated responses by blocking receptor-binding sites. 
However, prazosin can also lead to an upregulation in the expression of a i-
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which now precludes their use as antihypertensives [Guthrie & Siegel, 1999]. Subtype
selective oci-antagonists may prove to be more suitable drugs for the treatment of 
hypertension, if unwanted side effects and increased mortality are to be avoided.
Tamsulosin has fewer side effects than other a i antagonists because it does not cause 
hypotensive responses at therapeutic doses [Fogler et al, 1995]. The reduction in side 
effects has been proposed to be due to tamsulosin having low affinity for the aiB-
■ ::
adrenoceptor [Hein et al, 2000]. However, in vitro studies show that this drug has 
selectivity for cXi A /ocm-adrenoceptors. Given these results, it can be concluded that 
tamsulosin does not cause a significant reduction in blood pressure because, at 
therapeutic doses, it does not antagonise am-mediated responses. This data also
provides evidence that the am-adrenoceptor plays a more significant role in the control
1.1.19 Ligand mediated changes in adrenoceptor expression levels
1
adrenoceptors. In contrast to the effects of prazosin, the cxiA-selective antagonist, 
KMD3213 does not alter the expression levels of ai-adrenoceptors; furthermore 
reserpine, which leads to a depletion of cathecholamine stores has no effect on
demonstrated in vivo [Zhang et al, 2002].
adrenoceptor expression levels in vitro [Zhang et al, 2002]. Intraperitoneal injections of
!prazosin cause an upregulation of and a i a-adrenoceptors in the rat atria and 
enhance expression of ais-adrenoceptors in the rat spleen. The significance of this is as 
yet unclear, but suggests that the effects of prazosin treatment in vitro can be
To test whether inverse agonism is specific to prazosin and what role, if any, the 
sympathetic nervous system plays in this response, KMD3213 and reserpine-induced 
responses were studied. KMD3213 has no effect on oci-receptor expression levels in all 
of the tissues studied. Reserpine attenuates increases in tissue noradrenaline levels, 
while prazosin and KMD3213 have no effect. Leading to the conclusion that prazosin- 
mediated upregulation of ai-adrenoceptors may result from increased sympathetic nerve 
activity. This is supported by the results gained with reserpine, which prevents this 
from occurring [Zhang et al, 2002].
I
Inverse agonists increase receptor density in cells expressing constitutively active 
receptors and decrease G protein coupled receptor activity [Shyrock et al, 1998]. 
Prazosin acts as an inverse agonist at all three ai-adrenoceptor subtypes when they are 
expressed in cultured cell lines [Rossier et al, 1999]. Responses to KMD3213 and 
prazosin have been studied in CHO cells expressing constitutively active aia- 
adrenoceptors. In this cell line, prazosin acts as an inverse agonist. Upon stimulation, 
the expression of am-adrenoceptors is increased. This is coupled to decreased GTP
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-gamma S basal binding and an attenuation of IP3 levels. KMD3213 causes a parallel, 
rightward shift of the phenylephrine-induced concentration response curve, indicative of 
competitive antagonism [Zhu et al, 2000]. KMD3213 also reverses the actions of 
prazosin, and therefore leads to an elevation in second messenger levels. These findings 
are important clinically because of the unpredictability of the side effect of inverse 
agonists m vivo.
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Antagonists have previously been considered as having an efficacy value of zero (and 
therefore are unable to produce a measurable response), but this is not actually the case. 
Prolonged exposure to antagonists in cell lines can cause an upregulation of receptors.
A phenomenon that has been explained by a receptor theory, where, for the sake of
simplicity, receptors can be considered as existing in two conformational states 
[Milligan et al, 1995]. R is considered as being inactive, while R* is free to couple to G
proteins and lead to down stream signalling. Overexpressing a given receptor subtype 
is proposed to increase the number of copies of the receptor that exist in the active state.
Drugs proposed to act as inverse agonist (these drugs are frequently antagonists, but not
fi
exclusively) have been proposed to have higher affinity binding for the inactive (R) 
state of the receptor compared with the active form (R*). This makes cell lines 
overexpressing receptors suitable systems for the study of the activity of drugs proposed 
to act as inverse agonists.
The kidney is an important organ that functions to maintain and control blood pressure. 
The expression of adrenoceptors in the kidney has been studied in animal models of 
hypertension. It came as no great surprise when an upregulation of both a i- and a i- 
adrenoceptors was found in the kidney of the SHR [Sanchez et al, 1986].
s
Stimulation of postsynaptic a i -adrenoceptors leads to contraction of smooth muscle 
cells in a plethora of arterial beds. Experiments in the pithed rat have shown that 
prazosin can inhibit nerve-induced tachycardia, and prevent contraction of the vas 
deferens [Docherty et al, 1984].
1.1.20 Receptor Signalling
Bovine am adrenoceptors have been expressed in rat-1 fibroblasts and used to study 
phenylephrine-induced responses. Studies in cell lines have shown that a i- 
adrenoceptors can activate a vaiiety of signalling pathways. The pathway activated 
appears to be dependent on the extracellular conditions and the cell line used to 
investigate intracellular signal transduction.
Stimulation of ai-adrenoceptors can lead to the activation of multiple signalling 
pathways. The pathway activated and the physiological outcome appears to depend on 
the G protein recruited [Garcia-Sainz et al, 1999], and the vessel or tissue type studied. 
All three a%-adrenoceptor subtypes mobilise calcium and activate phosphoinositide 
signalling. However the degree of activation that occurs, depends on the subtype 
stimulated.
All adrenoceptors belong to the G protein coupled receptor superfamily, and produce 
their effects by binding guanine nucleotide binding proteins (G proteins). In addition to 
adrenoceptors, other receptors belonging to this family include inflammatory mediators, 
serine pro teases, neurotransmitters and hormones [Grady et al, 1997].
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Molecular cloning studies reveal that there is a high degree of sequence homology 
between G protein coupled receptors. Leading to the hypothesis that all G protein 
coupled receptors may have evolved from a common ancestral gene [Piascik & Perez, 
2001].
The serpentine structure of a G protein results in the formation of three intra and three 
extracellular loops. The third extracellular loop is often the site of agonist/receptor 
interactions [Piascik & Perez, 2001]. G proteins consist of an ct, p and y subunit and 
have a heterotrimeric structure. Receptor/G protein subunit interactions normally occur 
at the plasma membrane [Gilman et al, 1987]. The interaction of an adrenoceptor 
agonist with a G protein causes the release of bound GDP for GTP. GTP then 
associates with the larger a  subunit of the G protein and the py subunits dissociate from 
the GaGTP complex. The active GaGTP complex is now free to produce a response by 
activating downstream signalling pathways. Hydrolysis of GTP to GDP permits 
reassociation of the py to the a  subunit of the G protein, and terminates the response 
[Summers & McMartin, 1993].
There is a great deal of homology in the structure of G protein coupled receptors. They 
all have a serpentine membrane-spanning domains consisting of 20-25 hydrophobic 
residues that form a  helices. These receptors possess an intracellular carboxy terminus 
and an extracellular amino terminal with three extracellular loops. Intracellular receptor 
domains contain sites that can be phosphorylated by protein kinases after receptor 
activation [Grady et al, 1997].
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a]-adrenoceptors consist of a single chain of polypeptides composed of between 429- 
561 amino acids. These receptors are characterised by a long carboxy terminus and 
compared with other G protein coupled receptors have a short third cytoplasmic loop 
[Summers & McMartin, 1993]. A conserved site in the third cytoplasmic loop is 
responsible for the formation of a hydrophilic catecholamine-binding domain [Graham 
et al, 1996].
Once activated, ai-adrenoceptors predominantly bind to pertussis toxin-insensitive G 
proteins of the Gq/n family. Some selectivity exists among the a i subtypes with the am  
coupling via Gq or Gn, and not the G u and G ig, unlike the am  subtype. The am- 
adrenoceptor can mediate responses by binding to the G u and G u when they are 
transfected in cos-7 cells, in addition to coupling to Gq and Gu [Wu et al, 1992].
a i -adrenoceptor stimulation leads to the activation of phospholipase C, D and Ai 
[Exton, 1996]. Activation of these enzymes leads to the opening of Ca^^ channels, 
activation and or inactivation of channels and activation of the Na- Ca^^ exchanger 
[Graham et al, 1996], all of which are important determinants of membrane potential.
Interactions of ai-selective agonists with receptors result in an increase in the 
concentration of cytosolic calcium by activation of phospholipase C. An elevation in 
cytosolic Ca^^ leads to the production of 1,4,5-triphosphate (IP3 ) and diacyl glycerol. 
Diacylglycerol in turn, activates protein kinase C, which phosphorylates intracellular 
sites and modulates the transcription of genes [Graham et al, 1996]. IP3 formation 
promotes the release of Ca^^ from intracellular stores [Cowlen & Toews, 1988]. I
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Hydrolysis of IP3  promotoes the release of Ca^ *^  stored in the endoplasmic and 
sarcoplasmic reticulum [Minneman, 1988], facilitating contractile responses.
cxi-stimulation can also cause an influx of Ca^ "^  from the extracellular environment by 
opening voltage-dependent Ca^ "^  channels [Graham et al, 1996]. This is evidenced by 
the fact that removal of extracellular Ca^ '*' inhibits aiA-mediated contractions in isolated 
vascular smooth muscle [Han et al, 1987]. In 1996, Graham and co workers recorded 
differences in the way that aiA and am-adrenoceptors mobilise Ca^^. They proposed 
that the a i A-adrenoceptor acts to increase Ca^”^ levels by opening voltage-dependent 
Ca^ "^  channels, while the am-adrenoceptor causes a rise in intracellular calcium via 
phospholipase C and IP3 [Graham et al, 1996]. However in other tissues, such as the rat 
vena cava am-adrenoceptors can cause an influx of extracellular calcium [Perez et al, 
1993].
Vascular contractions brought about by stimulation of ai-adrenoceptors leads to 
enhanced actin-myosin chain interactions. An increase in intracellular calcium causes 
activation and recruitment of calmodulin. Calmodulin/ Ca^ '*' complexes activate myosin 
light chain kinase (MLCK), which promotes actin myosin interactions via 
phosphorylation and hence, causes contraction of vascular smooth muscle cells.
1.1.21 Inflammatorv responses involving ai-adrenoceptors 
Cytokines are the chemical messengers of the immune systems, and as such can 
regulate and alter the functioning of cells. Cytokines can also regulate the expression of 
mRNA for ai-adrenoceptors in human monocytic and endothelial cells [Heijnen et al.
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2002]. For example, in patients with chronic juvenile arthritis, stimulation of ai- 
adrenoceptors leads to the release of the cytokine IL- 6  from mononuclear cells.
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Mononuclear white cells express am and a ^  mRNA. The cytokines, TNFa and IL-lp 
cause a decrease in a^a mRNA in THP-1 monocytic cells, but am mRNA levels are 
unchanged. In addition to the am and am-adrenoceptors, the cytokines IL-lp and
:TNFa lead to enhanced expression of am mRNA on mononuclear cells. Therefore, 
cytokines can regulate expression levels of a i mRNA, but the changes in receptor 
expression are dependent on the subtype studied and the tissue type used [Heijnen et al,
2002]. Surprisingly, cultured human endothelial cells have been shown to express ai- 
adrenoceptors [Heijnen et al, 2002], a novel finding that requires further investigation.
This supports the finding that relaxant responses mediated by ai agonists require an 
intact endothelial surface.
1 .1 . 2 2  a i-adrenoceptors and hvpoxic conditions 
The abdominal aorta divides into two common iliac arteries. In the rat iliac artery the 
administration of noradrenaline and phenylephrine leads to vascular contraction. Iliac 
and femoral arteries appear to be more vulnerable to hypoxic conditions than other 
arterial beds [Maniot & Marshall, 1990]. In the iliac and femoral arteries there is no 
evidence to suggest that a 2 ~adrenoceptors are involved in contractile responses. 
Therefore, contractions of these arteries appear to depend solely on the activation of a i- 
adrenoceptors. In the absence of a functional endothelium, increasing concentrations of 
noradrenaline produce a biphasic response curve, while the phenylephrine-induced 
responses are monophasic. Hypoxic conditions reduce the maximal response to 
noradrenaline and phenylephrine, without affecting sensitivity. This data suggests that
a i -mediated vasoconstriction of the rat iliac artery is affected by PO2  levels [Bartlett & 
Marshall, 2002]. The extent to which low oxygen levels alter a%-mediated contractions 
is not discussed further here because it is outwith the scope of this thesis.
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1.2 a 2-adrenoceptors
1.2.1 Background
Cloning studies have identified three genes encoding oc2 -adrenoceptors. These genes 
correspond to the ot2 A, 0 C2 b and the ot2 c receptor subtypes [Bylund et al, 1994]. Since the 
discovery of these three a 2 -receptors, the presence of a fourth subtype has been 
suggested, namely the a 2 o* The consensus now is that the Œ2 A and « 2 0  represent species 
homologues, and mediate similar functions in different species. In humans’ three 
separate genes, located on chromosomes 10, 2 and 4 encode the Œ2 A, (XiB and (%2 c- 
adrenoceptors respectively [Lomasney et al, 1990]. The a 2 A-adrenoceptor is found 
almost exclusively in humans, while the 0 C2 D receptor is expressed in rodents [Harrison 
et al, 1991]. a 2 A-adrenoceptors cloned from humans [Stai’ke et al, 1995] and porcine 
tissue, have a slight difference in amino acid sequence to those cloned from the rat, 
[Bylund et al 1992], mouse and the guinea pig.
Although (X2  adrenoceptors were initially discovered prejunctionally, they have since 
been shown to exist on the postjunctional membrane [Docherty and McGrath, 1980]. 
However since their molecular identification a great deal of research has focused on 
identification of the prejunctional receptor subtype. Most of the data presented points 
towards the a 2 A/D-subtype, evidenced by (X2 A/D knockout mice having a ninety percent 
reduction in presynaptic feedback control [Altman et al, 1999]. Radioligand binding 
experiments have confirmed that the remaining responses are mediated by the « 2 0 - 
subtype [Trendelenberg et al, 1994]. Without transgenic mice, the identification of the 
two % receptor subtypes mediating autoinhibition of noradrenaline release would have 
been impossible [Hein et al, 1998].
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Postjunctional ^-adrenoceptors mediate contractile responses in a wide variety of veins 
and these responses have been studied extensively. However the identification and 
determination of responses mediated by (%2 -adrenoceptors in arteries has proved more 
difficult. Contractions in the venous circulation have been subtyped and generally 
result from stimulation of a^A/o receptors. One notable exception to this is the human 
saphenous vein. There, contractile responses are mediated by the a 2 c-i'eceptor subtype 
and are not mediated by the a 2 A/o [Gavin et al, 1997].
1.2.2 Presvnaptic m-adrenoceptors
a 2 -adrenoceptors are expressed in the nucleus tractus solitaris and nucleus reticularis 
lateralis. Both of these areas of the brain are actively involved in the control of blood 
pressure [Rosin et al, 1993], leading to the hypothesis that, presynaptic (Xz- 
adrenoceptors are involved in the control of blood pressure. Stimulation of 0 (2 - 
adrenoceptors in the nucleus tractus solitaiis reduces vasomotor tone, and leads to 
hypotension [Zendberg et al, 1979].
Autoreceptors regulate the release of their own transmitter, while heteroreceptors 
modulate the release of transmitters acting upon other receptor subtypes [Starke et al, 
1989]. (%2 -adrenoceptors can be defined as autoreceptors, because they inhibit the 
release of noradrenaline from presynaptic nerve terminals. Early work to elucidate the 
functional responses controlled by (%2 -adrenoceptors suggested that all a 2 -adrenoceptors 
were located on the presynaptic terminal, where they act solely to regulate the release of 
noradrenaline from nerve teiminals by means of a negative feedback loop [Starke et al.
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1975]. The regulatory role of « 2 -adrenoceptors in mediating autoinhibition of 
noradrenaline release is now widely accepted [Starke, 2001]. While aa-adrenoceptors 
oppose further noradrenaline release, it is interesting to note that p-adrenoceptors 
actually enhance noradrenaline release [Starke et al, 1989].
..'î(%2 A/D and oc2 c-adrenoceptors regulate the release of noradrenaline from sympathetic 
nerve terminals. Inhibitory actions of the (X2 a/d receptor appear to occur more rapidly 
than those mediated by the a 2 c-adrenoceptor. An explanation for this may be that 
expression levels of each subtype are different in neonates. Indeed it has since been 
shown that (X2A/D-mediated autoinhibition exists at birth, while a2c-mediated reductions 
in noradrenaline release are not established until much later in murine development 
[Schelb et al, 2001].
When ot2 A/D and Œ2 c receptors are expressed in the same cell line, their ability to 
activate potassium and calcium channels is comparable, as are their expression levels 
[Bunemann et al, 2001]. However, when activated, a 2 c-receptors remain activated after 
%A/D-rnediated inhibition of noradrenaline release has ceased. a2c-adrenoceptors have 
a higher affinity for noradrenaline than the a 2 A/o [Link et al, 1992]. This higher affinity 
suggests that the a 2 c-adrenoceptor may control transmitter release at low frequency 
stimulation, while the (%2 A/D responds to, and regulates, noradr enaline release after 
maximum nerve activity. So the differences in noradrenaline sensitivity between the 
0 C2 A/D and a 2 c~adrenoceptors can be explained by altered receptor activation kinetics 
[Bunemann et al, 2001]. The a 2 B-adrenoceptor does not regulate noradrenaline release
A
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from sympathetic nerve terminals [Bucheler et al, 2002], but does control noradrenaline 
release from the rat thalamic nuclei [MacDonald & Scheinin, 1995].
The levels of noradrenaline found in human tissues increase with advancing age, which 
has been proposed to be due to a decline in central aa-adrenoceptor inhibitory effects 
[Zeigier et al, 1976]. Alternatively, it may be a result of a decrease in neuronal uptake, 
or possibly a combination of both. This area has not been fully explored, and future 
work will be of great importance for the treatment of hypertension.
(XzA/D-adrenoceptors regulate sympathetic nerve activity in a variety of species. Many 
of the experiments performed that led to this conclusion were carried out in mice 
lacking functional azA/n, oczb and azc-adrenoceptors. Kable and co workers used these 
tools to confirm earlier findings, which suggested that oczA/D and azc-adrenoceptors 
regulate ‘negative feedback’ of neuronal noradrenaline [Kable et al, 2000].
The regulation of noradrenaline and dopamine levels in the murine brain appears to be 
controlled by two az-adrenoceptor subtypes. This has since been confirmed by the use 
of mice harbouring gene-directed deletions of each az-adrenoceptor subtype. The 
principal subtype responsible for the control of dopamine release is thought to be the 
cozA/D-subtype [Trendelenburg et al, 1994]. The (Xzc subtype, which is expressed at 
much lower levels in the murine brain, plays a secondary role [Tavaret et al, 1996].
Therefore, central ocz-adrenoceptors act not only as autoreceptors, by inhibiting the 
release of noradrenaline, they also act as heteroreceptors by regulating dopamine 
release. The subtype responsible for the control of dopamine release in the rodent brain
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has been proposed to be the (XzA/o-subtype [Trendelenburg et al, 1994]. Dopamine and 
noradrenaline release ai'e regulated by (%2 -adrenoceptors, as is the control of 
acetylcholine from cholinergic motor neurons [Scheibner et al, 2002]. Non-selective 
stimulation of az-receptors decreases noradrenaline release by 96% in the cortex of the 
murine brain and reduces dopamine release from the basal ganglia by 76%.
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So how does stimulation of an az-adrenoceptor cause a decrease in noradrenaline 
release from sympathetic nerve terminals? Two possible modes of action have been 
suggested. In the locus coeruleus, an increase in K conductance mediates inhibition of
noradrenaline release from adrenergic nerves, and has been proposed to participate in 
the response in other anatomical locations [Starke et al, 1989]. However, the hypothesis 
that is the major ion responsible for modulation of noradionline release is debatable, 
because many studies have shown that an inhibition of Ca^^ entry, following nerve 
depolarisation prevents autoinhibtion, thus preventing exocytosis of vesicles enriched 
with neurotransmitters [Starke et al, 1989]. ttz-adrenoceptors located on neurones within 
the central nervous system inhibit P, Q and N type calcium channels upon activation 
[Delmas et al, 1999].
1.2.3 Desensitisation of az-adrenoeeptors
Desensitisation of presynaptic az-adrencoceptors occurs in the mouse atria [Bucheler et 
al, 2002]. In vitro studies have shown that az-adrenoceptors are prone to agonist- 
induced receptor desensitisation [Eason et al, 1992]. Furthermore, Bucheler and 
colleagues demonstrated that prolonged exposure to selective agonists attenuates azc- 
mediated autoinhibition [Bucheler et al, 2002], and consecutive noradrenaline response 
curves have a progressive reduction in maximal responses, which is indicative of
i
receptor desensitisation [Rodiiguez-Martinez et al, 1999]. This may be the result of 
desensitised az-adrenoceptors. Taken together, this provides evidence that az- 
adrenoceptors are susceptible to desensitisation.
1.2.4 Postsvnaptic az-adrenocentors
Studying the responses mediated by prejunctional az receptors has been relatively easy 
compared with the problems associated with the identification of postjunctional az- 
adrenoceptor-mediated responses, in vitro. In vivo az-adrenoceptor-mediated responses 
play a key role in the regulation of cardiovascular function in the central nervous 
system, and in the periphery. In the pithed rat, postsynaptic az-adrenoceptors mediate 
vasoconstrictor responses [Docherty & McGrath, 1980]. Vascular contractions of 
peripheral blood vessels following stimulation of az receptors have been attributed to 
activation of azA/o-adrenoceptors. This hypothesis is supported by studies in the D79N 
azA/D mutant mouse, where vasoconstrictor responses to az agonists aie absent m vivo 
[MacMillan et al, 1996].
Agonist-induced contractions of isolated aortic rings from female azA/o knockout mice 
ai'e significantly smaller in size than responses gained in control arteries [Vandeputte & 
Docherty, 2001]. Yohimbine is a relatively non-selective az-adrenoceptor antagonist, 
but has slightly higher affinity for the azB and azc-adrenoceptors over the OzA subtype 
[Link et al, 1992]. Yohimbine enhances noradrenaline-mediated contractions in aorta 
from control but not from azA/o knockout mice. Surprisingly, this suggests that the 
azA/D receptor may act to inhibit noradrenaline-evoked contractions in the aoita.
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In « 2 a/d knockout mice noradrenaline administered in the presence of an a i antagonist 
has no effect on resting blood pressure [Duka et al, 2000]. However in azB and oczc 
knockouts an alteration in blood pressure responses is observed [Duka et al, 2000]. This 
data suggests that the azA/o receptor is responsible for peripheral vasoconstrictor 
responses. Yet, the initial pressor response occurring after intravenous administration 
of an az agonist is lost in azB knockout mice [Link et al, 1996]. In addition to 
peripheral effects on arteries, az-adrenoceptors cause contraction of veins, in particular 
the saphenous vein of the rabbit [Daly, 1993] and human [Gavin et al, 1997].
1.2.5 Cellular location of az-adrenoceptors
The location of az-adrenoceptors within a cell may dictate their function. In order to 
ascertain if this is the case, a number of studies have been carried out to determine 
where each az-subtype resides in a cell. In cultured, transfected fibroblasts azA/o and 
azB-adrenoceptors are located on the plasma membrane after receptor activation, but 
only the azB exhibits reversible endocytosis [Daunt et al, 1997]. Quiescent azc- 
receptors are found in close association with the golgi and endoplasmic reticulum.
Upon activation and/or exposure to cold temperatures, these receptors translocate to the 
plasma membrane [Jeyaraj et al, 2001], where they mediated enhanced contractile 
responses [Chotani et al, 2000].
1 .2 . 6  a? selective ligands
Clonidine has been used as an az-selective agonist, but has affinity for both a i and az- 
adrenoceptors [Millan et al, 2000]. Chloroethylclonidine (CEC) is an alkylating 
analogue of clonidine and has affinity for all a i and az adrenoceptor subtypes [Michel
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et al, 1993]. Unlike clonidine, CEC is an irreversible agonist of az-adrenoceptors, but is 
frequently used to distinguish responses mediated by the aiB-adrenoceptor, because it 
alkylates plasma membrane-bound receptors [Nunes & Guimares, 1993].
Xylazine, is an az-receptor agonist, which causes concentration-dependent contractions 
of the guinea pig epididymis, when this tissue has been precontracted with 
phenylephrine [Haynes et al, 1999]. Incubation of the Gia2 mRNA antisense 
oligonucleotide attenuates xylazine-mediated contractions, without affecting tissue 
sensitivity. It appears that in the guinea pig epididymis az-adrenoceptors cause 
contractions in preconstricted tissues by coupling to the Gia2 receptor subunit [Haynes 
etal, 1999].
In the human saphenous vein, stimulation of postjunctional az receptors leads to the 
development of contractile responses. Surprisingly, in this blood vessel, ai-mediated 
vasoconstrictions are essentially absent [Docherty, 1998]. The az adrenoceptor 
responsible for contraction in this blood vessel is proposed to be the azc-subtype [Gavin 
et al, 1997]. az-mediated contractile responses have also been shown in blood vessels 
from the pig and the dog [Hicks et al, 1991].
I
1.2.7 Responses mediated bv a^-adrenoceptors arc affected bv increasing age 
Cerebral arteries from young and old sheep contract in response to az-selective agonists 
[Bishai et al, 2002]. The expression levels and density of az-adrenoceptors is greater in 
foetal arteries when compared with cerebral arteries from mature sheep [Bishai et al, 
2002]. Cerebral arteries from sheep in utero express both pre and postsynaptic az~
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adrenoceptors. However, in cerebral blood vessels from mature sheep, contractile 
responses resulting from activation of postjunctional (%2 -adrenoceptors cannot be 
detected [Bishani et al, 2002]. This suggests that the expression of az-adrenoceptors in 
cerebral arteries decreases with advancing age, the process whereby this occurs, and the 
physiological significance has yet to be determined.
1 .2 . 8  az-mediated relaxant responses
An intact, functional endothelial surface is essential for the maintenance of 
physiological functioning of a blood vessel [Busse et al, 1998]. az-adrenoceptor- 
mediated relaxations require an intact endothelium and have been studied in coronary, 
renal and mesenteric arteries [Cocks & Angus, 1983]. In porcine coronary arteries the 
azA/D and azc-adrenoceptor subtypes are both expressed. Although the azc- 
adrenoceptors is expressed at a much greater level, it is the azA/o-adrenoceptor that 
mediates endothelium-derived relaxations in this artery, az-mediated responses were
characterized with [^H] rauwolscine in endothelial membrane preparations. The 
competition binding curves and the use of ligands, proposed to distinguish between the 
two subtypes suggests that the azA/o-adrenoceptor mediates relaxant responses
I
[Bockman et al, 1993]. az-mediated vasodilatations have also been studied in the rat. 
Stimulation of endothelial azA/o-adrenoceptors, in the rat mesenteric resistance arteries 
causes relaxation, which is due to altered cAMP levels [Bockman et al, 1996].
1.2.9 Tail arterv
Activation of postjunctional azc-adrenoceptors in the rat tail leads to vasoconstrictor 
responses [Craig et al, 1995]. The rat and mouse tail artery have a dense sympathetic 
innervation and contain a functional population of az-adrenoceptors [Medgett &
I
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Langer, 1984], which are most probably both pre and postjunctional in location. 
Catecholamine-mediated contractions of this artery tend to increase in size in older 
animals. The increase in maximal contractions and changes in agonist sensitivity may 
be a result of altered oxidative stress [Diaz-Velez et al, 1996].
Malondialdehyde (MDA) is used as a marker for increased oxidative stress in an artery; 
high MDA levels are indicative of elevated oxygen radicals, which lead to vascular 
injury [Janero et al, 1990]. Enhanced plasma MDA levels have been reported in 
humans showing eaiiy signs of vascular disease [Sanderson et al, 1995].
In the rat tail artery plasma oxidative stress is elevated with age, evidenced by an 
increase in MDA and decreased levels of glutathione peroxidase in older animals 
[Rodriguez-Mai'tinez et al, 1999]. MDA potentiates noradrenaline-evoked contractions 
in tail arteries from young, old and very old rats, but has no effect on catecholamine 
sensitivity.
Superoxide dismutase scavenges oxygen radicals, and in the rat tail artery has been 
shown to reverse age related changes in agonist responses, while hydrogen peroxide and 
scavengers of hydroxyl radicals were ineffective [Tsai et al, 1993]. Scavenging oxygen 
and hydroxyl radicals may reduce the supersensitivity to exogenous and endogenous 
agonists that often occurs in aiteries from elderly patients. In doing so it may help to 
reverse functional alterations that can contribute to the development of pathological 
conditions.
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1.2.10 Development of contractile responses in the rodent tail arterv 
ai-mediated contraction of the rat and mouse tail artery are predominantly mediated by 
the aiA-subtype, with little, if any, contribution for the am  and am-adrenoceptors 
Piascik et al, 1996, Daly et al, 2002]. The rat tail artery receives a rich blood supply via 
three arteries and veins which run the entire length of the tail, making this an important 
organ involved in thermoregulatory control [Rand et al, 1965].
Mibefradil is a non-selective calcium channel antagonist that blocks L, T and N type 
calcium channels [Bezprozvanny & Tsien, 1995]. Contractions mediated by 
endogenous catecholamines all depend on calcium, evidenced by the inhibiting effects 
of calcium antagonists such as mibefradil. Given our knowledge of this drug, it seems 
likely that transmitter release is inhibited by blocking N type calcium channels located 
on the prejunctional sympathetic nerve [van der Lee et al, 2000].
lit
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Xiao and colleagues have shown that az-mediated vasoconstriction can enhance 
responses to a i agonists in the rat tail artery, by altering calcium levels [Xiao et al, 
1989]. Noradrenaline causes contractions in proximal sections of the rat tail artery in a 
concentration-dependent manner [Medgett et al, 1984]. In hypertension noradrenaline 
contractions are enhanced [Medgett et al, 1984]. Enhanced az-adrenoceptors-mediated 
responses can be affected by prostaglandin release, which often complicates the 
interpretation of data. To prevent this, a number of blocking agents need to be used 
during experiments.
The development and study of responses mediated by postjuctional az-adrenoceptors 
have proven difficult to study in vitro. One possible explanation for this is that in vitro
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conditions do not mimic those in vivo. In the rat tail artery inereasing the level of tone 
with arginine vasopressin allows az-mediated vasoconstrictor responses to be studied 
[Templeton et al, 1989]. This was a major breakthrough in the study of az-mediated 
responses. However, the responses gained display a high degree of variability and 
depend on the synergist used to raise tone, and the species used to study vascular 
responses. In proximal arterioles of the rat intestine sympathetic-induced elevations in 
vascular tone, did not reveal az-mediated contractile or relaxant responses. This data 
indicates that, at least in proximal arterioles, postjunctional az-adrenoceptors are 
essentially absent [Nase & Boegehold, 1998].
1.2.11 Thermore gul ation
The tail artery is an important organ involved in thermoregulatory control in the rodent. 
Due to this, vascular responses of the tail aitery from mice and rats have been studied at 
varying experimental temperatures. Maintaining low temperatures of 28^C enhances 
az-mediated vasoconstrictions in cutaneous arteries of the mouse. The effect of 
temperature on contractile responses is proposed to result from the activation of 
quiescent azc adrenoceptors, which then participate in vascular contractility [Chotani et 
al, 2000].
In addition to the local effects of temperature, stimulation of central az-adrenoceptors 
causes a reduction in core body temperature. These hypotheimic responses are absent 
in D79N mice, but dose-dependent reductions in core body temperature occur in WT, 
azB and azc knockout mice [Hunter et al, 1997]. In human and animal species, the azc- 
adrenoceptor has been implicated in the development of responses to cooling in limb 
and saphenous veins [Vanhoutte et al, 1985, Vanhoutte & Flavahan 1986, Chotani et al,
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2000]. Central azc-adrenoceptors have since been proposed to play a minor role in the 
control of hypothermic responses, because in the azc knockout mouse, hypothermic 
responses that normally result from stimulation of central az-adrenoceptors aie 
abolished [Sallinen et al, 1997].
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Reducing the experimental temperature to 28^C causes a significant enhancement of 
UK14304-mediated contractions, in pressurised, myograph mounted aiterial segments. 
The potentiation in responses is confined to the distal end of the murine tail, where a%- 
mediated contractions are attenuated [Chotani et al, 2000]. In HEK 293 cells 
stimulation of expressed azc-adrenoceptors at 37^C (with an az-selective agonist) has 
no effect on forskolin-induced cAMP accumulation. However, at 28 C, activation of
azc-adrenoceptors causes a concentration-related reduction in cAMP production. 
Subcellular fractioning of HEK 293 cells shows that at 37°C the azA-subtype is 
primarily located on the plasma membrane, while azc-adrenoceptors are sequestered on 
intracellular organelles, such as the golgi. [Jeyaraj et al, 2001]. However, at 28^C, the 
azc-adrenoceptor translocates to the plasma membrane, where its expression becomes 
greater than that of the azA subtype. Evidence in support of this hypothesis is provided 
by the use of the drug, MK912. MK912 is an antagonist proposed to be selective for the 
azc-adrenoceptor, and at 28*^0, MK912 competitively antagonises az-adrenoceptor 
mediated contractile responses of the pressurised tail artery [Chotani et al, 2000].
Patients suffering from Raynaud’s phenomenon experience involuntary, vasospastic 
contractions of the fingers and toes. This is usually triggered by exposure to extremely 
cold temperatures, azc-mediated contractions are enhanced in Raynaud’s [Freedman et
al, 1989]. Given this, drugs that selectively antagonise contractile responses-mediated 
by this receptor subtype may have therapeutic benefits over non-selective antagonists.
Noradrenaline and phenylephrine cause concentration-dependent contractions of human 
hand veins, with noradrenaline being twenty four times more potent that phenylephrine. 
Enhanced sensitivity to noradrenaline indicates the presence of az-adrenoceptors in 
human hand veins, that when stimulated participate in contractile responses. Prazosin 
and rauwolscine, given alone, failed to attenuate noradrenaline-mediated contractions 
but a combination of both drugs abolishes catecholamine-induced contractions.
In addition to the az-adrenoceptor-mediated response, stimulation of 5HT receptors has 
also been shown to lead to contraction of human hand veins. Ketanserin and 
methergoline are antagonists at 5HT receptors. Ketanserin competitively inhibits 5HT- 
mediated contractions in human hand veins, while methergoline causes a significant 
reduction in maximal contractions. From this data it appears that contractions of human 
hand veins results from activation of a mixed population of receptors that include a%, Og 
and 5HT receptors [Amer & Hogestatt, 1986].
1.2.12 Effect of ai-adrenoceptor stimulation on gastrointestinal motilitv and gastric 
sections
In vivo, the az-agonist clonidine causes a significant decrease in gastrointestinal 
motility, and abolishes cholinergic mediated contractions. Histamine is known to 
inhibit gastrointestinal motility. Surprisingly, az-mediated inhibition of gut motility is 
significantly greater than the inhibitory effects of histamine at comparable doses 
[Pozzoli et al, 2002].
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Functional ag-adrenoceptors are expressed on cholinergic nerve terminals, and are 
involved in the regulation of gastric acid secretion [Tazi-Saad et al, 1992].
Furthermore, studies in pylorus-ligated rats have shown that intracerebroventricular 
(i.c.v) injections of clonidine or oxymetazoline cause a dose-dependent reduction in 
gastric acid secretion [Mullner et al, 2002]. The inhibitory effect of clonidine on gastric 
acid secretion is due in pait, to stimulation of az-adrenoceptors located on presynaptic 
fibres in the stomach lining [Mullner et al, 2002]. In the pylorus-ligated rat the major 
anti secretory effect of az-agonists can be attributed to central azA/o-adrenoceptors. 
Direct, gastroprotective effects of stimulating az-adrenoceptors in the stomach appear to 
be mediated by the azs-receptor subtype [Gyires et al, 2000b].
Mullner and co-workers found that the anti secretory actions of clonidine and 
oxymetazoline are inhibited by the opioid-selective antagonists naloxone and 
matrindole. In addition to this the | L t / ô  opioid agonist ^-endorphin causes comparable 
decreases in gastric acid secretion to those produced by az-adrenoceptor ligands. This 
led to the hypothesis, that the antisecretory actions of clonidine cannot be attributed to 
direct stimulation of az-adrenoceptors. Indeed, the antihypertensive and 
gastroprotective effects of clonidine have been proposed to result from opioid receptor 
activation [Gyires et al, 2000c].
Agonists that stimulate az and opioid receptors cause hyperpolarisation of neurones by 
increasing potassium conductance [North et al, 1987]. In the pylori-ligated rat i.c.v 
injections of glibenclamide, a K a t p  channel antagonist, prevent the antisecretory effects 
of clonidine, oxymetazoline and p-endorphin. Whether az-adrenoceptors indirectly
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cause K a t p  channel activation, or promote the release of endogenous agonists such as p ~  
endorphin that act upon opioid receptors to stimulate K a t p  channels, requires further 
investigation [Mullner et al, 2002].
oczA/D adrenoceptors found within the gastrointestinal tract act solely to inhibit further 
transmitter release, unlike the inhibitory functions of az-adrenoceptors located in the 
central nervous system, which require assistance from the azc-receptor subtype 
[Scheibner et al, 2002].
1.2.13 a? A/n-adrenoceptors
Transgenic mice with mutated or deleted receptors are useful tools in elucidating the 
functions of individual adrenoceptor subtypes. Gene targeting causes a point mutation 
of an asparagine for an aspartate at position 79 of the second transmembrane spanning 
domain of the azA/o-adrenoceptor; a mutation which is expressed in the D79N mouse. 
This substitution mutation selectively uncouples the azA/o-adrenceptor from its K^ 
channel, but activation of voltage gated Ca^ '*' channels is unaffected [Suprenant et al,
1992]. Remarkably, although this is not a receptor knockout, binding analysis in 
isolated brain membranes reveals an eighty percent reduction in available receptor 
binding sites. So in essence the D79N mutation acts as a functional knockout. The 
remaining azA/o-adrenoceptors in the D79N mouse are functional, and bind ligands 
normally [MacMillan et al, 1996].
In the D79N mouse, baseline blood pressure is unchanged compared with WT controls. 
Upon administration of UK14304 or dexmedetomidine (proposed to be selective 
agonists for az-adrenoceptors), there is an attenuated decrease in blood pressure and
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heart rate in the D79N, compared with controls. This indicates that the blood pressure 
lowering effects of central az-adrenoceptors are lost in this mouse. This supports the 
hypothesis that the azA/D subtype is responsible for the hypotensive effects of slective 
az-agonists. Although devoid of central azA/o mediated effects; in the periphery, the 
D79N mouse has a sufficient receptor reserve, capable of mediating contractions that 
result from activation of az-adrenoceptors.
E xp ression  lev e ls  o f  az-adrenoceptors have been  m easured to determ ine i f  rem oval o f  
on e reeeptor leads to upregulation  o f  the other az-adrenoceptors-subtypes. In m ice  
hai'bouring knockouts o f  the azA/o, oczb or azc-adrenoceptor the exp ression  lev e ls  o f  the 
rem aining az-adrenoceptor subtypes are unchanged  [Link et al, 1995 &  A ltm an et al, 
1999]. F unctional studies earn ed  out in the D79N and azA/o knockout m ou se, confirm  
that central azA /o-adrenoceptors m ed iate  h yp oten sive  responses to a z  agon ists. W h ile  in 
the azB knockout m ou se az-m ed iated  pressor resp on ses are absent. T his led  the authors 
to con clu d e that azB-adrenoceptors m ediate vasoconstrictor resp on ses to a z -se lec tiv e  
ligands [M acM illan  et al, 1996]. A lth ou gh  prev iou sly  used  as su ccessfu l  
antihypertensives, stim ulation o f  az-adrenoceptors, w ith se lec tiv e  agon ists, produces a 
num ber o f  unw anted  side effects. T h ese  in clu d e a dry m outh and sedation; both o f  
w h ich  have been  attributed to the azA/o-receptor subtype. T h is precludes the u se  o f  
such com pounds, as their b en efic ia l e ffects  cannot be ach ieved  w ithout causing  
unw anted sid e  effects.
D e le tio n  o f  the azA/o-adrenoceptor cau ses an increase in sym pathetic ou tflow . T he  
azA/D knockout m ou se is tachycardie at rest and has d ep leted  noradrenaline tissu e  lev e ls .
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These changes are accompanied by a down regulation of (3-adrenoceptors in cardiac 
tissue [Altman et al, 1999].
Analysis of functional responses in the cczA/o, 0 C2 B and azc knockouts and in the D79N 
mouse, have shown that the major adrenoceptor subtype controlling sympathetic 
outflow is the azA/o- Electrical stimulation of adrenergic nerves in the mouse vas 
deferens promotes the release of endogenous noradrenaline, and leads to contractile 
responses. The presence of an az-agonist prevents these contractions from developing. 
In the D79N, the inhibitory effect of az-agonists is significantly reduced, but not 
abolished, suggesting the involvement of another receptor in the regulation of 
noradrenaline release [Altman et al, 1999]. In the rat atria azA/o-mediated 
autoinhibition of noradrenaline release also appears to be assisted by another az- 
receptor subtype.
D79N mice and azA/o knockouts have different resting heart rates, with the azA/o 
knockout having a higher rate per minute than the D79N. An explanation for the 
different resting heart rates in these animal models may be that the combined removal of 
central and peripheral azA/o-mediated responses in the knockout leads to an increase in 
heart rate. In the D79N mutant, there may be a sufficient receptor reserve in the 
peripheral circulation to prevent an elevation in resting heart rate [Altman et al, 1999].
Chronic exposure to noradrenaline leads to a downregulation of P-adrenoceptors in 
cardiac tissue [Chang et al, 1982]. In mice lacking functional azA/o-adreno cep tors there 
is a twenty-five percent reduction in functional P-adrenoceptors compared with control
animals [Altman et al, 1999]. The downregulation of p-adrenoceptors probably results 
from overexposure to noradrenaline. In the absence of functional (XzA/D-receptors, 
noradrenaline release from adjacent sympathetic nerve terminals can occur unchecked, 
and persistent stimulation of p-adrenoceptors leads to a downregulation in the number 
of receptors expressed.
%  agonists stim ulate central az-adrenoceptors, w h ich  causes a decrease in  sym pathetic  
ou tflow  (fo llo w in g  pressor e ffec ts), w h ich  u ltim ately  leads to a drop in  b lo o d  pressure, 
w h ile  stim ulation  o f  peripheral azB-adrenoceptors, m ediates pressor e ffects  by  
activating peripheral receptors, w h ich  leads to vascular contraction [Gavras et al, 2001]. 
In con sc io u s, unrestrained h eterozygou s azB knockout m ice , the pressor e ffects o f  az- 
adrenoceptor agonists a ie  absent, w h ile  azA/o-m ediated h yp oten sive  responses rem ain, 
and are potentiated in s ize , but the bradycardia norm ally ob served  w h en  central az- 
adrenoceptor are stim ulated , is  u naffected  [L ink et al, 1996]. T he azc-adrenoceptor has 
not been  im plicated  in  the resgulation  o f  b lood  pressure, but stim ulation o f  this subtype  
appears to b e  responsib le  for enhanced  vasoconstrictor responses at 28^C, a function  
that m ay be im portant in  controlling  b lood  flo w  to ex p o sed  tissu es, such as the digits  
[Chotani et al, 2000].
1.2.14 a 9 R-adrenoceptors
G enerally , exp ression  lev e ls  o f  the azB -adrenoceptor are m uch low er  than the azA/o in  
the central nervous system . azB exp ression  is  concentrated in  tw o  m ain areas o f  the 
brain and these are the thalam us and nucleus tractus solitaris area o f  the brain stem  
[Tavares et al, 1996]. In the peripheral circulation, there is m ore d iffu se  exp ression  o f
89
the azB-receptor than in central areas. azB-adrenoceptors located on vascular smooth 
muscle are thought to mediate peripheral vasoconstrictor responses to az-agonists [Link 
et al, 1996]. The majority of results that support this hypothesis have come from 
experiments on transgenic mice. In azB knockout mice, the pressor responses that 
normally precede blood pressure lowering effeets of az agonists are absent [Hein et al, 
1998]. In addition to the effects of central az-adrenoceptors, studies in the rat have 
revealed that the azB-adrenoceptor-subtype is the dominant adrenoceptor found in the 
kidney [Pettinger et al, 1987].
1.2.15 Fertilitv and sexual development
T ransgenic m ice  harbouring a g en e directed  deletion  o f  the azB-adrenoceptor have been  
produced by m anipulation o f  m urine gen es u sin g  m olecu lar techn iques. H ow ever  
h om o zy g o u s azB knockouts do not breed w e ll, and therefore o n ly  h eterozygou s  
knockouts have b een  u sed  for experim entation  [M akaritsis et al, 1999]. T he fact that 
h om o zy g o u s knockouts have reduced fertility , su ggests that the azB-adrenoceptor is  
im portant in sexu al d evelop m en t and/or m ay be essen tia l for the m aintenance o f  fertility  
[A ltm an et al, 1999], both o f  th ese  areas o f  study require further investigation .
H eterozygou s azB knockouts sh ow  a sign ifican t reduction in azB-receptor exp ression  
lev e ls  [L ink et al, 1996]. T h ey  have low er  end poin t b lo o d  pressure than WT controls, 
and are unable to increase b lo o d  pressure in resp on se  to salt load in g  and subtotal 
nephrectom y [M akaritsis et al, 1999]. G iven  this they have b een  deem ed  suitable  
m od els for studying the resp on ses m ed iated  b y  azB-adrenoceptors.
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1.2.16 Œzr Adrenoceptors
Stimulation of az-adrenoceptors with selective agonists such as clonidine and xylazine 
cause a number of clinically important cardiovascular effects, none of which have been 
attributed to stimulation of the azc-receptor subtype. The majority of responses 
mediated by central azc-adrenoceptors appear to be secondary to the dominant role of 
the azA/D subtype in regulating the release of noradrenaline from presynaptic nerve 
terminals.
Mice overexpressing the azc-adrenoceptor are healthy, and sexually viable receptor 
[Sallinen et al, 1997]. Overexpressing the azc-adrenoceptor leads to enhanced 
dopamine turnover, while azc knockouts exhibit diminished dopamine levels compared 
with controls [Sallinen et al, 1997]. This suggests that the azc-adrenoceptor regulates 
dopamine release, in addition to noradrenaline, and therefore acts not only as an 
autoreceptor, but also as a heteroreceptor. These finding are extremely important 
because dopamine levels are an important determinant of mood, and behaviour. 
Furthermore, stress-dependent depression is altered by genetic mutations of the azc- 
adrenoceptor [Sallinen et al, 1997].
1.2.17 Blood pressure regulation
Hypertension is diagnosed following a period of elevated blood pressure, which 
normally is the result of a persistent increase in resistance to blood flow. High blood 
pressure is regained as a major risk factor for the development of other cardiovascular 
diseases, such as atherosclerosis and heart failure. The incidence of hypertension in the 
developed world has now reached epidemic proportions, hence the need for intensive 
research in this field.
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az-adrenoceptors are important regulators of cerebrovascular tone in a variety of animal 
species, including humans [Usui et al, 1985]. Under hypoxic conditions and in 
hypertension adrenergic nerves appear to maintain vascular tone in cerebral arteries 
[Busija & Heistad, 1984], but this depends on the species studied. For example, in 
canine cerebral arteries, az-adrenoceptors play only a minor role in mediating 
vasoconstrictor responses [McPherson et al, 1994].
Patients at risk of developing hypertension participated in a series of haemodynamic 
and biochemical studies. A significant number of these patients had abnormal 
responses to az-selective ligands. These findings suggest that the az-adrenoeeptor is 
involved in the development of hypertension before the onset of clinical symptoms 
[Dao et al, 1998]. The azA/o receptor is a potential target for subtype selective 
antihypertensives, as this receptor is responsible for the prolonged hypotensive effects 
of oral and intravenous az agonists [Altman et al, 1999]. However, the side effects 
associated with stimulation of peripheral receptors preclude their use in a clinical 
setting.
1.2.18 Development of Salt sensitivitv in hvnertension
Salt sensitivity is a frequent complication that develops in patients with essential 
hypertension. Experimentally, salt sensitivity ean be induced in animal models by 
giving high doses of salt in drinking water with noimal feeding. In addition to other 
risk factors, increased age and impaired renal function can enhance salt sensitivity in 
patients with essential hypertension [Oparil et al, 1988].
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The development of salt sensitivity appears to depend on the expression of functional 
az-adrenoceptors. Therefore it has been suggested that genetic background may 
predispose certain ethnic groups to develop salt sensitivity with hypertension. One 
example of this is the prevalence of the development of salt sensitivity with 
hypertension in the African American community [Oparil et al, 1988]. Whether 
individuals within this race have altered expression levels of az-adrenoeeptors has yet to 
be confirmed. All that is known is that both the sympathetic nervous system and az- 
adrenoceptors play a role in the development of salt sensitivity in hypertension [Tsai & 
Lefkowitz, 1978].
azB-adrenoceptors m ediate contractile resp on ses in  peripheral arteries, and h ave been  
im plicated  in the d evelop m en t o f  sa lt-sen sitiv ity  w ith  hypertension , b ecau se  fo llo w in g  
subtotal nephrectom y azB knockout m ice  are resistance to salt load in g  [Gavras et al, 
2001]. N ep h rectom y and salt in fu sion , cau ses a slight decrease in  system ic  b lood  
pressure in  the azB knockout, w h ile  azA/o and azc-k n ock ou ts and W T  controls have  
eleva ted  b lood  pressure [M akaritsis et al, 1999]. T he elevation  in  b lood  pressure cau sed  
by salt load ing  has sin ce  been  attributed to central azB -teceptors, and appears to be  
independent o f  peripheral receptors [K intsurashili et al, 2002].
1.2.19 Svmoathetic nervous svstem: A role in hvpeitension?
In addition to transgenic mice, two non-genomic models of human hypertension have 
been developed in the mouse; these are the renovascular two-kidney models, and the 
mineralocorticoid deoxycorticosterone-salt induced model of hypertension [Conrado et 
al, 1996].
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It is well known, and documented that the sympathetic nervous system is involved in
:
the control of blood pressure. Hence, this has become an area of great interest in 
relation to the development, and maintenance of hypertension. Research has focused on 
studying the changes that occur within the sympathetic nervous system in animal 
models with established hypertension [Mark et al, 1996].
Sympathetic nerve endings release noradrenaline as their primary transmitter in addition 
to other vasoactive substances sueh as ATP [Vanhoutte & Luscher, 1986]. Enhanced 
noradrenaline release often results from an elevation in sympathetic tone. Elevated 
sympathetic tone can, in turn, lead to an increase in blood pressure and, hence, will 
ultimately lead to a hypertensive state in humans and animal models [Eerrier et al,
1993].
Inhibition of nitric oxide synthase causes hypertension to develop in the rat. In vitro.
contractile responses mediated by az-adrenoceptors have been studied in arteries 
isolated from hypertensive animals when the activity of nitric oxide synthase has been 
prevented in vivo. Contractile responses are significantly enhanced in arteries from 
animals treated with L-NAME. The enhancement in contractility appears to be caused
by the activation of two pathways, both of which involve calcium. One is a Ca^ '*'
:
pathway independent of tyrosine kinase; the second is tyrosine kinase-dependent, and 
controls intracellular Ca^ "^  concentrations [Caiter & Kanagy, 2002].
A technique used to determine the activity of the sympathetic nervous system in humans 
in microneurography; where an electrode takes electrical recordings from patient’s 
arteries [Delius et al, 1972]. This gives an indication of muscle sympathetic activity
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(MSA), and reflects the output of the sympathetic nervous system as a whole. A great 
deal of research has focused on this area because MSA is a major contributor to 
peripheral resistance, and measurements of MSA offer a non-invasive technique 
whereby alterations in sympathetic discharge patterns can be studied in 
pathophysiological situations. In young and borderline hypertensives, increases in 
MSA are common [Anderson et al, 1989, Lawton et al, 1990]. These patients also show 
alterations in sympathetic dischaige patterns following exposure to elevated external 
stress factors.
1.2.20 Structural changes occumng in hvpertension
Structural changes in the architecture of the vascular wall from patients with 
hypertension were first recorded over one hundred and fifty years ago. Yet the 
mechanisms leading to these structural alterations, and the order in which they develop, 
are still unknown. In fact, the distribution of cells within a healthy blood vessel wall is 
still poorly defined. But advances in confocal microscopy and the availability of 
fluorescent ligands have advanced our knowledge greatly.
Essential hypertension may be the result of endothelial dysfunction, possibly due to a 
lack of az-mediated relaxant responses. This seems unlikely because it is well 
established that conection of hypercholesterolaemia can reverse endothelial 
dysfunction. Furtheimore, blocking the release of oxygen radicals reverses 
hyperhomocysteinemia, which enhances flow-induced dilatations of coronary arteries 
[Ungvari et al, 2003]. Hypertension may also develop when receptors, located on the 
vascular wall, become supersensitive to endogenous agonists. Although increased 
contractile responses are common in blood vessels from hypertensives, data in support
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of this hypothesis is often contradictory. It seems more likely that uncontrolled cell 
growth leads to vascular changes that increase pressure levels within blood vessels. As 
yet, the triggers for uncontrolled growth have not been established [Cooper, 1997].
The most common structural alteration that occurs in resistance arteries, isolated from 
hypertensive humans and animals is a reduced lumen size and an increase in the 
media:lumen ratio [Anibas et ai, 1997]. An altered media to lumen ratio is indicative of 
vaseular remodelling, and can be defined as a rearrangement of cells already present 
within the vascular wall. Vascular remodelling is quite distinct from vascular 
hypertrophy, which is caused by an excessive amount of vascular growth within a blood 
vessel [Mulvany, 1992]. Until recently, the study of functional responses and structural 
alterations in resistance arteries, have proved difficult to study because of the size of 
vessels, but the development of wire and pressure myographs has overcome this 
problem. Both of these systems have provided a great deal of information on structural 
and functional changes that affect resistance arteries in pathophysiological conditions 
[Aalkjaer et al, 1987].
1.2.21 Inflammatorv responses involving (X9 -adrenoceptors 
Atherosclerosis can be defined as an anti-inflammatory disorder, because the cells 
involved in the development and progression of symptoms belong to the immune 
system, and under normal circumstances play an active role in immunity, az- 
adrenoceptors have been shown to affect the responses of cells that are active in the 
maintenance of immunity. Given this, it has been proposed that antagonism of az- 
mediated responses may be a potential treatment to control the progression of 
atherosclerotic lesions in human coronary arteries [Bumgart et al, 1999].
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The symptoms of many vascular diseases are localised in larger arteries, such as the 
carotid artery and the aorta. One such vascular disease is atherosclerosis. Mice lacking 
the apoE protein fed a normal diet develop hyperlipidemia and atherosclerosis [Smith & 
Breslow, 1997]. It is thought that apoE knockout mice develop vascular disease in large 
conduit arteries because the absence of apoE decreases LDL and VLDL clearance from 
the circulation [Smith & Breslow, 1997]. The klotho protein appears to protect against 
the development of atherosclerotic lesions and age related changes associated with 
vascular disease. The study of this protein may be useful for atherosclerosis research, in 
addition to the study of premature ageing conditions, such as progeria [Kuro-o et al, 
1997]. The role of the aa-adrenoceptor in the maintenance and development of 
atherosclerosis requires clarification.
In addition to atherosclerosis, (Xi-adrenoceptors have also been implicated in the 
development of a number of other inflammatory conditions. Inflammed joints of the rat 
develop an increased responsiveness to %  receptor agonists, while -mediated 
responses become attenuated [McDougall, 2001]. This is indicative of a shift in 
adrenoceptor expression levels, which may be triggered by inflammatory mediators.
1.2.22 Drug-induced responses mediated by a 9 -adrenocet)tors
Drugs that stimulate ccz-adrenoceptors are used clinically as adjuncts to anaesthesia, to 
treat glaucoma and attention deficit disorder, in addition to their classical 
antihypertensive effects [Kable et al, 2 0 0 0 ].
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<In vivo, activation of postjunctional aa receptors causes vasoconstriction, but this is 
followed by profound peripheral vasodilatation, which can lead to postural hypotension 
[Isaac, 1980]. As a result of this, drugs such as clonidine are rarely used clinically. The 
quest to find drugs that stimulate beneficial responses mediated by a 2 -adi*enoceptors 
without causing persistent side effects continues.
Imidazoline receptors are located in the central nervous system and in the periphery, and 
it has been suggested that ota-agonists produce antihypertensive responses by non- 
selectively stimulating central imidazoline receptors. However, data from studies 
carried out on the D79N and on knockout mice suggests otherwise. In fact, drugs that 
selectively stimulate imidazoline receptors, namely rilmenidine and moxonidine are less 
effective than clonidine as antihypertensive treatments.
Stimulation of central imidazoline receptors leads to a reduction in blood pressure, in 
the absence of aa-mediated effects. However, when both imidazoline and %- 
adrenoceptors are stimulated simultaneously, blood pressure lowering effects are 
enhanced [Bruban et al, 2002]. This is interesting, given that it has previously been 
proposed that drugs acting at imidazoline receptors produced hypotension, without the
'side effects associated with a 2 -receptor stimulation [Van Zwieten, 1999].
1.2.23 Drug treatments for hypertension
A wide variety of compounds that do not stimulate adrenoceptors are used clinically to 
treat hypertension. These include calcium channel antagonists, ACE inhibitors.
Angiotensin II antagonists [Johansson et al, 2000] and nitrates. For simplicity sake, the
actions of these compounds will not be discussed further here, but for completeness I 
felt it necessary to record their use and availability.
CuiTent drug therapies for the treatm ent o f  h ypertension  are su ccessfu l, in as m uch as 
they decrease b lo o d  pressure. H ow ever, n o  treatm ent has yet b een  d eve lop ed  that fu lly  
reverses the structural and functional ch an ges that have d eve lop ed  in b lood  v e sse ls  
iso la ted  from  hypertensive patients.
1.2.24 Future drug therapies
Bivalent ligands that bind as dimers may increase drug/receptor selectivity. This 
method has already been used successfully to enhance the selectivity of drugs that 
stimulate opioid and 5HT receptors, both of which are G protein coupled receptors, as 
are all subclasses of adrenoceptors.
Monovalent yohimbine has selectivity for a 2 -adi*enoceptors, but fails to distinguish 
between the three subtypes [Zheng et al, 2000]. In an attempt to overcome the lack of 
subtype selectivity, yohimbine dimers have been developed. Dimers are produced by 
reacting yohimbinic acid with aliphatic a, co-diamines under peptide coupling 
conditions. All of the yohimbine dimers produced have a higher selectivity for 
transfected human a 2 b and a 2o adrenoceptors expressed in CHO cells.
These studies identified that the extracellular binding loop of the human a 2 A/0 “ 
adrenoceptor has a greater number of acidic residues than the a 2b. So at physiological 
pH, the ligand-binding pocket of the human a 2 b-adrenoceptor has a greater positive
■
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charge than the other (Xg subtypes. In the future, these binding properties may be 
exploited to develop subtype selective ligands [Zheng et al, 2000].
1.2.25 Analgesia, sedation and behaviour
In addition to the classical cardiovascular effects caused by stimulation of a 2~ 
adrenoceptors, a 2  ligands can also be used to treat behavioural disorders such as 
attention deficit hyperactivity disorder [Hunt et al, 1995]. The (%2 -receptor subtype 
responsible for enhancing cognitive functions in behavioural disorders is unknown.
Compounds that act as agonists at a 2 -receptors have strong analgesic effects alone, or in 
combination with other drugs [Sullivan et al, 1987], and early indications are that all 
three a 2 -adrenoceptor subtypes mediate analgesic responses. In mice lacking functional 
a 2 B-receptors, the analgesic effects caused by nitrous oxide are completely abolished, 
suggesting a dominant role for the 0 C2 B subtype in mediating this response [Sawamura et 
al, 2 0 0 0 ].
Intrathecal administration of moxonidine inhibits substance P-induced behaviour in WT 
and D79N mice. These responses are antagonised by SK&F86466 and efaroxan 
showing that the anticociceptive effects are receptor specific. Clonidine increases tail- 
flick latency in WT, but not in D79N mice. This suggests that these responses are not 
mediated by the (%2 A/D-adrenoceptor, and are a result of stimulating another 
adrenoceptor subtype [Fairbanks & Wilcox, 1999]. Antinociception achieved by 
stimulating the remaining oci subtypes, namely ot2 B and or « 2 0 , is more desirable 
because aiA/o-adrenoceptor-mediated side effects can be avoided.
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The tail flick latency test has been used to assess the antinociceptive effects of N2 O in 
WT and D79N mice [Guo et al, 1999]. a 2 -adrenoceptors located in the spinal cord of 
the rat ai’e proposed to mediate the antinociceptive effects of nitrous oxide (N2 O). N2 O 
causes antinociception in WT mice, but responses are slightly attenuated in the a 2 A/o 
mutant, the D79N. Antinociception responses mediated by dexmedetomidine are 
antagonised by yohimbine, but unaffected by prazosin. This provides evidence that the
effects.
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response obtained does not result from stimulation of oci-adrenoceptors, and is mediated 
solely by a 2 -adrenoceptors. In addition to the effect of dexmedetomidine, opiate 
antagonists also prevent the antinociceptive effect of N2 O. Suggesting that %  agonists 
may cause antinociception by an indirect mechanism as well as receptor-mediated
î'i'
a 2 -selective agonists do not cause antinociception in the D79N mouse, but N2 O causes
*
the release o f  an agent w ith  activ ity  for the (X2-adrenoceptor that m ediates analgesic
responses. In the absence o f  functional a 2A/D~adrenoceptors the (X2B and (%2c receptor  
subtypes m ediate an tin ocicep tive responses [G uo et al, 1999], In addition to analgesic, 
vasoconstrictor and antihypertensive actions, (%2-agonists are u sed  postoperatively  for  
their sedative and hypnotic effects . E xperim ents on transgenic m ice  have proven that 
the sed ative e ffec ts  produced b y  ^ -a g o n is t s  are m ediated  so le ly  b y  the a 2A/D- 
adrenoceptor [Lakhlani et al, 1997]. T he d evelop m en t o f  drugs w ith  se lectiv ity  for the 
Œ2B and (%2c  receptors over  the Œ2A/D subtype m ay produce an a lgesia  w ithout the  
unw anted side e ffec t o f  sedation  or hypotension .
I
Stimulation of central tta-adrenoceptors has a profound effect on behaviour [Bjorklund 
et al, 2000] and memory [Tanilla et al, 1999]. Drugs selective for otzA/o and a 2 B- 
receptors have huge potential uses for the treatment of disorders where cognitive 
functions are affected. While selectivity for the a 2 c-adrenoceptor may be a future
■
:therapy for schizophrenia, and other conditions where there is an altered startle response 
[Sallinen et al, 1998]. Mirtazepine is used clinically as an anti depressant, and is a 
known antagonist of (%2 -mediated responses, so in addition to other uses, antagonists for 
a 2 -adrenoceptors may be potential therapies for depression, obesity [Hieble & Buffalo,
1991] and erectile dysfunction [Monoz et al, 1994].
Gene targeted mutations of the a 2 A/D-receptor have shown that this subtype plays an 
important antiepileptogenic role in the murine brain [Janumpalli et al, 1998], making 
%  A/D-selective compounds a potential therapy for epilepsy.
1.2.26 a?-adrenoceptors and motor control
Parkinson’s disease affects one person in every hundred aged over sixty-years. This 
condition is diagnosed following an alteration in gait, and is thought to result from 
degeneration of dopamine neurones, but can spread to affect other areas of the brain 
[Javoy-Agid, 1984]. The (%2 -antagonist idazoxan given at a dose of 2.9mg/kg causes a 
marked improvement in motor abnormalities (abnormalities that are similar to those 
occurring with Parkinson’s disease) in MPTP-treated monkeys. Improvements in motor 
skills are marked when compared to L-DOPA treatment, which is used to treat motor 
dysfunction. Idazoxan leads to a decreased in muscle rigidity and improved smoothness 
of movement. This study highlights the potential benefits of mainpulating %- 
adrenoceptors to treat disorders that exhibit Parkinson-like motor dysfunction.
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Dexmedetomidine causes dose-dependent reductions in locomotion in 0 C2 B and (X2 c 
knockout mice, but has no effect on locomotion in the D79N mouse [Hunter et al,
1997]. Qki agonists cause sedation in the mouse by stimulating central (X2 a/d- 
adrenoceptors in the locus coeruleus of the murine brain [Nacif-Coelho et al, 1994]. 
Furthermore, a lack of functional (XiA/o-adrenoceptors abolishes antinociceptive 
responses to dexmedetomidine, while tt2 B and (%2 c knockouts are unaffected and 
respond like WT controls [Hunter et al, 1997].
1.2.27 Regulation of lipolvsis
In addition to all of the physiological responses affected by stimulation of %- 
adrenoceptors, it has now been hypothesised that (X2 -adienoceptors are involved in the 
regulation of fatty acid metabolism and lipolysis. When functional Œ2  receptors are 
expressed in the absence of functional Ps-adrenoceptors, mice develop diet-induced 
obesity. The subtype(s) involved in the development and/or maintenance of this 
condition are unknown [Valet et al, 2000].
1.2.28 Signalling path wavs activated bv g^-adrenoceptors
Cellular signalling pathways utilized by (%2 -adrenoceptors have been studied 
extensively, but the G protein coupled to prejunctional receptors has not yet been 
detennined. It has been proposed that activation of a 2 -adrenoceptors leads to an 
inhibition of further noradrenaline release from sympathetic neurones. Experiments in 
rodents have shown that the G proteins involved in autoinhibitory functions are 
pertussis toxin-insensitive [Allgaier et al, 1996]. Other work has shown that the 
prejunctional autoreceptors can signal via a pertussis sensitive G protein in the rat heart
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and vas deferens [Docherty, 1988]. Stimulation of ag-adrenoceptors activates tyrosine 
kinases, which regulates calcium levels during contraction of the rat aorta [Carter & 
Kanagy, 2002].
Prejunctional az-adrenoceptors mediate their responses by negative coupling to 
adenylate cyclase. However, the signalling pathways activated by postjunctional 
receptors have been more difficult to elucidate. In isolated guinea pig smooth muscle 
cells receptor coupling prevents the accumulation of cAMP [Gupta et al, 1998]. In 
contrast, in human resistance arteries voltage operated Ca^^ channels are activated 
following agonist/receptor interactions [Parkinson & Hughes, 1995]. Unlike cti- 
adrenoceptors, stimulation of (X2 -adrenoceptors has not been shown to cause 
phospholipase C production. The signalling pathways activated by ^-adrenoceptors 
vary between blood vessels and species, as is often the case for G protein coupled 
receptors.
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Statement of aims
In this th esis « 2  and cxi-adrenoceptor-m ediated responses have b een  studied  in tw o  
m urine arteries, the tail and first order m esenteric  resistance arteries. In the tail artery, a 
series o f  p rotocols w ere in vestigated  to determ ine suitable con d ition s to study a 2- 
adrenoceptor-m ediated  resp on ses in th is artery, in an attem pt to increase our 
understanding o f  the e ffec t o f  stim ulating peripheral (X2-adrenoceptors exp ressed  in  
cutaneous b lood  v esse ls . Furtherm ore, a m ou se  caiTying a functional knockout o f  the 
0C2A/D-adrenoceptor w as em p lo y ed  to in vestigate  w hat role th is receptor subtype p lays in 
resp on ses in the tail artery and in m esenteric  resistance arteries.
T h e aiA -adrenoceptor is the m ajor a i-recep to r  subtype lead in g  to contraction o f  the 
m urine tail, and first order m esenteric  resistance arteries [D aly  et al, 2 0 0 2 ]. H ow ever, 
aiB  and am -ad ren ocep tors are a lso  exp ressed  in these b lood  v esse ls . T o  determ ine if  
th ese receptors are in v o lv ed  in vasoconstrictor responses in th ese arteries, aiB  and a m  
receptor knockout m ice  w ere u sed  in com bination  w ith  subtype se lec tiv e  ligands.
T he fo cu s o f  m y  research has been  to delineate the role o f  adrenoceptors in tw o  
resistance arteries, n am ely  the tail artery, also  refem ed to as the caudal artery and first 
order m esenteric  resistance arteries. In th ese  arteries, I have studied  the function  o f  both  
a , -  and a 2-adrenoceptors.
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Chapter two
Materials and General Methods
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2.1 Method used to study functional responses in isolated blood vessels
2.1.1 Wire mvograohv
The wire myograph was first described in 1976 [Mulvany & Halpern, 1976]. The 
development of this system has revolutionised the study of small blood vessels. Before
1976, the majority of in vitro studies of vascular function were carried out in an organ 
bath set up. Although this technique proved reliable, and gave reproducible responses, 
it had one major limitation i.e., which was the size of the vessels that could be studied. 
Therefore, until the development of the wire myograph, larger diameter blood vessels 
were the focus of in vitro studies. The wire myograph provides a system that allows 
functional responses in resistance arteries to be investigated. Resistance arteries have a 
diameter of between 100 and 400pm, and are thought to contribute to peripheral
resistance because they are primarily located at sights where there is a dramatic change 
in the pressure that blood flows against (for example when blood vessels branch, and 
the resistance to flow is greatly increased). Both of the vessels studied in the work 
presented here fall into that category on the basis of size, but the location of the tail 
artery questions this definition and only first order mesenteric arteries (because of their 
anatomical location), can be regarded as resistance vessels. The middle section of the 
mouse tail artery measures 314.5 ± 1.5pm in diameter. While first order mesenteric 
resistance arteries are smaller, having a diameter of 216.6 ± 3.5pm.
I
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2.1.2 Myographs: description of equipment
The myographs used in all of the work within this thesis were purchased from Danish 
Myotech and were model type 600A or 610A. The myograph has a stainless steel bath 
containing two detachable stainless steel heads. The stainless steel heads can be 
replaced with perspex mounting heads containing a fixed electrode allowing the nerves
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within the vessel wall to be electrically stimulated. Although this technique was not 
used in this work, I have included this description for completeness. The head on the 
far side of the myograph is mounted on a stainless steel arm that is connected to a 
micrometer. This arm can be moved backward and forward with the micrometer to 
form a vice like structure in the centre of the bath. On the near side of the myograph the 
mounted head is attached to a transducer, which measures force generation. These 
measurements are sent to an interface that gives a force reading in mN. The myograph 
interface sends an output to a Linseis 4 channel chart recorder (L65I4-1I), there upon 
producing a trace recording of force generated by a contracting vessel. A number of 
traces are shown throughout the results chapters. These were recorded from 
experiments using Adinstruments PowerLab software. A diagram showing an overview 
of a myograph bath is shown below in figure 2.1.
Figure 2.1
suction
micrometer
transducer
5ml bath
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2.2 Vessel dissection
2.2.1 Dissection of mouse tail artery
There are three arteries and three veins, which run the entire length of the mouse tail 
artery. The artery most frequently used experimentally is the one running down the 
base of the tail, which is facing upward when the animal is in the supine position (face 
forward). The artery to which I refer was used for the experiments contained within this 
thesis.
All mice were killed by schedule one method, in accordance with Home Office 
guidelines. Mice were asphyxiated with CO2 , followed by cervical dislocation. 
Immediately after death, the mouse was laid on its back, belly facing toward researcher. 
Then an ink mark was made on the base of the tail to allow identification, after the tail 
has been detached from the body. Tails were stored in cold Ki'ebs until the artery was 
removed. Before any further dissection, the tail arteries were measured and a 1.5cm 
segment beginning 2.5cms from the base of the tail was marked with ink. The average 
length of the murine tail artery was detennined as 8.09 ± 0.02cms.
From this point on, all further dissection of blood vessels was canied out with the aid of 
a Zeiss dissecting microscope (Stemi 2000). The thick, hairy skin on the tail was 
removed with dissecting scissors, exposing an artery and vein under a sheath of white 
connective tissue. The artery was removed from the tail, cleaned of any excess 
connective or fatty tissue and placed in fresh cold Ki'ebs.
The freshly dissected artery was then placed in a petri dish containing fresh Ki'ebs. 
Sections of ai'tery measuring approximately 2mm were then cut, and each segment then
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had a 40pm wire inserted into the vessel lumen. When the first guide wire was in place, 
the vessels were then ready to be transferred to the myograph bath, which contained 
cold, gassed Ki'ebs solution.
2.2.2 Mesenteric arterv dissection and vessel mounting
WT, D79N, aiB and 0(id knockout mice were killed by CO2  asphyxiation followed by 
cervical dislocation. The mesenteric arcade from these animals was removed from the 
abdominal cavity, and placed in fresh Ki'ebs at room temperature. The mesentery was 
then pinned out on a petri dish, and with the aid of a dissecting microscope, the superior 
mesenteric artery was located. First order mesenteric resistance aiteries are the first 
branch off the superior mesenteric artery; hence the nomenclature. Once located, 
several of these arteries were cleared of excess tissue and fat and stored in Krebs for in 
vitro studies.
2.3 Procedure for mounting vessels
Each stainless steel bath contained 5mls of fresh cold Krebs. The wire, with the vessel 
already mounted, was held within the stainless steel jaws to permit the wire to be 
secured to the near side arm using small metal screws. Once secure, heads were 
separated to allow insertion of a second 40pm wire. Insertion of a second wire was a 
technical challenge, and requires considerable expertise, if one is to avoid damaging the 
thin layer of endothelial cells, located on the vessel wall. To minimise damage, the 
second wire was slid along the primary mounting wire, which had already been secured. 
Once inserted and secured, the wires were lined up so that they became parallel, and just 
touching. Each stage of the mounting procedure has been summaiised 
diagrammatically in figure 2.2, below.
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After successful mounting of a blood vessel a perspex lid was fitted to the Krebs filled 
bath with a funnel attachment for delivery o f fresh Krebs. The tight fitting lid helped to 
control the temperature within the bath. Each bath had an oxygen supply and heating 
was achieved by switching on a heat pad that spans the length of the entire mounting 
block. Tail and mesenteric arteries were set a tension of 0.25 and 0.17gms Force 
respectively. This was determined as a suitable resting tension after completion of a 
series of length tension experiments.
Figure 2.2
a)
c)
e)
b)
d)
0
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2.4 Resting tension: normalisation
Although this procedure was rarely used in experiments earned out in this thesis, I feel 
it necessary to provide a brief description of the normalisation procedure because it is 
commonly used in myography. Mulvany and Halpern first described this method in 
1977. In brief, a rat mesenteric arterial ring was subjected to a series of stretches to 
determine the required tension the vessel should be set at to mimic in vivo conditions. 
The procedure was based on the law of Laplace, which described the relationship 
between wall tension, pressure and vessel radius.
Pi = Wall tension/(intemal circumference/27t)
Pi is defined as the effective pressure. This is not the actual pressure within the vessel, 
but an estimate of that pressure which was required to stretch the vessel wall to cause a 
change in internal circumference. Wall tension is the force divided by the length of the 
vessel wall.
Wall tension = Force (F)/(Length (L) x 2).
Caution is required here, because the wall length is actually twice the length of the 
mounted vessel segment. Repetitive stretching gave a series of Pi values that can be 
recorded on a hand held Hewlett Packard computer. This machine can calculate the 
internal circumference of the vessel by use of the following equation.
ICI = (micrometer reading at 1-micrometer reading at point B) x 2 + (ICB)
Point B is the point at which the two mounting wires were barely touching. If the wires 
used were both 40p.m in diameter, the ICB was always equal to 205.bum. The 
micrometer readings were equivalent to the distance between the two wires.
The equation can be reaiTanged to give 
Pi -  (2ti) X wall tension/ IC
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The values for internal circumference and wall tension were then plugged into the 
equation to give:
Pi = (271) X F / 2 X L (205.6 + (2 x distance between the wires))
This method was used to calculate a micrometer reading that sets the vessel at a tension 
that mimics transmural tension at ninety percent of the tension required to reflect a 
pressure of lOOmmHg.
So why was this technique not utilised in my work? There are several reasons; this 
method was developed for the study of third order mesenteric resistance arteries from 
the rat. As I have used two different vessels types in this study, neither of which are 
third order mesenteric, this was the first rationale for not succumbing to the pressure to 
normalise. Although the technique of normalisation provides several pieces of useful 
information about the vessel being studied, the procedure of repeated stretching has 
been shown to be extremely damaging. During the course of my training procedure, I 
did normalise a number of vessels, for practice, and to aid my understanding of this 
method. A highly elastic vessel, such as the carotid, aorta, or even the tail artery, had to 
be stretched to such a degree that it was almost impossible to successfully complete an 
experiment after normalisation.
2.5 Calibrating equipment
The myograph and Linseis pen recorder were calibrated at the beginning of each set of 
new experiments, because the procedure is labour intensive and time consuming. Each 
time the equipment was calibrated little variation was observed.
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2.6 Experimental Protocols
2.6.1 Wake-up protocol for mesenteric and tail arterv
Following an equilibration period of 30-35 minutes, each segment of tail artery was set 
at a resting tension of 0.25gms, and allowed to equilibrate for 20-30 minutes. At this 
stage, if required, tension was adjusted to reach 0.25gms. For all experiments involving 
UK14304, two sighting concentrations of the appropriate agonist (1 x lO'^M) were 
administered to each tissue, followed by four staggered washes with fresh Krebs over a 
fifteen minute period. A third concentration of agonist (1 x lO'^M) was added and the 
contractile response was allowed to reach a plateau. When the agonist-induced 
response was stable, acetylcholine (3 x 10‘^ M) was added to test viability of the 
endothelium. Acetylcholine-induced relaxations were determined in all vessels tested, 
if the relaxant response failed to reach thirty percent of the base contraction, vessels 
were excluded from further analysis. Acetylcholine can induce contractile responses, 
but only in the absence of endothelial derived relaxing factors [Chauhan et al, 2003], a 
phenomenon that did not occur in the vessels I studied. After completion of the wake 
up protocol, each tissue was washed four times, and allowed to rest for thirty minutes 
before commencing experimentation. Details of the drugs used during the experimental 
wake-up have been described in more detail in each appropriate results chapter.
2.6.2 Elevation of vascular tone
U46619 is a commercially available thromboxane mimetic. It is frequently used to 
elevate tone in functional experiments because it has a long duration of action, and 
provides a stable contraction, unlike thromboxane, which is rapidly broken down. In 
experiments investigating the relaxant effect of UK14304 in mesenteric arteries, 
U46619 (I x 10‘^ M) was used to constrict each vessel segment. U466I9 was also the
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experiments, an initial curve to phenylephrine was constructed. After a wash out and
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synergist of choice for experiments on tail artery, where an elevation in vascular tone 
was required to investigate contractile responses to the cci-selective agonist UK14304.
In these experiments, the synergist was added in increasing concentrations until a level 
of tone approximately fifty percent of that gained to noradrenaline (1 x 10 M) was 
achieved.
2.6.3 Assessment of the effects of antagonists
Each antagonist drug used was incubated with a tissue segment for 30 minutes prior to 
experimentation. In most of the protocols involving UKI4304, desensitisation of
i:
contractile responses occuiTed. To overcome this problem, the effect of the antagonist 
drugs rauwolscine and prazosin were detennined against first curves. With the
I
exception of these experiments, unless otherwise stated, the antagonist was added after a 
first curve to the appropriate agonist, and allowed to equilibrate for 30 minutes.
2.6.4 Combined use of two antagonist drugs
A series of experiments were carried out in first order mesenteric resistance arteries 
where two antagonist drugs were used to block responses in the same tissue. In these
rest period, 5MeU was added to the bath. After a 30 minute equilibration period, a
second cumulative curve to phenylephrine was carried out. This was followed by four ■w:
consecutive washes, carried out over a 30 minute rest period. To prevent any drug 
interactions when more than one antagonist was used on a given vessel, a lag period 
was allowed between drug additions. So the first antagonist was added and allowed to 
equilibrate for 10 minutes, and then the second antagonist (namely BMY7378) was 
added to the bath. When the last drug was added, a 30 minute equilibration period was 
allowed before the construction of another phenylephrine curve.
i
2.7 Maintenance of Animals
All animals were housed in the University animal holding unit, where temperature is
in several ways. Contractile responses have been shown as gms Force. This data was
maintained at approximately 21^0. Humidity levels were approximately sixty percent 
and the air was filtered every hour while animals were kept in an artificial twelve-hour
light/dark cycle. Animals used in the experiments were bred locally from ancestors 
gifted from other laboratories. All of the mice used were male and had been caged in 
batches, unless required for breeding. Mice were fed on a standard chow diet and 
provided with distilled drinking water (ad libitium).
2.8 Data analvsis
2.8.1 Results
Data from each set of in vitro experiments was grouped together for the calculation of 
means, standard deviation and standard error values. The results gained were expressed
not normalised or manipulated in any way. To assess the sensitivity of each tissue to a 
given agonist before and after treatment with an antagonist, data was expressed as a 
percentage of its own maximum, or a control curve maximum. For control data, results 
were expressed as a percentage of their own maximum. When an antagonist drug was 
used, the data was expressed as a percentage of the appropriate control curve. By 
expressing data in this way, pECso values could be determined. In studies carried out in 
the mouse tail artery where only one concentration response curve was constructed, 
responses were expressed as a percentage of their own maximum, or where appropriate, 
as a percentage of the noradrenaline response, gained during the wake-up protocol.
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2.8.2 Agonist Potency
pECso values are standard measurements that indicate how sensitive a given tissue is to 
an applied agonist. The pECso can be defined as the - log of the EC5 0  (the concentration 
of agonist needed to produce fifty percent of the maximum response). These values 
were either calculated using a template spreadsheet, or by the use of Graph Pad Prism 
which can extrapolate data to estimate such values. For studies in the «ib knockout 
mice, it was necessary to calculate PEC2 5  values. The same principals applied for these 
calculations.
2.8.3 Antagonist potency
Antagonist potency can be estimated by calculating a pKe and or a pA% value. Where 
applicable, these values were determined. A pKs is the - log of the Kb, which is the 
dissociation equilibrium constant for an antagonist, and can be defined as the 
concentration of drug that occupies fifty percent of available receptors. pKe values are 
generally calculated when a single concentration of antagonist has been used in an 
experiment. The pKo values determined in this work were calculated as follows:
PKb = - log Kb where the Kb = [Antagonist] / r-1
r is equal to the antagonist concentration ratio, which is [A’] / [A], that is the 
concentration of agonist needed to produce an equal effect in the presence of [A’] and 
absence of antagonist [A]. This is where the EC5 0  value is utilised.
When several concentrations of antagonist have been used in an experiment (noiTnally a 
minimum of three), a pA2  value can be calculated. The pA2  is the log of the 
concentration of antagonist required to shift the response curve to an agonist by two 
fold compared to the control response. Where pA2  values were calculated in this thesis,
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they have been done in the manner previously described by Arunlakshana & Schild 
(1959). In order to do this, one must plot values obtained for log (dose ratio-1) (see 
previous section) against the concentration of antagonist used. When the antagonism 
was competitive in nature, the graph gave a straight line that had a slope that was not 
significantly different from unity. The point where the line intercepts the x-axis is the 
log Kb and the pA% = -log Kb-
It should be noted that although such values provide a considerable amount of 
information on receptor/drug interactions, they are only estimates and will be treated as 
such. However the validity of their use has been well established over the last fifty 
years, and they provide an invaluable tool for pharmacological studies.
2.9 Statistical analysis
Statistical comparisons between groups of two or more data were assessed using one­
way analysis of variance (ANOVA), followed by a (Bonferroni) post-test, to determine 
points of significant difference. Comparisons between two experimental groups were 
made using a Student’s t-test for paired and unpaired data sets where appropriate. It has 
become standard to regard a p value < 0.05 as statistically significant. In keeping with 
this I used the same criteria throughout this work. Graph Pad Prism, versions 2 and 3 
were used for all statistical analysis.
2.10 Drugs and Solutions
2.10.1 Solutions
Krebs-Heinslets solution was prepared on a daily basis and had the following 
composition: NaCl 118.4mM, KCl 4.7mM, CaCh 2.5mM, K H 2 P O 4  1 .2 mM, MgS0 4
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1.2mM, NaHCOa 25mM and glucose ll.lm M , bubbled with 95% O2  5% O2  to pH 7.4 
at 37^C. In chapter five, experiments in mounted tail arteries were earned out at room 
temperature. During the course of these experiments the laboratory temperature was 
monitored and recorded and found to be 2I.5-23.5^C. Krebs used to wash bathing 
arterial rings, was kept at room temperature, while gassed, and the pH was monitored 
throughout to confirm that it did not deviate from physiologically acceptable levels.
2.10.2 Drugs
The table below provides a comprehensive guide to the drugs used in this work, their 
supplier and the method used to dissolve the compound. Where water has been used 
this indicates the use of distilled water. DMSO is an abbreviation for 
dimethylsulphoxide, which was used to dissolve UK14304, according to manufacturers 
guidelines. Ethanol used to dissolve certain compounds was 100%. Where possible 
drugs were dissolved in distilled water, but some compounds required sonication. 
Compounds dissolved in solvents were made at concentrations higher than that required 
for experimentation and diluted down, to minimise solvent effects on responses. With 
the exception of Nifedipine and L-NAME, all other compounds were made fresh, stored 
in the freezer and used for five consecutive experiments. Nifedipine stock was stored in 
-2(fC  freezer, and diluted daily, while L-NAME was made fresh for each use.
119
Table 2.1
Drug/ Compound Supplied by Solvent for stock
Noradrenaline hydrochloride Sigma 23 pm EDTA, diluted in 
water
Phenylephrine hydrochloride Sigma Water (IM  stock)
UK14303 (5-Bromo-6(2~imidazolin- 
2 yamino)quinoxaline)
Tocris DMSO (1 X 10'^M)/Water
U46619 (9, 11-Dideoxy-l i a -  
epoxymethanoprostaglandin Faa
Ethanol (1 x 10'^M)/Water
L-NAME (N“-nitro-L-arginine 
methylester)
Sigma Water (IM  Stock)
Rauwolscine hydrochloride Research Biochemicals Water (1 x 10"'^M)/60min 
sonication
Prazosin hydrochloride Tocris Water (1 x 10’'^M)/60min 
sonication
5-methylurapadil (5-Methyl-6(3-[4- 
(2 -methoxyphenyl) - 1  - 
piperazinyl]propyl)amino] 1 - 
Sdimethyluracil
Reseai'ch Biochemicals Water (1 x 10"^M)/30mins 
sonication
BMY7378 (dihydrochloride 8-[2- 
[4-(2-methoxyphenyl)-l- 
piperozynl]ethyl]-8 ~ 
azaspiro(4,5} decone-7,9-di one)
Research Biochemicals Water (1 x 10'^M)/60mins 
sonication
5-Hydroxy try ptamine Sigma Water (1 x 10"'^M)/20mins 
sonication
Nifedipine Sigma Ethanol (1 x 10"^M)/Water
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Chapter three
Development of a protocol to investigate ag-adrenoceptor-
mediated responses in the murine tail artery in vitro
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3.1 Introduction
In vivo, the study of az-adrenoceptor-mediated responses has been relatively 
straightforward. However, in vitro, responses mediated by a 2 -adrenoceptors are often 
difficult to obtain, probably because in vitro conditions are unsuitable. The main 
objective of the work contained within this chapter was to develop a number of 
protocols, in an attempt to provide conditions that permit the study of consistent, 
reproducible ccz-adrenoceptor-mediated responses.
In the pithed rat, pressor effects of exogenous a-adrenoceptor agonists are the result of 
dual activation of postjunctional ai-and Œg-adrenoceptors [Docherty & McGrath, 1980]. 
Œz-adrenoceptor-mediated increases in blood pressure have been shown to be inhibited 
by the (X2 -selective antagonists rauwolscine and idazoxan, but are unaffected by 
treatment with the ai-selective antagonist, prazosin.
The rat tail artery contains a functional population of pre and postjunctional ai- 
adrenoceptors [Medgett & Langer, 1984]. In vitro, the existence of a mixed population 
of functional oti and a 2 -adrenoceptors in peripheral arteries was first suggested 
following experiments that utilised ai and a 2 -selective antagonists. Prazosin 
competitively antagonised noradrenaline-induced contractions, but the combination of 
prazosin and idazoxan caused a significantly greater reduction in the noradrenaline- 
induced response, greater than the effect of prazosin alone [Rajanayagam & Medgett, 
1987]. This indicated that in addition to the a i, a 2 -adrenoceptors also mediate 
contractile responses in vitro.
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UK14304 and noradrenaline cause contraction of the isolated perfused rat tail by 
stimulation of a 2 -adrenoceptors. However, the development of these contractile 
responses only occurs in the presence of elevated vascular tone [Templeton et al, 1989]. 
Temp]eton and co workers increased the perfusion pressure within the isolated tail with 
a low concentration of arginine vasopression (A VP). In the absence of A VP-induced 
tone, UK14304 had no effect on perfusion pressure. However, when the tone was 
raised, UK14304 caused concentration-dependent increases in pressure that had a 
maximum effect that was comparable to thirty percent of the increase in perfusion 
pressure caused by noradrenaline. In the presence of elevated tone UK14304-induced 
contractile responses were selectively antagonised by rauwolscine, and were insensitive 
to prazosin.
Therefore, it can be concluded that the rat tail artery contracts by stimulation of a mixed 
population of a i and (X2 -adrenoceptors. The ai-adrenoceptor appears to be the major 
contractile receptor, which is readily activated by noradrenaline or phenylephrine in the 
absence of tone [Templeton et al, 1989]; but c%2 -adrenoceptors play a small, but 
significant contractile function under specific physiological conditions (for example 
when vascular tone has been elevated). Since the discovery of (%2 -adrenoceptor- 
mediated contractile responses, much work has been carried out to determine which 
receptor subtypes contribute to responses in different arterial beds, and animal species. 
It has been reported that contractile responses of the rat tail artery results from 
activation of postjunctional a 2 c-adrenoceptors [Craig et al, 1995]. To determine what 
(%2 -subtypes were involved in mediating responses in the murine tail artery the D79N 
mouse has been used here.
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f3.2 Methods
WT (C57BL/6c/129Sv) and D79N (a 2 A/o mutant) mice aged four-months were obtained 
from the University animal house for this study. Males of between 29.6-34.2g were
-
killed by asphyxiation with carbon dioxide and the tail arteries were removed.
Î
3.2.1 Vessel dissection and mounting
The main artery running down the base of the tail was located and a section 2.5cm from 
the base, measuring 1.5cm in length was marked. The skin was then removed to expose 
the artery, cleared of excess connective tissue and fat, was mounted in 5ml myograph 
baths (Described in detail in chapter two). Once mounted, resting tension of 0.25g was 
placed on each vessel (determined to be the optimal tension, from preliminary 
experiments). Each arterial ring was placed in Krebs, heated to 37^C, bubbled with a 
gas mixture of 95% O2 , 5% CO2  and allowed to equilibrate for 20-30 minutes.
3.2.2 Experimental Protocols
A variety of different protocols were performed throughout the course of the 
experiments contained within this chapter. The aim of each protocol was to determine 
the influence of a particular aspect of the experimental conditions provided for the study 
of 0 (2 -adrenoceptor-mediated responses. Each protocol has been described in detail 
below.
I3.2.3 Control Experiments 
In control experiments arterial segments were set up, as described previously. After a 
resting period, a cumulative concentration response curve to the a 2 -selective agonist
1'
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UK14304 was constructed in half log units (1 x 10'^ ~ 3 x lO'^M). No other drugs were 
present in the myograph bath during this protocol.
3.2.4 Elevation of vascular tone with U46619
U46619 is a thromboxane mimetic, this was used to raise vascular tone in mounted tail 
artery rings. Two different protocols were employed that made use of this compound.
In the first, a predetermined low concentration of U46619 (3 x 10"^M) was added to 
each vessel segment to raise tone. When U46619-induced contractions reached a 
contractile plateau, a UKI4304 curve was then constructed in each artery. In a second 
protocol, U46619 was added in half log units to give a contractile response comparable 
to fifty percent of the contraction obtained with noradrenaline (1 x 10‘^ M). Responses 
varied from tissue to tissue so the concentration of U46619 used ranged from 3 x lO'^M 
to 1 X lO'^M, dependent on the responsiveness of each mounted vessel.
3.2.5 Blockade of nitric oxide svnthase with L-NAMB
L-NAME covalently bonds to the enzyme nitric oxide synthase, and in doing so, 
prevents the release of the endothelial derived relaxing factor, nitric oxide. L-NAME, at 
a concentration of 1 x lO’^ ^M was used in three protocols. In the first, L-NAME was 
incubated with mounted arterial rings 20-25 minutes before construction of a 
cumulative UK14304 response curve. In the second, L-NAME was used, prior to 
elevation of vascular tone with the synergist, U46619. In the final protocol, L-NAME 
was administered to each myograph bath before raising vascular tone to fifty percent of 
the noradi'enaline maximum, with increasing concentration of U46619. At the end of 
each protocol where L-NAME was used, the relaxant effect of acetylcholine was tested 
to confirm that L-NAME had successfully prevented the release of nitric oxide.
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3.3 Results
3.3.1 Responses to cumulative UK143Q4
Figure 3.1 shows the responses gained to cumulative concentration response curve to 
UK14304, constructed in tail aiteries from four-month old WT (figure 3.1 A) and D79N 
(figure 3.1 B) mice. In arteries from both strains, contractions at lower concentrations 
were absent or extremely small. At higher UK14304 concentrations small but 
significant contractile response was achieved. The maximum contraction gained in 
arteries from WT mice was 0.11 ± 0.05gms Force (p = 0.007**). In D79N arteries the 
maximum change in tone was a mere 0.04 ± 0.02gms Force, which was not significantly 
different from zero (p = 0.051).
3.3.9 Comparison of all the protocols tested
Figure 3.2 summarises the results gained in all of the experimental protocols tested in 
WT (figure 3.2 A) and D79N (figure 3.2 B) tail arteries. In terms of size and sensitivity, 
high levels of vascular tone provided the most advantageous experimental conditions 
for the study of a 2 -adrenoceptor-mediated contractions, in both murine strains.
3.3.2 Effect of elevated tone alone and with L-NAMB on the maximum size of 
UK14304-induced contractions
Contractile responses to UK14304 were investigated when vascular tone had been 
elevated with a low concentration of the synergist, U46619 (3 x lO'^M). Cumulative 
concentration response curves to UK14304 were constructed in tail arteries from WT 
(figure 3.2 A) and D79N (figure 3.2 B) mice. At a concentration of 3 x lO’^ M U46619 
caused small, but stable, contractions. In WT arteries, the size of U46619-induced 
contractions was 0.13 ± 0.04gms Force, while in arteries from D79N mice the response
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Figure 3.1: The UK14304 response in tail arteries from 4-month old WT and 
D79N mice. A Cumulative response curve to increasing concentrations of 
UK14304 (o, n = 7 ) in WT arteries. B Cumulative response curve to 
increasing concentrations of UK14304 (°, n = 10 ) in D79N arteries. Each 
point represents mean ± standard error.
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Figure 3.2: Responses in tail arteries from 4-month old WT and D79N mice. To UK 
only (o), with U19 (•, 3 x lO'^M), U19 with L-NAME (■, 1 x lO'^M), L-NAME only 
(□), and U19 (A, 50 % of NA max), respectively. A UK curves in WT arteries, n = 7, 6 , 
8 , 7, and 12. B UK curves in D79N arteries, n = 10, 10, 9, 10, and 13. Each point 
represents mean ± standard enor.
tended to be smaller at 0.05 ± O.Olgms Force. Statistical analysis showed that U46619- 
induced contractions in WT were no different from the D79N, probably because of the 
high variability of responses.
In the presence of low levels of vascular tone contractile responses to UK14304, 
although still small, were significantly greater than those achieved in a control curve.
In WT arteries, U46619, at a concentration of 3 x lO'^M significantly enhanced 
UK14304-induced contractions. In the presence of low concentration of U46619 the 
maximum UK14304 contraction was 0.25 ± O.Obgms Force, compared with the control 
curve maximum of 0.11 ± 0.05gms Force (p = 0.02*).
In tail arteries from four-month old D79N mice, elevation of vascular tone with a low 
concenti’ation of U46619 also enhanced contractile responses. In the presence of 
U46619-induced tone, the maximum UK14304-mediated contraction was 0.12 ± 
0.07gms Force, which was significantly greater than the control curve maximum of 0.04 
± 0.02gms Force (p = 0.04*)
Incubating mounted tail arteries with L-NAME prior to elevation of vascular tone, and 
construction of a UK14304 response curve provided no advantage over using each agent 
separately (p = 0.22). In the presence of L-NAME the contractile response to a low 
concentration of U46619 (3 x lO'^M) was 0.18 ± O.Obgms Force in WT arteries, and 
0.10 ± 0.02gms Force in aiteries from D79N mice, again analysis of these responses 
gained showed that they were not significantly different (p>0.05).
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In WT and D79N mice, in the presence of U46619 (3 x 10‘^ M) and L-NAME, UK14304 
caused concentration-dependent contractions that were significantly greater than 
UK14304 control curves. The maximum contraction in arteries from WT mice was 
0.24 ± 0.04gms Force, compared with that gained in the presence of low U46619 alone 
0.25 ± 0.05gms Force.
In tail arteries from D79N mice, incubation with L-NAME prior to elevation of tone 
with U46619 (3 x lO’^ M) gave a contractile maximum of 0.13 ± 0.03gms Force, which 
was significantly greater than the control curve maximum of 0.04 ± 0.02gms Force (p = 
0.01*). However, the maximum response gained with U46619-induced tone and L- 
NAME was not significantly different from the maximum with U46619 (3 x 10‘^ M) 
alone, which was 0.12 ± 0.07 (p = 0.8163).
3.3.3 Sensitivitv to UK14304 is enhanced in the presence of U46619-induced tone 
In the presence of low levels of U46619-induced (3 x lO'^M) tone the sensitivity to 
UK14304-mediated contractions was enhanced in the mouse tail artery. In WT arteries 
the pECso value calculated is 6.5 ± 0 . 2  compared with a value of 5.9 ±1.0 for the 
control protocol (p = 0.029*). In tail arteries from D79N mice, U46619-induced tone 
shifts the pECso value from 5.7 ± 0.01 in the control curve to 7.0 ± 0.2 (p = 0.003**). 
Therefore, it appears that the presence of the synergist, U46619, even at low levels, 
increased the sensitivity of the murine tail artery to UK14304-mediated contractions, in 
WT and D79N strains.
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3.3.4 Effect of L-NAME on UK143Q4-itiduced contractions alone and with elevated 
tone
In this series of experiments L-NAME was used in two ways. Firstly, L-NAME (1 x 
lO'^^ M) was incubated with mounted arterial segments prior to construction of a 
concentration response curve to UK14304. Secondly, L-NAME incubation preceded 
elevation of vascular tone with low concentrations of the synergist, U46619.
The contractile responses to UK14304 in tail arteries from four-month old WT and 
D79N mice are shown in figure 3.2. In arteries from WT mice (figure 3.2 A), 
incubation with L-NAME significantly increased the maximum contraction from 0.11 ± 
O.OSgms Force in a control curve, to 0.22 ± 0.04gms Force with L-NAME (p = 0.04*). 
The combination of L-NAME, and U46619-induced tone gave a UK14304-mediated 
contraction with a maximum response of 0.24 ± O.OSgms Force. The size of 
contractions gained with L-NAME, and U46619-induced tone (3 x 10 ^M) was no 
greater than when L-NAME was given alone (p>0.05).
Figure 3.2 B also shows UK14304-mediated contractions in tail arteries from four- 
month old D79N mice that have been incubated with L-NAME alone, and L-NAME 
before U46619-induced elevation of vascular tone. The size of the responses gained 
were generally smaller than those obtained in WT arteries. Response curves with L- 
NAME (1 X lO'^^M) had a maximum contraction to UK14304 of 0.12 ± 0.02gms Force, 
which was significantly greater than the control curve maximum of 0.04 ± 0.02gms 
Force (p = 0.04*). In the presence of elevated vascular tone, the maximum response 
gained in D79N tail arteries was 0.13 ± 0.03gms Force. Considering the results gained 
in WT and D79N arteries, it appears that the combination of elevating vascular tone and
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blockade of nitric oxide release provide no greater benefit than using U46619 to elevate 
tone, or L-NAME independently of each other.
3.3.5 Tail arteries are more sensitive to UK143Q4 in the presence of L-NAME 
In tail arteries from WT mice, the pECso shifts from 5.9 ± 1.0 in a control curve, to 6.4 ± 
0.2 in the presence of L-NAME (p = 0.0003***). In arteries from D79N mice, the 
pECso was shifted from 5.7 ± 0.01 in a control curve, to 6 . 8  ± 0.2 in the presence of L- 
NAME (p = 0.0015**). These findings show that incubating tail arteries with L-NAME 
increased the sensitivity to UK14304 in the WT and D79N. A table containing the 
maximum responses and the pECso values for the protocols tested is shown below.
WT D79N
pECso Max. pECso Max.
Control 5.9 ± 1.0 0.11+0.05, 
n = 7
5.7 + 0.01 0.04 ± 0.02, 
n = 1 0
[Low] U46619 6.5 ±0.2* 0.25+0.06,
n = 6 *
7.0 ± 0.20* 0.12 ±0.07, 
n = 1 0 *
L-NAME 6.4 + 0.2* 0.22 ± 0.04, n = 7* 6 . 8  ± 0 .2 0 *
0 . 1 2  + 0 .0 2 ,
n = 1 0 *
[High] U46619 8 . 0  ± 0 .2 * 0.39 + 0.07, 
n -  1 2 **
8 . 1  ± 0 .2 0 * 0.21 ± 0.04,
n = 13**
Table 3.1 Maximum response and pECso values in WT and D79N tail aiteries
3.3.6 Effect of elevating tone to fiftv percent of the noradrenaline maximum 
Figure 3.3 shows the contractile responses to UK14304 in a control curve, and when 
U46619 has been used to achieve a high level of vascular tone in tail arteries from WT 
(figure 3.3 A) and D79N (figure 3.3 B) mice. U46619 was added in half log units (3 x 
10'^ -  1 X lO'^M) to achieve a contraction comparable to fifty percent of the response to 
noradrenaline at a concentration of 1 x lO'^M. In the WT, U46619-induced tone
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Figure 3.3; Responses in tail arteries from 4-month old WT and D79N mice to UK 
only, and with U19 (3 x 10’'^  -  1 x to elevate tone to 50% of the NA
maximum. A UK control curves (°, n = 7 ), and with high U 19-tone ( A, n = 12), 
in the WT. B UK control curves (°, n = 10), and with high U19-tone ( A, n =13) 
in the D79N. Each point represents mean ± standard error.
reached a maximum of 0.34 ± 0.06gms Force, compared with 0.28 ± 0.04gms Force in 
the D79N arteries. Compaiison of these values showed that the size of the response 
gained is not statistically different (p = 0 .2 1 ).
In both murine strains, contractions to UK14304 were significantly greater than those 
obtained in the control protocol. In tail arteries from WT mice the control curve 
maximum was 0.11 ± 0.05, whilst in the presence of high levels of U46619-induced 
tone the maximum response was significantly greater at 0.39 ± 0.07gms Force (p = 
0.008*=*=). In arterial rings from D79N mice the maximum force generated in a 
UKI4304 control curve was 0.04 ± 0.02gms Force. In the presence of high levels of 
U46619-induced tone the maximum contraction in the D79N was significantly greater 
that controls, at 0.21 ± 0.04gms Force (p = 0.0018 **).
Contractile responses in WT and D79N mice in the presence of high levels of vascular 
tone are significantly greater than the contractions gained in a control curve. In addition 
to being significantly greater than controls, contractile responses were also significantly 
larger than all of the other protocols tested. These include, U46619 at 3 x lO'^M, L- 
NAME (1 X lO'^^ M) alone, and L-NAME with [low] U466I9 (p<0.05). When the 
maximum responses gained in WT and D79N tail arteries were compared, it was found 
that contractions in the WT were significantly greater than those obtained in the D79N
(p = 0 . 0 2 1 0  *).
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3.3.7 Sensitivitv to UK14304 is enhanced in the presence of high levels of U46619- 
induced tone
In figure 3.4 the contractile responses to UK14304 in a control curve, and in the 
presence of high levels of U46619-induced tone are shown for the WT (figure 3.4 A) 
and D79N (figure 3.4 B) mice, and have been expressed as a percentage of their own 
maximum response. In WT arteries the control curve pECso was 5.9 ± 1.0, while in the 
presence of the high levels of U46619-induced tone the pECso was shifted to 8.0 ± 0.2 
(p = 0.0002***). Similarly, pEC^o values are also shifted in tail arteries from D79N 
mice. For the control curve a pECgo value of 5.7 ± 0.01 has been deteimined, while in 
the presence U46619 the value was shifted to 8.1 ± 0.2 (p = 0.0007***).
3.3.8 Combined contractile response to high levels of vascular tone and increasing 
concentrations of UK14304
Figure 3.5 shows the combined contractile response to high levels of U46619-induced 
tone, and increasing concentrations of UK14304, in tail arteries from four-month old 
WT (figure 3.5 A) and D79N (figure 3.5 B) mice. In WT arteries the combination of 
UK14304 and U46619 gave a contractile maximum of 0.73 ± O.OSgms Force, while in 
D79N arteries the maximum was 0.42 ± O.Obgms Force. Comparison of the results 
gained in WT and D79N arteries revealed that, again, the contractile responses were 
significantly greater in arteries from WT mice (p = 0.02*).
3.3.10 Combined contractile responses approach an adrenergic maximum in WT but not 
in D79N
Figure 3.6 shows the combined contractile response to high levels of U46619-induced 
tone and UK14304 in tail arteries from the WT (figure 3.6 A) and D79N (figure 3.6 B),
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Figure 3.4: The UK14304 response in tail arteries from 4-month old WT and D79N 
mice, expressed as a percentage of the max. response. A UK control curves (°, n = 
7 ), and in the presence of high U19-tone ( A, n = 12) in the WT. B UK control 
curves (o, n = 10 ), and in the presence of high U 19-tone ( A, n = 13) in the D79N. 
Each point represents mean ± standard error.
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Figure 3.5: Combined contractile response to UK and U19 (to 50% of the NA max) 
in tail arteries from 4-month old WT and D79N mice. A A UK curve in WT arteries 
(A, n = 12). B A UK curve in D79N arteries (A, n = 13). A it o w s  are indicative of 
the U 19-induced increase in basal tone. Each point represents mean ± standard error.
A WT
125
100
75O)
50
25
7 6
Log M [UK14304]
B D79N
125
00
75O)
50
25
"9 "8 "7 "6 -5
Log M [UK14304]
-4
Figure 3.6: Combined contractile response to UK and U19 (to 50% of NA 
maximum), expressed as a percentage of the NA max (1 x in tail arteries
from 4-month old WT and D79N mice. A The combined contractile response 
(A, n = 12) in WT arteries. B The combined contractile response (A, n = 13) in 
D79N arteries. Each point represents mean ± standard error.
expressed as a percentage of a noradrenaline maximum (1 x The combination
of U46619-induced tone and UK14304 produced a considerable contraction, given the 
size of the vessels studied. Expressing the combined contraction as a percentage of the 
noradrenaline response, showed that in WT arteries UK14304-mediated contractions on 
top of U46619-induced tone reached 101 ± 14.0 % of the response to sighting 
concentrations of noradrenaline. However, in tail arteries from D79N mice the 
combined response to U46619-induced tone and UK14304 only reached 6 8  ± 8 . 8  % of 
the contraction to noradrenaline.
3.3.11 Effect of L-NAME on UK-induced contractions in the presence of high levels of 
elevated vascular tone
Having established that high levels of U46619-induced tone provide favourable 
conditions for studying a 2 -adrenoceptor-mediated responses in the murine tail artery, 
one additional protocol was tested. L-NAME was incubated with arterial rings before 
raising vascular tone to high levels. Response curves to UK14304 were then performed 
in tail arteries from four-month old WT and D79N mice.
In WT arteries (figure 3.7 A), contractions tended to be smaller in the presence of L- 
NAME and had a maximum response of 0.25 ± O.OSgms Force. However, when 
compared with responses gained in the absence of L-NAME no significant difference 
was found (p = 0.44). In tail arteries from D79N mice (figure 3.7 B), contractile 
responses were significantly potentiated in the presence of L-NAME. The maximum 
response gained in the presence of high U46619-induced tone was 0.21 ± 0.04gms 
Force, while with L-NAME the maximum reached was 0.41 ± 0.04gms Force (p = 
0 . 0 2 5 Comparing the responses gained in D79N with WT arteries showed that in the
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Figure 3.7: The effect of L-NAME (1 x on the UK response in tail arteries
from 4-month old WT and D79N mice in the presence of high U19-induced tone. A 
The UK response in the presence of tone (A, n = 12), and tone with L-NAME (*, n = 
6 ) in the WT. B The UK response in the presence of tone (A, n = 13), and tone with 
L-NAME (*, n = 8 ) in the D79N. Each point represents mean ± standard error.
presence of high levels of U46619-induced tone and L-NAME, contractile responses 
were significantly greater in the D79N (p = 0.02*).
3.3.12 Effect of age on contractile responses in tail arteries from D79N mice 
Contractile responses can change with increasing age. Therefore, when a number of 
mice aged twelve-months became available, I decided to investigate if UK14304- 
mediated contractions were altered in old D79N mice. Figure 3.8 shows the contractile 
responses at four and twelve-months in tail arteries from D79N mice. Figure 3.8 A, 
shows the contractile responses to UK14304 on top of U46619-induced tone at both age 
points. In arteries from four-month old mice, the maximum contraction was 0.21 ± 
0.04gms Force, while at twelve-months the maximum response achieved was 0.17 ± 
0.03gms Force. Analysis of the responses gained at the different age points confirmed 
that UK14304-medi ated contractions are not significantly different at four and twelve­
months (p>0.05). However, when the combined contractile response to U46619- 
induced tone and UK14304 was compared, the results were quite different.
The combined contractile responses in arteries from twelve-month old D79N mice 
(figure 3.8 B) was significantly greater than the response at four-months (p = 0.01*). In 
arteries from twelve-month old mice, combined contractions reached a maximum of 
0.79 ± O.OSgms Force, but at four-months the maximum was 0.45 ± O.Obgms Force. In 
arteries from four-month old D79N mice the U46619-induced contraction was 0.24 ± 
0.04gms Force, at twelve-months contractions were significantly potentiated, and had a 
maximum response of 0.67 ± O.Obgms Force (p<0.0001***).
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Figure 3.8: Responses in tail arteries from 4 and 12-month old D79N mice with high 
U 19-tone. A UK curve on top of tone in arteries from 4 ( A, n = 10) and 12-month 
old (^, n = 6 ) mice. B Combined response to UK and U19-tone in arteries from 4 ( 
A, n = 10) and 12-month old ('*', n = 6 ) mice. Arrows are indicative of the U19- 
induced increase in basal tone. Each point represents mean ± standard error.
Therefore, the combination of elevated tone, and UK14304-mediated contractions leads 
to a significantly enhanced contractile response in arteries from older mice. However, 
the potentiation of responses can be attributed to an enhancement of the U46619- 
induced contraction, and is not UK14304-medi ated.
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3.4 Discussion
A small elevation in vascular tone uncovers UK143Q4-mediated contractions of the 
murine tail arterv
In the rat tail artery elevation of vascular tone with either 5HT [Templeton et al, 1988] 
or arginine vasopression (AVP) provides an environment that is suitable for studying 
(%2 -adrenoceptor-mediated contractile responses [Templeton et al, 1989]. Given these 
findings, it seemed logical to determine if similar conditions are required for the study 
of a 2 -adrenoceptor-mediated responses of the murine tail artery.
In the mouse tail artery, UK14304 causes, little, if any contractile effect in arteries from 
WT and D79N mice. However, low levels of vascular tone, elevated with U46619 (3 x 
lO'^M) allow contractile responses to be studied; by providing conditions that are 
similar to those required for (%2 -adrenoceptor-mediated pressor response to be studied in 
the rat tail artery [Templeton et al, 1989].
The thromboxane mimetic, U46619 was used to elevate vascular tone because the 
contractions that occur are independent of a i and (%2 -adrenoceptors. In the past, 
phenylephrine has been used to raise tone within a blood vessel. However, the 
complication of using phenylephrine is that a 2 -selective agonists, such as UK14304 can 
act as inverse agonists at oti-adrenoceptors in some rodent blood vessels (unpublished 
observation for our laboratory). Therefore, leading to an incoiTect interpretation of 
experimental results. For example, activation of a 2 -adrenoceptors could be falsely 
proposed to mediate relaxant responses in arteries preconstricted with phenylephrine, 
when, in fact, the "^-selective" agonist opposes ai-adrenoceptor-mediated contractions 
by acting as an inverse agonist. Under these experimental conditions, a 2 -adrenoceptor-
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mediated relaxations and activation of oti-adrenoceptor with an inverse agonist both 
lead to a reduction in the force generated within a mounted arterial ring.
In addition to the effects in the rodent tail artery, elevated vascular tone has been shown 
to enhance Œz-adrenoceptor-mediated responses in the isolated canine saphenous artery 
[Sulpizio & Hieble, 1987]. Furthermore, in the presence of an ai-selective antagonist, 
agonist-induced increases in blood pressure in the pithed rat, induced by agonists 
proposed to be selective for « 2 -adrenoceptor agonists are mediated by postjunctional 
a 2 -adrenoceptors, in vivo [Docherty & McGrath, 1980]. In the absence of a functional 
central nervous system, high circulating levels of angiotension II and catecholamines 
may act to maintain vascular tone. These conditions may provide a favourable 
environment for (%2 -adrenoceptor-mediated pressor effects.
In vitro, the elevation of vascular tone in the perfused rat tail is presumed to lead to an 
increase in intracellular calcium concentrations, which provides conditions suitable for 
(%2 -adrenoceptor-mediated contractions [Xiao et al, 1989]. Presumably, U46619 causes 
similar effects in the murine tail artery.
Elevated tone and inhibition of nitric oxide release provide no further enhancement of 
UK14304-mediated contractions
The contractile response to U46619 is not significantly greater in size in the presence of 
L-NAME. This data provides evidence that in the mouse tail artery, nitric oxide release 
is not constitutive. If nitric oxide release were constitutive in this artery, then it would 
act to oppose the contractions caused by U46619. Under these circumstances, L-
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NAME would be expected to cause a significant potentiation in the size of U46619- 
induced contractions, which is not the case.
The combined use of low levels of synergism and inhibition of nitric oxide release, do 
not enhance UK14304-mediated contractile responses in WT and D79N tail arteries. 
Therefore, it is more advantageous to use only one of these techniques as opposed to
■using both, which add another variable to an already complex experimental set-up.
7
Inhibiting nitric oxide release enhances UK14304-mediated contractions of the murine 
tail arterv
L-NAME can be used to prevent the release of nitric oxide in vivo, by adding the drug 
to an animal’s drinking water. Arteries isolated from animals given L-NAME in vivo
■I
show enhanced contractions to a 2 -selective agonists, in vitro [Carter & Kanagy, 2002]. 
Constitutive nitric oxide release can occur in isolated in vitro preparations [Furchgott
■ T
and Vanhoutte, 1989], and blockade of its release has been shown to enhance contractile 
responses in vivo [Conrad & Whittemore, 1992]. Therefore, I examined what effect L- 
NAME has on UK14304-mediated responses in the murine tail. L-NAME iiTeversibly 
binds to the enzyme nitric oxide synthase, which prevents the release of nitric oxide, 
which is a potent endothelial derived relaxing factor [Akaike et al, 1993]
L-NAME enhances UK14304-mediated contractions in tail arteries from WT and D79N 
mice. This could be caused by constitutive release of nitric oxide countering contractile 
responses that are mediated by ^-adrenoceptors. However this appears unlikely, 
because L-NAME does not potentiate contractile responses to other agonists in the 
murine tail artery.
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compared to a reference noradrenaline contraction.
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If the release of nitric oxide in the murine tail artery is not constitutive, then it must be 
caused by exogenous UK14304. Stimulation of ai-adrenoceptors, located on the 
endothelium of blood vessels leads to nitric oxide release [Bockman et al, 1993]. In the
:m ou se  tail artery, L-NAME enhances contractile  responses in both  W T  and D79N 
arteries. T herefore, this su ggests that otzAm-adrenoceptors do not m ediate nitric ox id e  
release, and that i f  UK14304 stim ulates nitric ox id e  release b y  direct m ech an ism s, they  
m ay result from  stim ulation  o f  a 2B and/or a 2c-adrenoceptor subtypes. A lternatively ,
UK14304 may indirectly lead to the release of nitric oxide. In order to determine if this 
is the case further experiments are required.
The mechanism whereby L-NAME leads to a potentiation of a 2 -adrenoceptor-mediated 
contractions in the mouse tail artery, are likely to involve calcium. In vivo, blocking 
nitric oxide release leads to an enhancement of a 2 -adrenoceptor-mediated contraction in 
vitro by activating two calcium pathways. One is tyrosine kinase dependent, the other 
does not depend on the activation of tyrosine kinases [Carter & Kangy, 2002].
High levels of vascular tone provide the most favourable conditions for the studv of 
UK14304-mediated contractions
Although low levels of U46619-induced tone permit UK14304-mediated contractions, 
the responses gained are still small, and highly variable. Therefore, I decided to 
increase the tone by using higher concentrations of the synergist, U46619. In an 
attempt to standardise the experimental conditions U46619-induced contractions were
1
In WT and D79N tail arteries the size of UK14304~mediated contractions (in the 
presence of high levels of U46619-induced tone) is significantly greater than any of the 
other protocols tested. In addition to enhancing the size of these responses, mounted 
arteries also become more sensitive to UKI4304, evidenced by higher pECso values. 
Given this, it appears that high levels of vascular tone are the most favourable 
conditions of all the protocols studied.
L-NAME potentiates UK143Q4-mediated contractions in the presence of high levels of 
vascular tone in the D79N but not in the WT
Having determined suitable conditions for the study of UK14304-induced contractions 
of the mouse tail artery, I then tested what effect L-NAME would have on the responses 
produced, under suitable experimental conditions.
In arteries from four-month old WT mice L-NAME has no effect on the size of the 
responses to UK14304. The vaiiability within the contractions gained is high, and is 
most probably due to the development of rhythmic arterial contractions, which are a 
complication of studying contractile responses in tail and mesenteric arteries. However 
in the D79N, incubation with L-NAME, prior to U46619-induced tone and a UK14304 
response curve causes a significant potentiation of the contractions gained.
The enhancement of responses by L-NAME may be the result of several different 
mechanisms, occurring alone, or in combination with each other. L-NAME may inhibit 
constitutive release of nitric oxide, which may occur in D79N mice, but not in the WT. 
This seems unlikely, as there is no evidence to support constitutive release, because L- 
NAME does not affect resting tone or U46619-induced contractions. Another
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possibility is that in the absence of a fully functional a2A/D-adrenoceptor-pool,
UK14304 may enhance nitric oxide release. The existence of normal, functional Œ2 A/D- 
adrenoceptors in the WT mouse may explain the difference in the results gained. This 
suggests that ^-adrenoceptors may be involved in the regulation of nitric oxide release 
in murine blood vessels. A hypothesis that is supported by results gained for the D79N 
in chapter six of this thesis. Where oc2 -adrenoceptor-mediated vasodilatations in 
mesenteric resistance arteries are significantly attenuated by L-NAME in the D79N, but 
not the WT.
U46619-induced contractions are significantlv enhanced with increasing age 
Responses to endogenous and exogenous agonists can be affected by advancing age 
[Rodriguez-Martinez et al, 1999]. However, the mechanisms involved are often 
complex and have been attributed to a variety of physiological alterations.
UK14304 causes concentration-dependent contractions in tail arteries from four and 
twelve-month old D79N mice. Contractions gained are of comparable size and 
sensitivity at the different age points. This suggests that UK14304-mediated 
contractions of cutaneous murine blood vessels are not altered in older animals. 
However, the combined contractile response to U46619-induced tone and UK14304 is 
significantly greater at twelve-months when compared with the responses gained at four 
months. The enhanced contractions result from a significant potentiation in U46619- 
mediated responses.
U46619 is a thromboxane mimetic, and the responses gained are intended to mimic the 
effects of endogenous contracting factors. Altered contractile responses to endothelial
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contracting factors are a common finding in blood vessels from elderly patients 
[Docherty, 1990]. Yet, it is often unclear if the elevation in vascular tone, that 
accompanies advancing age and leads to elevated blood pressure, results from increased 
release of vasoactive contracting factors, altered receptor numbers, or an alteration of 
the native receptor population within a blood vessel.
In tail arteries from old D79N mice, altered contractile responses may reflect a change 
in the sensitivity of endothelial receptor to U46619. A number of receptors are known 
to develop enhanced sensitivity to agonists with age, and under pathophysiological 
conditions. Therefore, this seems a probable hypothesis to explain the potentiation of 
U46619~induced contractions. Alternatively, U46619-mediated contractions may be 
enhanced by a reduction in the release of endothelial derived relaxing factors, which act 
to oppose contractile responses. In order to determine if this is the case, a further series 
of experiments are required. It would be interesting to determine what effect L-NAME 
and prostacyclin have in arteries from older mice. Unfortunately the completion of 
these studies was impossible during my experiments, as we had limited stocks of elderly 
mice, and the study of U46619-induced contractions is outwith the scope of this thesis.
Comparison of responses gained in WT and D79N tail arteries
UK14304-medi ated contractions of the murine tail artery are consistently smaller in the 
D79N than WT, in almost all protocols tested. The one notable exception is when tone 
has been elevated with high concentrations of the synergist, U46619, and arteries have 
been preincubated with L-NAME prior to construction of a UK14304 response curve.
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Excluding the last protocol, data strongly suggests that the point mutation in the a 2 A/o 
adrenoceptor has a detrimental effect on contractile responses of the murine tail artery. 
Indicating that the a 2 A/D-adrenoceptor plays a role in a 2 -adrenoceptor-mediated 
contractions of peripheral blood vessels. The remaining contractile response in the tail 
artery of the D79N may result from stimulation of a 2c-adrenoceptors, which are known 
to mediate vasoconstrictor responses in the rat tail [Craig et al, 1995]. Alternatively, 
they may result from non-selective stimulation of ai-adrenoceptors. However, the 
results contained in chapter four may suggest an alternative explanation for the altered 
responsiveness of the D79N tail aitery (where the non-cumulative response in the WT 
and D79N is comparable). The results, to which I refer, will be discussed in detail in 
chapter four.
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Chapter four
UK14304-induced contractions are complicated by 
receptor-desensitisation
144
4.1 Introduction
The development of persistent rhythmic contractility upon agonist administration is 
common in resistance arteries, and has been termed vasomotion [Peng et al, 2001]. 
Adrenoceptor-selective agonists and synergists such as U46619 can lead to the 
development of rhythmic contractions in murine blood vessels. Both of the resistance 
arteries studied in this thesis develop rhythmic contractions when stimulated with 
exogenous agonists. Although vasomotion is interesting in its own right, the 
development of rhythmic waves makes it extremely difficult to separate drug-induced 
contractions from spontaneous movements. In order to combat this, an adaptation of the 
original protocol was made. This was the addition of a low concentration of nifedipine 
(1 X 10'’M),
The UK14304-mediated response tends to ‘fall off’ at high agonist concentrations, 
which was indicative of agonist-induced receptor desensitisation and internalisation 
[Ferguson et al, 1997]. To ascertain whether desensitisation occurred in tail arteries 
challenged with UK14304, consecutive response curves were constructed in tail arteries 
from WT and D79N mice.
In addition to this, a series of non-cumulative response curves to UK14304 were 
performed. This was done to determine if the non-cumulative UK14304 response was 
less variable than that of the cumulative, and whether contractility was maintained at 
high agonist concentrations. The UK14304-medi ated response to non-cumulative 
administration was compai*ed with that of the cumulative, to determine if the size of 
contractile responses was affected by the way in which the agonist was administered.
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Having established suitable conditions that uncovered UK-mediated contractile 
responses, the use of selective antagonists was employed. The aa-selective antagonist, 
rauwolscine was used to confiim that the contractile response mediated by UK14304
I
resulted from stimulation of vascular a 2 -adrenoceptors. Prazosin, an ai-selective 
antagonist (3 x 10“^ M) was also used, to exclude the possibility that the UK14304 
response arose from stimulation of ot]-adrenoceptors.
___
4.2 Methods
4.2.1 Vessel dissection and mounting
Mice weighing between 28.9-33.6gms were euthanised by asphyxiation with CO2 , tails 
were removed and placed in fresh, cold Krebs solution until dissection. Tails were then 
pinned out on a petri dish, measured, and a 1.5cm section beginning 2.5cms from the 
base of the tail was marked. The thick, hairy, skin covering the tail was removed and 
the artery underneath exposed. The tail aitery was then dissected using ultra fine 
forceps and dissecting scissors. Once removed, the section of artery was cleaned of 
excess connective tissue and fat and cut into 2mm rings. These rings were then 
mounted in 5ml stainless steel Mulvany/Halpem myograph baths (described in detail in 
chapter two) and allowed to equilibrate for 20-30 minutes before setting the resting 
tension. Arteries were then stretched to give a resting tension of 0.25gms Force, and a 
further 20-30 minute equilibration was allowed.
4.2.2 Wake-up protocol
Mounted arterial rings were stimulated with noradrenaline at a concentration of 1 x 10 
^M, and contractions were allowed to reach a plateau before being washed with fresh 
K ebs. Each bath was washed four times with warmed, gassed K ebs over a fifteen 
minute period. This procedure was then repeated. The last concentration of 
noradrenaline used was slightly lower than the first two, at 1 x lO'^M. When the plateau 
of contraction was stable, acetylcholine at a concentration of 3 x lO'^^ M was 
administered to each bath, to determine if the endothelium on the mounted vessel was 
intact.
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4.2.3 Incubation with nifedipine
Nifedipine stock solution (1 x lO'^M) was prepared in 100 % alcohol, and diluted in 
distilled water before each experiment to give a solution at the desired concentration ( 1  
X lO’^ ^M, final bath concentration of 1 x lO'^M). Nifedipine was used in all of the 
experiments where UK14304-medi ated responses were investigated. Mounted arterial 
segments were incubated with nifedipine for a minimum of twenty minutes before 
construction of a response curve.
4.2.4 Elevation of vascular tone
Prior to construction of an UK14304-mediated response curve, the tone within each 
mounted arterial ring was elevated with the thromboxane mimetic, U46619. I have 
already established that an increase in tone provides conditions that were suitable for the 
study of UK14304-induced contractions of the murine tail artery. In earlier experiments 
(shown in chapter three) U46619 was added in half log increments to give a contraction 
compamble to fifty percent of the noradrenaline response (1 x lO’^ M). In most cases, a 
stable contraction, close to fifty percent of the noradrenaline maximum was achieved 
with U46619 at a concentration of 1 x lO'^M. Therefore, in order to reduce variability, 
this concentration was used for all of the experiments contained within this chapter.
4.2.5 Effect of rauwolscine and prazosin on UK143Q4-induced contractions 
Rauwolscine and prazosin were prepared in accordance with the manufacturers 
guidelines (described in Chapter two). Both antagonists were used at the same 
concentration of 3 x lO'^M, and incubated for thirty minutes before construction of a 
response curve. For each antagonist the concentrations were chosen as being
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significantly above the pAi concentration for the receptor being blocked, but below the 
pA2  value for the other receptors, intended not to be blocked.
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4.3 Results
4.3.1 Nifedipine prevents the development of unwanted rhythmic contractions in the tail
Figure 4.1 shows a trace of the effect of nifedipine on the development of rhythmic 
contractions in the murine tail artery from a four-month old WT mouse. Figure 4.1 A 
shows that in the absence of nifedipine constriction with the synergist U46619, followed 
by a series of washes, caused rhythmic contractions to develop. In figure 4.1 B 
nifedipine ( 1  x lO'^M) has been incubated for twenty minutes prior to contraction with 
U46619 (1 X 10‘^ M). In the presence of nifedipine basal tone is stable, and the 
development of rhythmic contractions was blocked.
Nifedipine (1 x lO'^M) was incubated with tail aitery segment from four-month old WT 
(figure 4.2 A) and D79N (figure 4.2 B) mice before construction of a cumulative 
UK14304 response curve. Nifedipine prevented the development of vasomotion and 
tended to reduce the variability of the responses gained. In WT arteries the maximum 
UK14304 response was 0.27 ± 0.03gms Force at (3 x lO'^M) in the presence of 
nifedipine, whereas the maximum response at the same agonist concentration, without 
nifedipine was 0.33 ± 0.07gms Force (p>0.05). The size of the contractions gained in 
the D79N was unaffected by nifedipine, but the development of rhythmic contractions 
was halted. With UK14304 alone, the maximum UK14304 response at 3 x lO'^M was 
0.21 ± 0.05gms Force while in the presence of nifedipine the same agonist 
concentration produced a maximum of 0.19 ± 0.02gms Force (p>0.05). Thereafter, 
nifedipine was incubated with all mounted arteries used to study the UK14304-medi ated 
response in the tail artery.
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BFigure 4.1: A representative trace of the effect of nifedipine on the development 
of rhythmic contractions in the tail artery of a 4-month old WT mouse. A 
Rhythmic contractions in a mounted tail artery, previously exposed to UI9. B 
Abolition of rhythmic contractions in the presence of nifedipine (1 x lO'^M). 
The responses shown are in a single vessel.
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Figure 4.2: The UK response in tail arteries from 4-month old WT and D79N 
mice. A The cumulative UK response alone (o, n = 12), and with nifedipine (At 
1 X lO'^M, • , n = 12) in the WT. B The cumulative UK response alone (o, n = 
12), and with nifedipine (• , n = 12) in the D79N. Each point represents mean ± 
standard error.
4.3.2 UK143Q4-induced responses are susceptible to profound desensitisation 
Figure 4.3 shows the responses gained to consecutive, cumulative curves to UK14304 
in tail arteries from four-month old WT (figure 4,3 A) and D79N mice (figure 4.3 B).
In arteries from WT mice, UK14304 caused concentration-dependent contractions of 
tail arteries. However, a second curve, thirty minutes later to the (%2 -selective agonist 
could not be constructed. This showed that UK14304-mediated vasoconstrictor 
responses were profoundly desensitised. The maximum response gained in the first 
curve reached 0,27 ± 0.03gms Force, whereas in the second curve, the maximum was 
0.03 ± 0.03gms Force, in tail arteries from WT mice. Responses obtained in tail arteries 
from D79N mice were similar. The maximum response gained in a first UK14304 
curve was 0.19 ± 0.02gms Force, and is smaller than that of the WT (p = 0.018*).
Thirty minutes later a second curve produced significantly smaller contractions at all 
drug concentrations tested and had a maximum response of 0.10 ± 0.02gms Force. 
Again, this indicated that the receptors stimulated by UK14304 were desensitised.
4.3.3 Phenvlephrine-induced responses are not affected bv UK14304 desensitisation 
In figure 4.4 the cumulative phenylephrine response, and phenylephrine-induced 
contractions after, a UKI4304 curve, in tail arteries from four-month old WT mice are 
shown. In the vessels where phenylephrine was given alone one concentration response 
curve was constructed, while in those exposed to an initial UK14304 curve, two 
response curves were performed. Figure 4.4 A shows the absolute size of the responses 
gained to increasing concentrations of phenylephrine. Figure 4.4 B shows the 
phenylephrine response, expressed as a percentage of its own maximum. The first 
curve to phenylephrine, constructed before a cumulative UK14304 curve had a 
maximum of 1,08 ± 0.07gms Force, compared with the curve performed after
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Figure 4.3: Cumulative UK response curves in tail arteries from 4-month old 
WT and D79N mice. A A first (o, n = 12) and second (• , n = 6 ) UK response 
curve in WT arteries. B A first (°, n = 12) and second (• , n = 6 ) UK response 
curve in D79N arteries. Each point represents mean ± standard eiror.
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Figure 4.4: Cumulative phenylephrine response curves in tail arteries from 4- 
month old WT mice. A PE response curve before (o, n = 5), and after (•, n = 5) 
a cumulative UK curve. B PE response curves, expressed as a percentage of the 
maximum before (o, n = 5), and after (•, n = 5) a UK curve. Each point 
represents mean ± standard error.
UK14304, which had a maximum response of 1.04 ± 0.06gms Force. Thus, the size of 
contractions to phenylephrine were unaffected by previous exposure to UK14304. By 
expressing the data as a percentage of the maximum response, pECso values could be
'
calculated. In the curve carried out before a UK14304 curve, a pECso value of 6.1 ±
0.05 was obtained, compared with a value of 6.2 ± 0.04 for the curve performed after.
These pECso values indicated that the sensitivity of the tail artery to phenylephrine is 
unchanged by UK14304 treatment (p>0.05).
The phenylephrine response curves constructed after a first curve to UK14304 gave 
contractions that were of comparable size and sensitivity to those only exposed to
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Figure 4.5 shows the response to phenylephrine in a first curve, and the phenylephrine 
response curve constructed after an initial curve to UK14304, in tail arteries from four- 
month old D79N mice. Phenylephrine-induced contractions in the D79N tail arteries 
were generally smaller than those obtained in age matched WT arteries. Regardless of 
the smaller maximum when compared with the WT, the phenylephrine-mediated 
response was unaffected by prior exposure to UK14304. In phenylephrine curves, 
constructed before and after UK14304, the maximum contractile responses gained was 
of comparable size. The phenylephrine response curve, constructed before a cumulative 
UK14304 curve, had a maximum of 0.63 ± 0.05gms Force, compared with the 
maximum response after, which was 0.59 ± 0.09gms Force (figure 4.5 A). In figure 4.5 
B the phenylephrine response curves have been expressed as a percentage of their own 
maximum. The pECgo value for the curve before a UK14034 response was 5.7 ± 0.02, 
compared with a pECso value of 5.7 ± 0.02 calculated for the phenylephrine curve 
constructed after UK14304 treatment (p>0.05).
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Figure 4.5: Cumulative phenylephrine response curves in tail arteries from 4- 
month old D79N mice. A PE response curve before (o, n = 5), and after (• , n =
5) a cumulative UK curve. B PE response curves, expressed as a percentage of 
control maximum before (o, n = 5), and after (•, n = 5) a UK curve. Each point 
represents mean ± standard eiTor.
phenylephrine in the WT and D79N. This indicated that the desensitisation shown in 
figure 4.3 is specific to UK14304“induced responses, and was not caused by a 
generalised reduction in responsiveness to applied agonists.
The responses obtained in tail arteries from four-month old WT (figure 4.6 A) and 
D79N (figure 4.6 B) mice to the agonists phenylephrine and UK14304 aie shown in 
figure 4.6. Comparison of the data showed that contractions to phenylephrine, in tail 
arteries from WT mice, were significantly greater than those obtained in tail arteries 
from age matched D79N mice (p<0.0001*'^*). UK14304-induced contractions were 
smaller than phenylephrine-mediated vasoconstrictor responses in the WT and D79N. 
In both murine strains, a second response curve to UK14304 could not be obtained, 
because of profound, persistent, desensitisation of responses.
WT D79N
Maximum (gms Force) Maximum (gms Force)
Cumulative (nifedipine -) 0.33 ± 0.07 0.21 ±0.05
Cumulative (nifedipine +) 0.27 ± 0.03 0.19 ±0.02
Second curve 0.03 ± 0.03 0 . 1 0  ± 0 . 0 2
Non-cumulative curve 0.35 ± 0.02 0.36 ± 0.02
Table 4.1 The maximum UK response in tail arteries from the WT and D79N
4.3.4 The effect of rauwolscine on desensitised second curves to UK14304 
Figure 4.7 shows the responses obtained to a second, cumulative UK14304 curve, 
constructed in the presence of rauwolscine (3 x lO'^M) in tail arteries from four-month
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Figure 4.6: Agonist-induced responses in tail arteries from 4-month old WT and 
D79N mice. A A first (o) and second (•) cumulative UK curve, a first (a) and 
second (■) cumulative PE curve, respectively. A Agonist curves in WT arteries, 
n = 12, 6 , 5, and 5. B Agonist curves in D79N arteries, n = 12, 6 , 5, and 5. Each 
point represents mean ± standard enor.
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old WT (figure 4.7 A) and D79N (figure 4.7 B) mice. In WT arteries, a second 
cumulative response curve to UK14304 gave no measurable response. However, in the 
presence of rauwolscine, a second could be obtained. With rauwolscine, the UK14304- 
induced maximum was significantly greater at 0.47 ± 0.04gms Force than that of the 
first UK14304 curve maximum of 0.27 ± 0.03 (p = 0.0004*
Responses in tail arteries from D79N also exhibit desensitisation in a second response 
curve, but responses in the first control curve were smaller than that of the WT. A 
second, cumulative curve to UK14304 was impossible. However, when tissues were 
incubated with rauwolscine (3 x lO'^M) for thirty minutes, a second UK14304 curve 
could be obtained. The maximum response gained for the second curve to UK14304, 
alone was 0.10 ± 0.02gms Force, compared with that obtained in a second curve in the 
presence of rauwolscine, which was 0.26 ± 0.03gms Force, and significantly greater 
than the first curve maximum (p = 0.015*).
■ I'■S:
and D79N (figure 4.8 B) mice are shown in figure 4.8. In WT arteries, the maximum 
contraction obtained in the presence of rauwolscine reached 150.5 ± 13.5 % of the 
maximum gained in the control curve. Responses in tail arteries from D79N mice were 
also potentiated in maximum, and in the presence of rauwolscine reached 136.5 ± 10.0 
% of the first UK14304 curve maximum. Although potentiated in maximum in the WT 
and D79N the presence of rauwolscine shifted the response curve (at lower agonist 
concentrations) to the right, indicative of a shift in sensitivity. In the WT, the first curve
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Responses in a first curve to UK14304 alone, and a second curve constructed in the 
presence of rauwolscine, have been expressed as a percentage of the first curve
maximum. The results gained for tail arteries from four-month old WT (figure 4.8 A)
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Figure 4.7: The effect of rauwolscine (3 x lO'^M) on a second cumulative UK 
response curves in tail arteries from 4-month old WT and D79N. A A second 
UK curve alone (o, n = 6  ), and with rauwolscine (• , n = 6 ) in WT arteries. B A 
second UK curve alone (o, n = 6  ), and with rauwolscine (•, n = 6 ). Each point 
represents mean ± standard error.
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Figure 4.8: Responses to cumulative UK curves in tail arteries from 4-month old WT 
and D79N mice, expressed as percentage of the first curve maximum. A The UK 
response in a first (o, n =12 ) and second curve with rauwolscine (3 x lO'^M, • , n =
6 ) in WT. B The UK response in a first (o, n = 12) and second curve with 
rauwolscine (•, n = 6 ) in D79N. Each point represents mean ± standard eiTor.
has a pECso of 8 . 2  ± 0 .3 , which was significantly higher than the value gained for 
rauwolscine, of 6 . 6  ± 0.02 (p = 0.0002***). In the D79N first curve, the pECso was 8.1 
± 0 .3 , which was significantly higher than the pECso value of 6.55 ± 0.09, gained in the 
presence of rauwolscine (p<0 .0 0 0 1 ***).
4.3.5 Cumulative versus non-cumulative drug administration
Contractile responses to UK14304 in the cumulative response tended to ‘fall off’ at high 
agonist concentrations. In constructing the non-cumulative curve, tail arteries were 
exposed to each UK14304 concentration for approximately three minutes; responses 
constructed in this way, were not susceptible to a reduction in response over time, 
unlike the cumulative response. Figure 4.9 shows the responses gained in cumulative 
and non-cumulative curves to UK14304, constructed in tail arteries from four-month 
old WT (figure 4.9 A) and D79N (figure 4.9 B) mice. In WT arteries responses tended 
to be slightly greater in size, when UK14304 is administered non-cumulatively. The 
maximum contraction obtained for the cumulative curves was 0.27 ± 0.03gms Force, 
compared with a maximum contraction of 0.35 ± 0.02gms Force in the curve 
constructed non-cumulatively. Contractions gained in arteries from four-month old 
D79N mice were significantly greater in size at all agonist concentrations tested, with 
the maximum contraction in a cumulative curve being 0.19 ± 0.02gms Force, while in 
the non-cumulative curve, the maximum response of 0.36 ± 0.02gms Force was 
significantly higher (p<0 .0 0 0 1 ***).
Constructing a UK14304 response curve non-cumulatively, lead to a significant 
enhancement of the contractile responses in tail arteries from D79N mice. Contractions 
of the WT tail artery had a slight reduction in variability, but were not significantly
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Figure 4.9: UK response curves in tail arteries from 4-month old WT and D79N 
mice (Both first curves). A A cumulative (o, n = 9) and non-cumulative (• , n = 
11) UK response curve in WT arteries. B A cumulative (o, n = 7) and non- 
cumulative (• , n = 6 ) UK response curve in D79N arteries. Each point 
represents mean ± standard en'or.
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potentiated in size, when curves were constructed non-cumulatively. Given this, and 
the fact that construction of a second curve is prevented by desensitisation, the decision 
was taken to study the effects of antagonists on first, non-cumulative curves, as opposed 
to the traditional method of using, consecutive, cumulative response curves.
Mounted segments of tail artery were incubated with rauwolscine, at a concentration of 
3 X lO'^M, before constructing a non-cumulative UK14304 response curve. The 
responses gained in tail arteries from four-month old WT (figure 4.10 A) and D79N 
(figure 4.10 B) mice are shown in Figure 4.10. In WT and D79N arteries rauwolscine 
caused a rightward shift in the concentration response curve to UK14304, without 
causing a reduction in the contractile maximum.
In figure 4.11 the responses to non-cumulative UK14304 alone, and with rauwolscine (3 
X lO'^M), have been expressed as a percentage of their own maximum to determine 
pECso values. In arteries from WT mice (figure 4.11 A) the pECgo value for the control 
curve was 7.5 ± 0.3, compared with a lower pECso value of 6.5 ± 0.07 in the presence of 
rauwolscine, a difference that was highly significant (p = 0.0005***). This shift in the 
pECso value indicates that rauwolscine is antagonising UK14304-induced contractions. 
As only a single concentration of rauwolscine was used, a pAi value was not 
determined, but a pKs value of 8.5 ± 0.21 was calculated by deteimining the shift in the 
response in unpaired vessels. Rauwolscine had a similar effect in D79N tail arteries 
(figure 4.11 B). A pECso value of 8.1 ± 0.3 was calculated for the control curve and 
compared with a value of 6.5 ± 0.09 in the presence of rauwolscine (p = 0.0002***). 
The pKb value calculated for rauwolscine in the D79N tail artery was 8.7 ± 0.30.
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Figure 4.10: Non-cumulative UK response curves in unpaired tail aiteries from 4- 
month old WT and D79N mice. A The UK response alone (°, n = 12) and with 
rauwolscine (3 x 10"^M, • , n = 6 ) in WT arteries. B The UK response alone (o, n 
= 6 ) and with rauwolscine (• , n = 6 ) in D79N arteries. Each point represents mean 
± standard error.
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Figure 4.11: Non-cumulative UK response curves in unpaired tail arteries from 4- 
month old WT and D79N mice, expressed as a percentage of the maximum. A The 
UK response alone (o, n = 12) and with rauwolscine (• , n = 6 ) in WT arteries. B 
The UK response alone (o, n = 6 ) and with rauwolscine (• , n = 6 ) in D79N aiteries. 
Each point represents mean ± standard error.
4.3.6 The effect of prazosin on non-cumulative UK14304 curves in murine tail aiteries 
Figure 4.12 shows responses gained to non-cumulative UK14304 curves, alone, and in 
the presence of prazosin (3 x lO'^M), in tail arteries from four-month old WT (figure 
4.12 A) and D79N (figure 4.12 B) mice. The maximum contraction to UK14304, 
achieved in aiteries from WT and D79N mice was unaffected by the presence of 
prazosin. In WT arteries, contractions reached a maximum response of 0.31 ± O.Olgms 
Force in controls, compared with a maximum of 0.28 ± 0.02gms Force, gained in the 
presence of prazosin. Comparison of the pECso values gained for a control curve, with 
those incubated with prazosin showed no significant shift in the responses gained (p = 
0.10). Prazosin, unlike rauwolscine, did not cause a rightward shift in the concentration 
response curve. This suggested that the vasoconstrictor responses induced by UK14304 
are not due to the non-selective stimulation of % -adrenoceptors, even at high agonist 
concentrations.
A similar picture emerged for the D79N mouse. The maximum contraction gained in 
the control curve was 0.37 ± 0.03gms Force, compared with the maximum response 
gained in the presence of prazosin of 0.38 ± 0.04gms Force. Prazosin did not cause a 
rightward shift in the concentration response curve to UK14304. The pECso values 
gained were no different from that of a control curve (p = 0.52). Again, this suggested 
that, even at high agonists concentrations, UK14304 did not stimulate (%%-adrenoceptors.
157
A WT
0.75
0.50
0.25
0.00
l_9 568 7
Log M [UK14304]
B D79N
0.75
0.50
D) 0.25
0.00
-9 -8 -7 -6 -5
log M [UK14304]
Figure 4.12; Non-cumulative UK response curves in unpaired tail arteries from 4- 
month WT and D79N mice. A The UK response alone (o, n = 12) and with 
prazosin (3 x 10"^M, • , n = 6 ) in WT arteries. B The UK response alone (o, n = 
4) and with prazosin (• , n = 4) in D79N arteries. Each point represents mean ± 
standard eiTor.
4.4 Discussion
Low concentrations of nifedipine abolish rhythmic contractility 
Mounted segments of tail artery from WT and D79N mice develop rhythmic 
contractions in response to U46619 and the adrenergic agonists phenylephrine and 
UK14304. Incubation with the L type calcium channel antagonist, nifedipine (1 x 10' 
^M) prevents the development of rhythmic activity. In the presence of nifedipine, 
agonist-induced contractions still occur, but are slower to develop. Vascular 
contractions depend, in part, on calcium wave activity, which is regulated by the 
sarcoplasmic reticulum and mitochondria [Sward et al, 2002]. Exogenous agonists can 
stimulate calcium oscillations in vascular smooth muscle cells in vitro. The 
sarcloplasmic reticulum develops rhythmic oscillations in calcium release in response to 
InsP] [Ruehlmann et al, 2000]. The results gained with nifedipine, suggest that 
rhythmic contractions of the murine tail depend, in part, on extracellulai' calcium. In 
electrically excitable cells, stimulation of aa-adrenoceptors inhibits voltage-operated 
Ca^ "^  channels, which is in part responsible for the inhibition of noradrenaline release 
[Holz et al, 1986]. In the rat tail artery and canine saphenous vein, Ca^ '*' channel 
antagonists attenuate aa-adrenoceptor-mediated contractions, and when extracellular 
Ca^ "^  is removed from the suiTounding bathing solution, responses are abolished 
[Medgett & Rajanayagam, 1984]. This provides evidence that (%a-adrenoceptor- 
mediated contractions rely upon the influx of extracellular calcium ions, a process that 
nifedipine blocks in vitro [Dunn et ai, I99I]. By reducing the influx of calcium ions 
through L type channels in the mouse tail artery, nifedipine successfully blocks 
unwanted rhythmic movements, and in doing so provides experimental conditions that 
are suitable for further pharmacological analysis.
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Agonist-induced receptor desensitisation
UK14304-induced contractions of WT and D79N tail artery are subject to profound, 
persistent, agonist-induced desensitisation. The desensitisation that occurs persists, 
even when UK14304 has been removed from the suiTounding bathing solution, 
suggesting that the process of desensitisation begins during construction of the first 
UK14304 response curve. A series of washes with fresh Krebs and a rest period of 
thirty-minutes separate first and second curves. Yet a second, cumulative response to 
UK14304 is still not possible.
Agonist-dependent receptor desensitisation, like that occurring in the UK14304 
response, is mediated by G protein coupled receptor kinases and airestin molecules 
[Ferguson et al, 1997]. Once activated, receptor kinases and arrestins regulate the 
uncoupling and internalisation of agonist bound receptors. Active, agonist-bound 
receptors are internalised when they have been taigeted for sequestration.
Internalisation proceeds via dynamin-dependent clathrin coated vesicle endocytosis. A 
process that only proceeds when receptors tagged for internalisation have been 
phosphorylated, and are bound by anestin molecules [Ferguson et al, 1997].
Pre and postjunctional ai-adrenoceptors are both susceptible to drug-induced 
desensitisation. Presynaptic (%2 -adrenoceptors located in the mouse atria are prone to 
receptor desensitisation [Bucheler et al, 2001]. aac-adrenoceptor-mediated 
autoinhibition of noradrenaline release from nerve terminals is attenuated by prolonged 
expose to (%2 -selective agonists [Bucheler et al, 2002]. Desensitisation of postjunctional 
Œ2 -adrenoceptors also occurs in vitro, evidenced by a progressive reduction in the 
noradrenaline-mediated response curve maximum in sequential concentration curves
159
[Rodriguez-Mai’tinez et al, 1999]. A progressive reduction in the maximum 
vasoconstrictor response achieved is indicative of agonist-induced receptor 
desensitisation.
The % -adrenoceptor-mediated response in the tail is free from agonist-induced 
desensitisation
The magnitude of the response gained and the sensitivity of the tissue to phenylephrine 
are unaffected by repetitive stimulation of - adrenoceptors, and by previous exposure 
to UK14304. Consecutive responses to the aj-selective agonist phenylephrine can be 
obtained in the WT and D79N. This suggests that the profound desensitisation that 
occurs with UK14304 is confined to cxz-adrenoceptors, and does not result from a 
generalised reduction in tissue contractility.
T h e n on -cum ulative resp on se  to UK14304 overcom es reduced contractility  in the 
D79N. All o f  the resp on se curves sh ow n  in chapter three w ere constructed  
cu m ulatively . In each  protocol tested , m axim al contractions o f  the D79N are 
s ign ifican tly  sm aller than th ose obtained in  the W T . T h is in itia lly  led  to the con clu sion  
that the (%2A/D-adrenoceptor is a m ajor contributor to Œ 2-adrenoceptor-m ediated  
contractions o f  the m urine tail artery. H ow ever , the results sh ow n  here refute this.
The non-cumulative response to UK14304 in the D79N is significantly greater than the 
response gained in a cumulative curve, giving a response that is of comparable 
magnitude to that of the WT. The size of contractile responses in WT arteries is 
unaffected by the method in which UK14304 is administered.
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Incubation with rauwolscine permits a second cumulative curve with a potentiated 
maximum response
Consecutive, cumulative UK14304 response curves were constructed alone, and in the 
presence of the aa-selective antagonist, rauwolscine (3 x lO'^M). The control curve 
gained has already been shown (figure 4.1), and is subject to profound agonist-induced 
desensitisation. However, arteries incubated with rauwolscine have quite different 
responses.
In the presence of rauwolscine, the construction of a second cumulative response is 
possible. The responses gained are significantly potentiated in maximum, but are 
shifted rightward at lower agonist concentrations. So how does rauwolscine prevent, 
and essentially reverse UK14304-mediated desensitisation?
Stimulation of UK14304 sensitive receptors in the tail artery may lead to a response that 
is permanently ‘switched on’. The binding of rauwolscine, which has affinity for the 
receptor without having efficacy, may ‘switch o ff the second messenger cascade 
activated by UK14304. Alternatively, the binding of the antagonist to active receptors 
may retain them at the plasma membrane, thus preventing internalisation and 
sequestration to intracellular binding sites. Adrenoceptor antagonists can alter the 
activation state of constitutively active G-protein coupled receptors [Zhu et al, 2000]. 
Alternatively, rauwolscine may ‘switch on’ a response that is inhibited by UK14304- 
mediated stimulation of (%2 -adrenoceptors. This would suggest that (%2 -adrenoceptors 
aie constitutively turned off, a state which is overcome by U46619-induced tone.
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The potentiation in size of the response to UK14304 is more pronounced in the WT, 
than the D79N, suggesting two possibilities. It may be that the aaA/o-adrenoceptor is a 
major contributor to vasoconstrictor responses of the murine tail artery. Alternatively, 
UK14304 may stimulate the release of a relaxing factor that acts to oppose the 
development of contractile responses. In the absence of a functional aiA/o- 
adrenoceptor, responses that oppose contractions may proceed unchecked. This 
suggests a regulatory role for the c%2 A/D in mediating contractility at the vessel level.
Rauwolscine antagonises the UK14304 response in first curves constructed non- 
cumulativelv
In an attempt to standardise the experimental conditions used to study a 2 -adrenoceptor- 
mediated responses in the tail aitery, the decision was taken that first curves, 
constructed non-cumulatively are more suitable for pharmacological analysis. In WT 
and D79N arteries, rauwolscine shifts the UK14304-mediated response curve rightward, 
without affecting the maximum agonist-induced contraction. Under these experimental 
conditions, rauwolscine shifts the UK14304 response curve, therefore reducing the 
pECso value gained. This demonstrates that UK14304-mediated vasoconstrictor 
responses result from stimulation of a 2 -adrenoceptors located on the vasculai’ wall of 
the murine tail artery.
At high agonist concentrations, drugs marketed as subtype-selective, can stimulate other 
structurally related receptors. To determine if the contraction to UK14304 at high 
concentrations can be attributed to stimulation of vascular oci-adrenoceptors, the non- 
selective, potent ai-antagonist prazosin was used. Prazosin (3 x lO'^M) failed to shift
the UK14304 response, and had no effect on the magnitude of contractions gained in the
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WT and D79N. Although ineffective against the UK14304-mediated response, prazosin 
antagonises phenylephrine-induced contractions of the murine tail artery, causing a 
rightward shift in the concentration curve and a significant reduction in the maximum 
response at high antagonist concentrations (chapter seven). These results provide 
evidence that, at least in the murine tail artery, UK14304-mediated responses are not 
attributable to vascular ai-adrenoceptors.
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Chapter five
The effect of cold temperatures on contractions of
cutaneous blood vessels from WT and D79N mice
164
5.1 Introduction
Cutaneous blood vessels are primed to respond to subtle, physiological changes in the 
external environment. Most of the changes that occur are protective, and function to 
preserve vital physiological functions from cold-induced damage.
a 2 -adrenoceptors are expressed at high levels in cutaneous resistance arteries and veins. 
It is the high expression levels of (%2 -adrenoceptors at these sites that first lead to the 
hypothesis that these receptors may have a role in thermoregulation [Flavahan & 
Vanhoutte, 1986].
Cold temperatures stimulate a protective reflex that leads to an increase in sympathetic 
outflow and elevated levels of catecholamines, such as noradrenaline. In addition to the 
central effects induced by cold temperatures, local changes also occur [Vanhoutte, 
1980]. Local alterations are thought to lead to an enhancement of vasoconstrictor 
responses at cold temperatures (at 28^C), by activating quiescent (X2 -adrenoceptors of 
the a 2 c subtype [Chotani et ai, 2000]. The model system for these studies was the 
mouse tail artery.
However, under normal physiological conditions the surface temperature of the rat tail 
artery will be significantly lower than core body temperature [Redfem et al, 1995], and 
will reflect the temperature of the external suiToundings. This therefore raises the 
question of whether the a 2 c-adrenoceptor participates in vasoconstrictor responses 
“normal” physiological temperatures. This leads me to ask the question; “Should the 
study of functional responses in the rat and mouse tail artery be carried out at room 
temperature, as opposed to core body temperature of 37^C?”
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The tail artery of the rat and mouse is believed to be involved in thermoregulation, so its 
sensitivity to changes in temperature may relate somehow to this function. The tail 
artery has been used here to study the effects of temperature on a i- and Œz- 
adrenoceptor-mediated responses. The D79N mouse presents the opportunity to study
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the effect of cold on « 2 -niediated responses in the absence of the a 2 A/o and, therefore,
,..r-
potentially in a simpler situation regarding participation of different a 2 "Subtypes
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5.2 Methods
The middle section of the tail aitery from WT and D79N weighting 27.4-32.9gms mice 
was dissected and mounted in 5ml, stainless steel Mulvany/Halpern myograph baths (as 
described in detail in Chapter two).
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5.2.1 Effect of temperature on % and g^-adrenoceptor-mediated contractions of the 
murine tail artery
To determine the effect of cold temperatures on phenylephrine and UK14304-induced 
contractions, two experimental protocols were employed. The first series of these 
experiments was carried out at normal physiological temperatures of 37°C. In the 
second protocol, arterial rings were allowed to equilibrate in myograph baths at room 
temperature in a thermostatically controlled room, where the ambient temperature was 
set to 22^C (actual temperature ranged from 21.5-23.5°C). Fresh Krebs and any drugs 
used were all stored at room temperature for the duration of the protocol.
5.2.2 Wake-up protocol 
Mounted arterial rings were challenged with three concentrations of the non-selective 
adrenergic agonist, noradrenaline. Two concentrations of the drug were employed. The 
first (1 X 10 M) was used to give a contraction near to the adrenergic maximum. When 
a stable contractile plateau was obtained, vessels were then washed four times, over a 
fifteen minute period, before the procedure was repeated with the same agonist 
concentration. A second lower concentration of noradrenaline (1 x lO'^M) was then 
added, the contraction was allowed to reach a plateau, and acetylcholine (3 x lO’^ M)
was used to check that the endothelium of mounted vascular rings was intact.
5.3 Results
5.3.1 Agonists-induced responses in the WT and D79N tail artery 
Figure 5.1 shows the results gained for cumulative concentration curves to three 
agonists, in tail arteries from four-month old WT (figure 5.1 A) and D79N (figure 5.1 
B) mice. Response curves to phenylephrine, noradrenaline and 5HT were constructed 
in mounted tail arteries to determine the potency order of these agonists in each murine 
strain. This was an attempt to determine any changes in the general sensitivity to 
agonists in the D79N mouse.
In arteries from WT (figure 5.1 A) and D79N (figure 5.1 B) mice, all three agonists 
produced concentration-dependent contractions. Within each strain, the sensitivity and 
maxima of curves to phenylephrine and noradrenaline were of comparable size with the 
phenylephrine maximum being 1.08 ± 0.14gms Force, compared with the noradrenaline 
maximum of 1.12 ± 0.13gms Force (p>0.05). In both strains the response to 5HT was 
susceptible to desensitisation at high agonist concentrations, which gave a bell-shaped 
response curve. For example, in the WT the peak contraction occuned at a 
concentration of 3 x lO'^^ M and yielded a contraction of 0.84 ± 0.14gms Force. Each 
additional cumulative drug administration caused a further reduction in the contractile 
response, and at the highest 5HT concentration the contraction was reduced to 0.44 ± 
O.lSgms Force.
Agonist-induced responses in arteries from four-month old D79N mice tended to be 
smaller than those obtained in arteries from WT mice. The maximum response gained 
in a noradrenaline and phenylephrine response curve were significantly smaller than 
those gained in the WT (NA, p = 0.04*, PE, p = 0.03*). Both WT and D79N tissues
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Figure 5.1: Agonist response curves in tail arteries from 4-month old WT and 
D79N mice. A PE (o, n = 12), NA (•, n = 7) and 5HT (n, n = 8 ) response 
curves in WT arteries. B PE (o, n = 6 ), NA (•, n = 6 ) and 5HT (□, n = 6 ) 
response curves in D79N aiteries. Each point represents mean ± standard eiTor.
were more sensitive to noradrenaline than to phenylephrine. The sizes of the contractile 
responses to each agonist are recorded in table 5.1.
WT D79N
Maximum pECso Maximum pECso
Phenylephrine 1.08 ±0.14 
11 = 1 2
6.1 ±0.05 0.84 ± 0.08* 
11 = 6
5.9 ± 0.07
Noradrenaline 1.12±0.13 
11 = 7
6 . 6  ± 0.04 0.87 ±0.09* 
n = 6
6.3 ± 0.02
5HT 0.84 + 0.14 
n = 8
6 . 8  ± 0 . 1 0 0.78 ± 0.08 
11 = 6
6 . 8  ± 0.09
UK at 37"C(after PE) 0.21 ± 0.03 
n = 5
9.1 ±0.5 0.22 ± 0.05 
11 = 6
9.0 ±0.12
UK at 22^C (after PE) 0.54 ±0.06* 
11 = 7
8.5 ± 0.09 0.43 ± 0.04* 
n = 9
8.4 ±0.15
NA wake up at 37^C 1.09 ±0.03 
n = 5
0.79 ± 0.09 
n = 6
NA wake up at 22^C 1.27 ±0.12*, 
11 = 7
1.16 ±0.08*, 
11 = 9
Table 5.1 Response curves maxima and pECso values in WT and D79N tail artery
Figure 5.2 shows the agonist response curves in tail aiteries from four-month old WT 
(figure 5.2 A) and D79N (figure 5.2 B) mice to PE, NA and 5HT, expressed as a 
percentage of their own maximal response. In WT arteries, the agonist potency order 
was 5HT > NA > PE. The response curve to 5HT yielded a pECso value of 6 . 8  + 0.10, 
the NA curve was 6 . 6  ± 0.03, and the PE curve had the lowest pECgo value at 6.1 ±
0.05. In tail aiteries from D79N mice, the agonist potency order was 5HT > NA > PE, 
and was the same as that gained for the WT. The pECso values were as follows, 5HT 
6 . 8  ± 0.09, NA 6.3 ± 0.02, and PE 6.0 ± 0.02. Although the potency order was the same 
as that of the WT, the pECso value gained for the noradrenaline response curve was 
lower than the WT. A summary of maximal contractile responses gained and the pECso 
values obtained for phenylephrine, noradrenaline, and 5HT in both strains are contained
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Figure 5.2: Agonist response curves in tail arteries from 4-month old WT and 
D79N mice, expressed as a percentage of their own maximum. A PE (o, n = 12), 
NA (•, n = 7 ), and 5HT ( °, n = 8 ) response curves in WT arteries. B PE (o, n = 
6 ), NA (• , n = 6 ) ,  and 5HT ( □, n = 8 ) response curves in D79N arteries. Each 
point represents mean ± standard eiTor.
in table 5.1, in addition to the UK curve maxima at 37 and 22^C and the noradrenaline 
wake-up response at both temperatures.
5.3.2 Effect of temperature on phenvlephrine-induced contractions of WT and D79N 
arteries
Contractile responses to the cxi-selective agonist phenylephrine were investigated at 
37®C and at 22°C, in myograph mounted tail arterial segments from WT and D79N 
mice. Phenylephrine-induced contractions at room temperature are shown in figure 5.3. 
The contractile maxima at 22^0, in arteries from both strains were of comparable size.
In the WT the greatest response gained was 0.94 ± O.OSgms Force, and in the D79N, the 
maximal contractile effect of phenylephrine gave a response of 0.98 ± O.lOgms Force.
Figure 5.3 illustrates the effect that temperature had on phenylephrine responses in both 
murine strains. The maximum contraction in WT arteries (figure 5.3 A) was unaffected 
by temperature (22°C maximum 0.94 ± 0.08gms Force, and the maximum at 37^0 was 
1.1 ± 0.08gms Force), unlike the D79N (figure 5.3 B), where the maximum at 22^0 was 
significantly greater than the response at 37^C. In the D79N, the maximum at 22°C was 
0.98 ± O.lOgms Force compared with a maximum of 0.63 ± 0.05gms Force at 37^C. 
Thus when a comparison is made in the WT, a reduction in experimental temperature 
had no effect on the response gained. However, in arteries taken from D79N mice the 
maximum responses to phenylephrine was significantly larger at 2 2 ^C compared with 
that at 37^C (p = 0 .0 1 2 **).
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Figure 5.3: Phenylephrine response curves in tail arteries from 4-month old WT and 
D79N arteries at 37°C and 22^C. A PE response curves at 37®C (o, n = 5), and 22®C 
( • , n = 7) in WT arteries. B PE response curves at 37®C (o, n = 5), and 22^C ( • , n 
= 9) in D79N arteries. Each point represents mean ± standard enor.
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5.3.3 The effect of temperature on UK143Q4-induced contraction in WT and D79N 
aiteries
Agonist response curve to UK14304 and phenylephrine (constructed at 22®C) were 
compared in tail arteries from WT (figure 5.4 A) and D79N (figure 5.4 B) mice. The 
UK14304 response curve was non-sigmoid in shape, and the contractions obtained were 
small in comparison to those induced by phenylephrine. The maximum contraction 
obtained in WT arteries was 0.20 ± 0.03gms Force, while that achieved in D79N 
arteries was 0.22 ± 0.03gms Force. In contrast, the phenylephrine concentration curves 
gave a sigmoid curve, which tended to reach a plateau at the highest agonist 
concentrations tested.
Figure 5.5 shows the UK14304 response at room temperature in WT (figure 5.5 A) and 
D79N (figure 5.5 B) tail arteries, compared with the response gained at 37°C. In each 
strain responses follow the same pattern and were of comparable size. In the WT, the 
maximum contraction at 37^C was 0.23 ± 0.04gms Force compared with 0.20 ±
O.OSgms Force at 22°C. In the D79N, the maximum at 37®C was 0.22 ± 0.05gms Force 
compared with 0.22 ± O.OSgms Force at 22°C.
In addition to having an effect on the UK and PE response curves, a reduction in 
temperature also caused a significant enhancement of the sighting noradrenaline 
response (1 x lO ^M), tested during the wake-up protocol. In both strains, a reduction in 
temperature to 22®C caused a significant increase in the response gained. In the WT the 
response at 37°C was 1.09 ± 0.02gms Force, compared with 1.27 ± 0.04gms Force at 
22^C (p = 0.014="). In D79N tail arteries the response gained at 37^C was 0.79 ±
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Figure 5.4: Agonist response curves in tail arteries from 4-month old WT and 
D79N mice at 22®C. A PE (o, n = 7) and UK ( • ,  n = 7) response curves in the 
WT, B PE (o, n = 9) and UK ( • ,  n = 9) response curves in the D79N. Each 
point represents mean ± standard enor.
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Figure 5.5: UK response curves in tail arteries from 4-month old WT and D79N 
mice. A UK responses curves at 37^C (O, n = 5) and 22°C ( • ,  n = 7) in WT
arteries. B UK responses curves at 37°C (O, n = 6 ) and 22°C ( • ,  n = 9) in D79N 
arteries. Each point represents mean ± standard error.
0.09gms Force which was significantly potentiated to 1.16 ± O.OSgms Force at 22^C (p 
= 0 .02*)
5.3.4 Responses following a curve to another adrenergic agonist
Due to the nature of the protocols that were performed cumulative concentrations curves 
to the agonists UK14304 and phenylephrine were often performed in succession. So 
these responses were then analysed to determine if construction of a curve to another 
adrenergic agonist affected the response gained.
Two consecutive curves to phenylephrine were constructed in arteries from WT and 
D79N mice maintained at 22^C, before and after a UK14304 response curve. Neither 
the pECso nor the maximum showed a statistically significant difference. Figure 5.4 
shows the responses gained in tail arteries from WT mice. The maximum response in 
the first curve was 0.94 ± O.OSgms Force and the maximum gained in the second 
cumulative concentration curve was 1.1 ± O.lOgms Force (figure 5.6 A). pECso values 
were calculated for both curves. The first curve had a pECso of 6.2 ± 0.04, while the 
second curve had a pECso of 6.3 ± 0.01. This indicated that the sensitivity to 
phenylephrine was unchanged by a response curve to UK14304 (figure 5.6 B).
In the D79N, responses to phenylephrine, earned out at 22°C before and after a curve to 
UK14304 had similar maximal responses (figure 5.7 A) and sensitivity (figure 5.7 B) 
and are shown in figure 5.7. The maximum contraction gained to phenylephrine alone 
was 0.98 ± O.lgms Force, while that obtained after a cumulative UK14304 curve was 
0.89 ± O.OSgms Force. The first curve had a pECso of 6.1 ± 0.02, in the second curve, 
after a UK14304 response curve, the pECso was 5.9 ± 0.01.
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Figure 5.6: PE response curves in tail arteries from 4-month old WT mice, 
constructed before and after a cumulative UK curve at 22“C. A PE curve before
( • ,  n = 7) and after ( ■, n = 7) a cumulative UK curve. B PE response curves, 
expressed as a percentage of own maximum. Each point represents mean ± 
standard error.
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Figure 5.7: PE response curves in tail arteries from 4-month old D79N mice, 
constructed before and after a cumulative UK curve at 22^C. A PE response
before ( • ,  n = 9) and after ( ■, n = 9) a cumulative UK curve. B PE response 
curves, expressed as a percentage of their own maximum. Each point represents 
mean ± standard en'or.
Figure 5.8 shows the responses to cumulative UK14304 curves constructed alone, and 
following a curve to the ai-selective agonist phenylephrine at 37^C in both murine 
strains. In WT arteries (figure 5.8 A) responses were of comparable size, with the 
maximum to UK14304 alone being 0.25 ± 0.04gms Force, and that gained after an 
initial curve to phenylephrine being 0.21 ± O.OSgms Force. Responses in D79N arteries 
(figure 5.8 B) were small and highly variable. The maximum responses gained to 
UK14304 alone, was 0.26 ± O.Obgms Force, compared to a maximum of 0.23 ± 0.05gms 
Force, when a cumulative UK14304 curve was constructed after an initial curve to 
phenylephrine.
The responses to cumulative UK14304 alone, and after a phenylephrine curve at 22^C 
are shown in figure 5.9. Unlike the response at 37°C, the UK14304-mediated response 
at 22°C was significantly potentiated after an initial phenylephrine curve. In WT arteries 
(figure 5.9 A), contractile responses were significantly greater when a cumulative 
concentration curve to phenylephrine had been constructed prior to UK14304, The 
maximum response obtained when the UK14304 curve was carried out after an initial 
phenylephrine curve was 0.54 ± 0.06gms, which was significantly greater than the 
maximum to UK14304 alone of 0.20 ± 0.03gms Force (p = 0.0004=^**).
Responses in tail arteries from D79N mice (figure 5.9 B) also showed enhanced 
responses at 22°C, when an initial curve to phenylephrine had been constructed before 
the UK response. The maximum response gained in the curve after phenylephrine was 
0.43 ± 0.04gms Force, compared with that obtained to UK14304 alone, which was 0.22 
± 0.03gms Force. Statistical analysis showed that these responses were significantly
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Figure 5.8: UK responses curves in tail arteries from 4-month old WT and D79N 
mice at 37^C, constructed before and after a PE curve. A The UK response in WT
arteries before (O, n = 5) and after ( n = 5) a PE curve. B The UK response in
D79N arteries before ( 0 , n  = 6) and after ( o ,n  = 6 ) a P E  curve. Each point
represents mean ± standard eiTor.
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Figure 5.9: UK responses curves in tail artery from 4-month old WT and D79N mice 
at 22^C, constructed before and after a PE curve. A The UK response in WT arteries
before ( • ,  n = 7) and after ( ■, n = 7) a PE curve. B The UK response in D79N
arteries before ( • ,  n = 9) and after (■, n = 9) a PE curve . Each point represents 
mean ± standard error.
different, generating a p value of 0.0035'^''', The proportional increase was larger in WT 
than the D79N. At 22^C the response in the WT reached 270 % of the curve 
constructed without exposing the tissue to phenylephrine. In the D79N, the percentage 
increase in the maximum response was 195 % of the UK14304 curve maximum, 
constructed at 22®C, without prior stimulation with phenylephrine.
5.3.5 Combined contractile responses to U46619 and UK14304 at 22^C 
The combined contractile response to the synergist, U46619 and increasing 
concentrations of UK14304 in the WT (figure 5.10 A) and D79N (figure 5.10 B) are 
shown in figure 5.10. In WT arteries, the combined contraction alone reached a 
maximum of 0.64 ± O.lgms Force, while after construction of a phenylephrine curve the 
maximum was significantly greater at 0.80 ± 0.05gms Force (p = 0.04*). In D79N 
arteries, the combined contractile response to U46619 and UK14304, without previous 
stimulation with phenylephrine, had a maximum response of 0.59 ± O.OSgms Force. 
After construction of a phenylephrine curve the combined contractile response in the 
D79N tail artery was 0.75 ± O.OSgms Force (p = 0.047*).
To determine how close contractile responses at 22^C were to an adrenergic maximum, 
the contractions in the WT (figure 5.11 A) and D79N (figure 5.11 B) to UK14304 
alone, and to UK after a phenylephrine response curve, were expressed as a percentage 
of the noradrenaline maximum (1 x lO'^M). In the WT, maximum UK14304-induced 
contraction reached 15.4 ± 3.0 % of the noradrenaline maximum. After a phenylephrine 
curve the UK14304 curve maximum was increased to 44 ± 6.15 % of the noradrenaline 
response. In the D79N mouse, the UK14304-mediated contractile response at 22^C is
20.5 ± 3.3 % of the noradrenaline maximum (1 x lO'^M). However, after construction
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Figure 5.10: Combined contractile responses to U19 tone and UK in tail arteries 
from 4-month old WT and D79N mice at 22^C. A The UK/U19 response in WT
arteries before ( • ,  n = 7), and after ( ■, n = 7) a PE curve. B The UK/U19 response 
in D79N arteries before ( • ,  n = 9), and after ( ■, n = 9) a PE curve. Each point 
represents mean ± standard error.
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Figure 5.11: UK response curves in tail arteries from 4-month old WT and D79N 
mice at 22®C, expressed as a percentage of the NA maximum (1 x 10‘^ M). A The
UK response in WT arteries before ( • ,  n = 7), and after ( ■, n = 7) a PE curve. B
The UK response in D79N arteries before ( * , n  = 9), and after ( ■, n = 9) a PE curve.
Each point represents mean ± standard error.
of a phenylephrine curve the UK14304-induced contraction increased to 40.3 ± 4.7 % of 
the noradrenaline response.
So how close is the combined U46619/UK14304 contraction to an adrenergic 
maximum? The combined contractile response to U46619 and UK14304 at 22^C for 
the WT (figure 5.12 A) and D79N (figure 5.12 B) have been expressed as a percentage 
of maximum response to a sighting concentration of noradrenaline (1 x lO'^M). In WT 
arteries, after a phenylephrine response curve, the combined contractile response 
reached 64.5 ±6.1 % of the noradrenaline response. The combined contraction to 
U46619 and UK14304 without phenylephrine exposure was smaller, and reached 48.0 ±
6.4 % of the noradrenaline maximum. Similar results were obtained in tail arteries from 
the D79N mouse. Without an initial phenylephrine curve, the combined contraction 
reached 55.6 ± 9.5 % of the noradrenaline maximum, while after an initial 
phenylephrine curve the maximum was higher at 66.9 ± 6.3 %.
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Figure 5.12: The combined UK/U19 response in tail arteries from 4-month old WT 
and D79N mice at 22®C, expressed as a percentage of the NA maximum (1 x lO'^M).
A Responses in WT arteries before ( • ,  n = 7), and after ( ■, n = 7) a PE curve. B
Responses in D79N arteries before ( • ,  n = 9), and after ( ■, n = 9) a PE curve. Each
point represents mean ± standard error.
5.4 Discussion
A temperature of 22^C enhances UK and NA-mediated responses in the tail artery of the 
WT and D79N
In the presence of U46619-induced tone, a reduction in experimental temperature, to 
22^C, is insufficient to enhance UK14304-mediated vasoconstrictor responses in tail 
arteries from WT and D79N mice. These findings are in disagreement with those 
published by Chotani and co workers. What is the explanation for the discrepancy in 
our findings? The enhanced UK14304-medi ated response described by Chotani and co 
workers was uncovered in distal segments of the murine tail artery, mounted in a Living 
Systems pressure myograph. My experiments investigated the responses to UK in the 
middle section of the tail artery, mounted in a Mulvany/Halpern wire myograph. It 
seems doubtful that the difference in results can be fully explained by the different 
experimental conditions.
Surprisingly, the size of UK14304-induced contractions is significantly potentiated at 
22®C, when an initial curve to phenylephrine has been constructed before the UK14304 
response curve. The increase in size of vasoconstrictor responses occurs in the WT and 
D79N, and is of comparable size. This suggests that the a 2 A/D-adrenoceptor is not 
involved in the enhancement of responses at 22®C, which in this instance supports the 
conclusions of Chotani and co workers [Chotani et al, 2000], that the response at cold 
temperatures (in their case 28°C) is attributable to stimulation of the (%2 c-subtype.
Furthermore, the experiments performed by Chotani et al, also investigated the effect of 
cold temperatures (28^C) on phenylephrine-induced responses. Like us, they found that 
phenylephrine-induced contractions in WT mice are unaffected by a decrease in
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external temperature. Whether the response to UK14304 was studied after a 
phenylephrine stimulus is unclear from their publication. If phenylephrine-induced 
vasoconstrictions were investigated before the responses to UK14304, this would 
explain the discrepancy with the response shown here, and could explain the UK14304- 
mediated potentiation in contractility in pressure myograph mounted vessels.
But how does prior stimulation of oci-adrenoceptors lead to an enhancement of a%- 
adrenoceptor-mediated vasoconstrictor responses? Contractile responses, resulting from 
stimulation of ai-adrenoceptors are enhanced by ^-selective agonists in the rat tail 
artery. The potentiation in a 2 -adrenoceptor-mediated contractility results from an 
alteration in calcium levels [Xiao et al, 1989]. Whether reducing the experimental 
temperature to 22°C provides conditions whereby ai-stimulation can enhance calcium 
levels is unclear, but it does present a possible explanation for the results gained.
Cutaneous blood vessels are sensitive to subtle changes in temperature, and this is likely 
to be relevant to their role in thermoregulation. A reduction in external temperature to 
below 30^C can enhance vasoconstrictor responses in cutaneous blood vessels in 
rodents, and has been likened to the changes occurring in the vasculature of the human 
hand upon exposure to extremes of temperature [Thorington, 1966]. The elevation in 
contractility when cutaneous blood vessels are exposed to a reduction in temperature is 
thought to result from activation of vascular (%2 -adrenoceptors [Chotani et al, 2000]. 
Furthermore, a 2 -receptor antagonists have been shown to cause vasodilatation of the 
perfused rat tail, leading to an increase in surface temperature [Redfem et al, 1995]. 
Another factor affecting the noradrenaline response is the possible potentiation due to 
inhibition of the neuronal amine transporters at cold temperatures.
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Enhanced contractions of the murine tail artery at cold temperatures have been proposed 
to result from the recruitment and activation of quiescent a 2 c-adrenoceptors, which at 
37^C do not participate in vasoconstrictor responses [Chotani et al, 2000]. However, 
under normal physiological conditions, the rodent tail has an ambient temperature that is 
significantly lower than core body temperature, and generally reflects the external 
environment. This leads me to propose a hypothesis; under normal physiological 
conditions a 2 c-adrenoceptors will be involved in contraction of the murine tail artery.
At 37°C, the (%2 c-adrenoceptor may play a lesser role in a 2 -adrenoceptor-mediated 
contractions [Chotani et al, 2000], but should the tail ever reach this temperature, 
arteries will most probably be vasodilated (and sympathetic nerve activity ceased) to 
allow dissipation of heat from the surface of the tail, negating the need for activation of 
this receptor-subtype.
A t 22°C com pared w ith  37®C, the s ize  o f  the contractile response to sigh tin g  
concentrations o f  noradrenaline (1 x  lO’^ M) is  s ign ifican tly  potentiated  in the WT and  
D79N. T he enhanced  resp on se in  the WT can be attributed so le ly  to a potentiation  o f  
the a 2-adrenoceptor-m ediated  contraction , b ecau se  the phenylephrine resp on se is  
u naffected  b y  a reduction in experim ental tem perature to 22^C. H ow ever, in the D79N, 
resp on ses to noradrenaline, phenylephrine and UK14304, are enhanced  at 22°C. T his  
su ggests the in vo lvem en t o f  a i -  and a 2-adrenoceptors in enhanced  noradrenaline- 
m ediated  contractions. Furtherm ore, this data provides additional ev id en ce  that the 
% A/D-adrenoceptor is not in v o lv ed  in  the co ld -in d u ced  potentiation  in contractility, 
b ecau se the m agnitude o f  the change in s ize  o f  the noradrenaline resp on se  is 
com parable in the D79N and the WT.
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The contractile response to UK14304 alone, and in the presence of U46619 has been 
expressed as a percentage of the noradrenaline maximum to give an indication of the 
size of the a 2 -adi'enoceptor-mediated contraction in relation to the combined response to 
dual activation of cci and a 2 -adrenoceptors. In the WT and D79N, the response to 
UK14304 and the combined contraction to UK and U46619 is significantly less than the 
noradrenaline response. This data suggests that the UK14304-medi ated response at 
22^C is small in comparison to the noradrenaline response, which results from non- 
selective stimulation of a i- and a 2 -adrenoceptors, suggesting that even at low 
temperatures the (Xi-adrenoceptor-mediated contraction is substantial in compaiison to 
that mediated by a 2 -adrenoceptors.
Potency order for agonists in tail arteries from WT and D79N mice 
Before investigating the effect of a reduction in temperature on the vasoconstrictor 
response to the a 2 -selective agonist, UK14304, the effect of cumulative addition of the 
agonists, phenylephrine, noradrenaline, and 5HT were studied in the murine tail artery. 
This was done to deteimine if responses to other agonists are affected by mutation of 
the (%2A/D-adrenoceptors, because compensatory mechanisms cannot always be excluded 
as the reason for a unique phenotype. The potency order of the agonists tested is the 
same for the WT and D79N, and has been determined as 5HT > NA > PE. The 
responses to phenylephrine (smaller in size, but similar sensitivity) and 5HT were 
similar in size and sensitivity in arteries from both strains. This indicates no general 
change in sensitivity or contractility suggesting that ai-adrenoceptor and 5HT 
mechanisms are noimal in the D79N mouse at 37^C.
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However, the noradrenaline-mediated response in the D79N has a smaller maximum 
response and has reduced sensitivity, compared with the WT, at 37°C. This suggests 
that the presence of a fully functional (%2 A/D receptor pool is necessary for normal, full 
sensitivity to noradrenaline. This provides evidence that, at this temperature, the Œ2 A/D 
receptor is involved in contractile responses. It would therefore be expected that 
stimulation of (%2 A/D-adrenoceptors is, in part, responsible for UK14304-mediated 
contractions of the murine tail artery. The results shown in chapter three support this 
hypothesis, where the response to UK14304 is significantly smaller in the D79N than in 
the WT in all of the protocols tested. However, the data from chapter four is 
contradictory. The results presented there, show that the response gained is critically 
dependent on the method in which the agonist, UK14304, is administered. When 
UK14304 curves aie constructed non-cumulatively, the observed reduction in 
contractility in the D79N is abolished. This suggests that at 37®C the cumulative 
UK14304 response does involve the Œ2 A/D receptor, and that prolonged stimulation 
results in the development of desensitisation. At 22®C, responses to UK14304 in the 
WT and D79N are comparable, suggesting the involvement of a receptor other than the 
ot2A/D-adrenoceptor in this response.
PE-induced response is potentiated at 22^C in the D79N but not the WT 
Vasoconstrictor responses to UK14304 were studied by constructing cumulative 
response curves at a reduced experimental temperature, in keeping with the studies 
performed by Chotani and co workers. Reducing the experimental temperature to 22^0 
had no effect on the phenylephrine-induced contraction of the WT tail artery. However, 
in the D79N, in which the contraction to phenylephrine was smaller than in the WT at 
37^C, reducing the temperature to 22*^ C, significantly enhanced contractile responses to
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phenylephrine, giving a vasoconstriction that was of comparable size to that gained in 
the WT. This data suggests that at a reduced temperature of 22^C, the a r  adrenoceptor- 
mediated contraction in the D79N mouse is enhanced by a lack of functional aiA/o- 
adrenoceptors. How does this occur?
E n h a n c e m e n t  o f  v a s o c o n s tr ic t o r  r e s p o n s e s  a t c o ld  te m p e r a tu r e s  i s  p r o p o s e d  to  r e s u lt  
f r o m  s t im u la t io n  o f  q u ie s c e n t  a 2C“a d r e n o c e p to r s  [C h o ta n i e t  a l,  2000]. A c c o r d in g  to  
th a t s tu d y , at 37^ C  s t im u la t io n  o f  a 2 A /D -a d ren o cep to rs  c o n tr ib u te s  to  v a s o c o n s tr ic t o r  
r e s p o n s e s  in  th e  m u r in e  ta il  a rtery , b e c a u s e  a n ta g o n is t s  p r o p o s e d  to  b e  s e l e c t iv e  fo r  th e  
% A /D -a d r e n o c e p to r -su b ty p e , b lo c k  v a s o c o n s tr ic t o r  r e s p o n s e s .  In th e  a b s e n c e  o f  a 
fu n c t io n a l  a 2 A /D -a d ren o cep to r  p o o l ,  c o m p e n s a to r y  c h a n g e s  m a y  p e r m it  a n d /o r  re c r u it  
a i - a d r e n o c e p t o r s  to  p a r t ic ip a te  in  th e  c o ld - in d u c e d  r e s p o n s e . A t  22°C, th e  p o te n t ia t io n  
o f  p h e n y le p h r in e - in d u c e d  c o n tr a c t io n s  in  th e  D79N p r o v id e s  e v id e n c e  in  su p p o r t  o f  th is  
h y p o th e s is .  F u r th e r m o r e , g iv e n  th e  lo c a t io n  o f  th e  ta il ar tery , it  i s  r e a s o n a b le  to  a s s u m e  
th a t at p h y s io lo g ic a l  te m p e r a tu r e s , c o n tr a c t io n  of th is  artery  r e s u lts  f r o m  d u a l a c t iv a t io n  
o f  a i -  a n d  % - a d r e n o c e p to r s .
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ai^-adrenoceptor-mediated responses are not cross-desensitised bv previous exposure to 
UK143Q4
Cumulative UK14304 response curves are susceptible to profound, agonist-induced 
receptor desensitisation. Given that the response to phenylephrine was investigated at 
37^C and 22°C, this provided conditions where the effect of UK14304 on 
phenylephrine-induced contractions could be studied, to determine if the stimulation of 
UK14304 sensitive receptors results in cross desensitisation of the ai-adrenoceptor- 
mediated vasoconstrictor response.
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In the WT and D79N tail, the response to phenylephrine at 22 C and at 37 C is 
unaffected by previous exposure to the selective agonist, UK14304. This data 
confirms that, at cold temperatures and at 37^C (chapter four), ai-adrenoceptor- 
mediated responses are free from UK14304-induced receptor desensitisation. In 
essence, the desensitisation that affects UK14304-mediated responses is specific to the 
a^-adrenoceptor, and does not reflect a generalised reduction in responsiveness of the 
tail artery to exogenous agonists.
Summarv and conclusions
In summary, the results shown here confirm that (%2 -adrenoceptor-mediated 
vasoconstrictor responses of WT and D79N tail arteries are enhanced by a reduction in 
the experimental temperature. However, the elevation in contractility develops only 
when vessels have previously been exposed to a phenylephrine response curve, a result 
that may reflect conditions in vivo. The elevation in the size of contractile responses 
occurs in the WT and D79N, providing strong evidence that the a 2 a/d-adrenoceptor 
does not participate in the cold-induced response. Considering the responses gained and 
the difficulties associated with the study of CG2 -adrenoceptor-mediated responses (shown 
in previous chapters) I have highlighted many questions about the experimental 
conditions, and temperature at which responses of the tail artery are studied. This leads 
me to pose the question, should all contractile, and nerve-induced responses in the 
rodent tail artery be performed at lower experimental temperatures, to better mimic 
conditions in vivol
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Chapter six
UK14304-induced relaxations of mesenteric resistance 
arteries from WT and D79N mice
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6.1 Introduction
Resistance arteries play an important role in the maintenance of peripheral resistance, 
and as such contribute to the maintenance and control of blood pressure. Responses to 
exogenous agonists have been studied extensively in rat mesenteric resistance arteries, 
but to date, little is known about the pharmacology of murine blood vessels.
The initial aim of cairying out the experiments contained within this chapter was to 
study the effects of UK14304 on mesenteric blood vessels, and to determine if 
stimulation of aa-adrenoceptors causes contractile responses in another murine artery. 
However, a review of the available literature suggested that the response gained would 
be relaxant in nature.
In the rat, stimulation of endothelial ot2 -adrenoceptors on coronary, renal, and 
mesenteric arteries has a relaxant effect. In porcine coronary arteries, the Œ2 A/D- 
adrenoceptor mediates agonist-induced reductions in vascular tone according to analysis 
employing various antagonists with varying selectivity for the a 2 -subtype. This is in 
spite of the 0 C2 c subtype being expressed at much higher levels than the Œ2 A/D- 
adrenoceptor in porcine coronary arteries [Bockman et al, 1993].
In the rat, EDHF appears to be the major contributor to endothelium-dependent 
relaxations of mesenteric resistance arteries but plays little, if any, role in relaxation 
responses of large calibre blood vessels [Hwa et al, 1994]. EDHF has been shown to 
cause relaxant effects by inhibiting the opening of voltage-gated calcium channels, 
leading to hypeipolarisation of vascular smooth muscle cells, which leads to a reduction 
in vasculai' contractility [Nagao et al, 1991]. To determine what role EDHF plays in
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agonist-induced vasodilatations, the balance of positive ions in the surrounding bathing 
solution can be changed, this hyperpolarises the membrane potential in all cells and, 
relevantly, vascular smooth muscle cells which are thus prevented from responding to 
EDHF. Experimentally, when extracellular influx has been blocked, EDHF-induced 
relaxations were prevented [Chanhan et al, 2003].
When the response to UK14304 was established, the effect of L-NAME and 
rauwolscine were investigated, to determine the role of nitric oxide, and confirm that the 
response gained results from stimulation of ai-adrenoceptors. In addition, the D79N 
mouse was utilised to gain further insight into the subtype(s) mediating vascular 
responses in mouse mesenteric resistance arteries.
6.2 Methods
WT (C57BL/6c/129Sv) and D79N (azA/o mutant) mice aged four-months old were 
obtained from the University animal house for this study. Males of between 29.6-34.2g 
were killed by asphyxiation with carbon dioxide and the mesenteric arcade was 
removed, and placed in fresh Krebs.
6.2.1 Vessel isolation and mounting
The mesenteric arcade was pinned out on a petri dish containing cold Krebs and first 
order arteries located. Several arteries were dissected, cleaned of excess fat and tissue 
and stored at 4^C until use. These arteries were then set up in 5ml, stainless steel, 
Mulvany/Halpem wire myograph baths. After vessel mounting, a 30-35 minute rest 
period was allowed, during which time baths were gassed with a 95 % O2  5 % CO2  
mixture and heated to 37°C. Vessels were then washed with fresh Krebs, and a resting
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tension of O.lVgms Force (optimum resting tension, unpublished observation) was 
placed on each mounted arterial segment. Vessels were then washed four times with 
fresh Krebs and allowed a further 20-30 minute rest period before commencing the 
wake-up protocol.
6.2.2 Wake-up protocol
Each vessel was challenged with noradrenaline (1 x lO'^M) and contractions were 
allowed to reach a plateau. Vessels were then washed with, fresh, gassed Krebs (37^C) 
four times over a fifteen minute period. The entire process was then repeated once, with 
the same noradrenaline concentration, and a second time with a lower noradrenaline 
concentration of 1 x When the contractile response to the lower noradrenaline
response reached a plateau, acetylcholine at a concentration of 3 x lO'^M was added to 
test the viability of the endothelium. After each drug addition, the process of washing 
with fresh Kr-ebs four times over a fifteen minute period was performed.
6.2.3 Experimental protocols 
Elevation of vascular tone
Cumulative concentration response curves to the ^-selective agonist UK14304 were 
constructed in mounted arterial rings. Alone, UK14304 produced no notable responses. 
Therefore the use of the synergist, U46619 was employed to elevate vascular tone. 
Vascular tone was elevated for two reasons. Firstly, to determine if contractile 
responses occur when vascular tone is enhanced. Secondly, to ascertain if U46619- 
induced tone will be reduced by increasing concentrations of UK14304 (that is, does 
stimulation of az-adrenoceptors causes vasodilatation?).
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U46619 (1 X lO'^M) was added to each bath containing a 2mm aiterial ring, and the 
contractile response was allowed to reach a plateau. After this, UK14304 was added in 
half log units in a cumulative manner, alone, and in the presence of L-NAME (1 x 10" 
^M).
Cumulative UK14304 response curves
The experimental protocol was later changed because of the variability of responses to 
cumulative drug additions and the variability of U46619-induced tone over time. 
Furthermore, twenty experiments were set up to test the effects of cumulative UK14304 
on U44619-induced tone in first order mesenteric arteries. Of the twenty experiments 
performed only twelve gave a measurable response (Shown in figure 6.1).
Thereafter, UK14304-induced responses were studied by constructing randomised, non- 
cumulative concentration curves. The wake-up protocol, tension applied, and U46619 
concentration used, remained the same. Each non-cumulative concentration of 
UK14304 was given a minimum of twenty-five minutes apart (after the tone within the 
vessel had been elevated with U46619). All of the vessels in which a non-cumulative 
response curve was constructed were responsive to the applied drugs.
6.2.4 Effect of L-NAME and rauwolscine on UK14304-medi ated responses 
Given the problems associated with UK14304-mediated desensitisation (Chapter four) 
the effect of L-NAME and rauwolscine were assessed against first curves. L-NAME (1 
X lO'^^ M) was made fresh daily, and stored on ice throughout the course of each 
experiment. To assess the effect of blocking nitric oxide synthase production, L-NAME
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was incubated with mounted artery for a minimum of 20 minutes, prior to construction 
of an agonist curve.
The effect of rauwolscine on the UK14304-mediated response was assessed against 
randomised, non-cumulative first curves, in mesenteric resistance arteries from WT 
mice. Mounted arterial segments were incubated with rauwolscine (3 x lO'^M) for a 
minimum of thirty minutes prior to construction of a UK14304 response curve.
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6.3 Results
6.3.1 The response to cumulative UK143Q4 in WT arteries
Figure 6.1 shows the cumulative response to UK14304 in first order mesenteric 
resistance aiteries from four-month old WT mice, expressed as a percentage of U46619- 
induced tone. The cumulative administration of UK14304 caused concentration- 
dependent relaxations. The maximum relaxant response, at a UK14304 concentration 
of 3 X 10‘^ M was a 48.1 ± 6.4 % reduction in U46619-induced tone.
6.3.2 Effect of L-NAME on the cumulative UK14304 response
Figure 6.2 illustrates the effect of L-NAME (1 x lO'^^ M) on UK14304-induced 
relaxations in unpaired arteries. At low agonist concentrations the relaxant effect of UK 
was significantly attenuated in the presence of L-NAME. In the control curve a 
UK14304 concentration of 3 x lO'^M caused a 9.6 ± 4.09 % reduction in U46619- 
induced tone, but in the presence of L-NAME U46619-induced tone was unaffected (p 
= 0.02*). However, at high UK14304 concentrations the inhibitory effect of L-NAME 
became surmountable. The relaxations that occurred at high agonist concentrations 
were not significantly different from those in the control curve (p>0.05).
6.3.3 Non-cumulative UK14304 response curves in WT mice
With the exception of figures 6.1 and 6.2 all other curves shown were constructed in a 
randomised, non-cumulative manner. In Figures 6.3 A and 6.3 B representative traces 
of the effects of single concentrations of UK14304, investigated in first order 
mesenteric resistance arteries from a four-month old WT mice are shown. In figure 6.3 
A basal tone was elevated with the synergist, U46619 (1 x 10‘^ M). UK14304 at a 
concentration of 1 x lO'^M caused a significant reduction in U46619-induced tone. To
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Figure 6.1: UK14304-mediated response in first order mesenteric arteries 
from 4-month old mice WT mice. The variation in U46619-induced tone 
over time (□, n = 7) and the effect of a cumulative UK curve (o, n = 12). 
Both data sets were expressed as a percentage of U46619-induced tone. Each 
point represents mean ± standard enor.
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Figure 6.2: UK14304-mediated responses in first order mesenteric arteries 
from 4-month old WT mice. A cumulative UK response curve alone (o, n 
12), and in the presence of L-NAME (1 x n = 6). Both data sets
were expressed as a percentage of U46619-induced tone.. Each point 
represents mean ± standard eiTor.
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Figure 6.3: Representative trace of the relaxant response to a single concentration 
of UK in mesenteric resistance arteries from a 4-month old WT mouse. A The 
effect of 1 X lO'^M UK in the presence of U19-induced tone, B The non- 
cumulative response to UK at 1 x in a vessel previously exposed to a
cumulative UK14304 response curve. The responses shown are in a single vessel.
determine whether UK14304-mediated responses were prone to agonist-induced 
desensitisation, like those of the murine tail artery, a non-cumulative response curve to 
UK14304 was constructed on top of U46619-induced tone in a mounted mesenteric 
artery. After a thirty minute rest period, the response to a single concentration (1 x 10" 
^M) of UK14304 was tested (figure 6.3 B). The relaxant response gained was slight in 
comparison to the response gained without previous exposure to UK14304 (figure 6.3 
A). This indicated that in mesenteric arteries the UK14304-mediated response was 
prone to agonist-induced receptor desensitisation, much like the response in the mouse 
tail artery.
Figure 6.4 shows the non-cumulative response to UK14304 in first order mesenteric 
resistance arteries from four-month old WT mice. UK14304 causes concentration- 
dependent reductions in U46619-induced tone. At the highest agonist concentration 
tested, UK14304 (1 x lO’^ ^M) caused a 59.0 ± 5.6 % reduction in U46619-induced tone.
Figure 6.5 shows the cumulative and non-cumulative UK14304 response curves, 
constructed in first order mesenteric resistance arteries from four-month old WT mice. 
The cumulative and non-cumulative response curves follow each other closely. 
However, in cumulative time control curves a reduction in U46619-induced tone was 
observed. The maximum reduction in tone in the cumulative curve was smaller at 40.1 
± 6.4 % (3 X lO'^M) of elevated tone but was achieved at a lower concentration of 
UK14304. Although the difference in the responses to cumulative and non-cumulative 
drug additions is not apparent from the graph, non-cumulative UK14304 always 
produced a measurable response, unlike curves constructed cumulatively.
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Figure 6.4: The non-cumulative UK14304-mediated response in first order 
mesenteric arteries from 4-month old WT mice. The variation in U46619- 
inducted tone over time (o, n = 12) and the non-cumulative response curve 
to UK (o, n = 12). Both data sets were expressed as a percentage of 
U46619-induced tone. Each point represents mean ± standard eiTor.
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Figure 6.5: UK14304-mediated responses in first order mesenteric arteries 
from 4-month old WT mice. Cumulative (o, n = 12) and non-cumulative (• , 
n = 12) UK response curves, expressed as a percentage of U46619-induced 
tone. Each point represents mean ± standard error.
6.3.4 Effect of L-NAME on non-cumulative UK143Q4 in WT arteries
Figure 6.6 shows the effect of L-NAME on UK14304-mediated relaxant responses. L- 
NAME significantly attenuated agonist-induced relaxations at 1 x 10'  ^(p = 0.049*) and 
1 X lO^M (p = 0.008**). At higher UK14304 concentrations the effects of L-NAME 
were surmountable.
6.3.5 Effect of L-NAME on U46619-induced elevations in vascular tone
To test whether L-NAME affects the contraction produced by U46619, responses were 
compared before and after incubation with L-NAME. In arteries from WT mice the size 
of U46619-induced contractions was unaffected by the presence of L-NAME (p = 0.56). 
Similarly, L-NAME had no effect on the contractile responses to U46619 in arteries 
from D79N mice (p = 0.82).
6.3.6 Effect of rauwolscine on the UK14304 response in WT arteries
Figure 6.7 shows the non-cumulative UK14304 response alone, and in the presence of 
rauwolscine (3 x lO'^M), in first order mesenteric resistance arteries from four-month 
old WT mice. Rauwolscine attenuated UK14304-mediated relaxations at low agonist 
concentrations. Incubating arterial rings with rauwolscine abolished agonist-induced 
relaxations at UK14304 concentrations of 1 x lO '^M, while in control vessels a 13 ± 4.0 
% reduction in U46619-induced tone occurred (p = 0.04*), Rauwolscine also 
attenuated relaxations at a UK14304 concentration of 1 x lO^M. In the control curve 
UK14304 reduced U46619-induced tone to 78 ± 3.9 % of basal levels, but in the 
presence of rauwolscine, tone was only reduced to 88.5 ± 2.6 % of the U46619-induced 
contraction (p = 0.0003***). At higher agonist concentrations, the antagonism 
produced by rauwolscine was suimountable, and at the highest UK14304 concentration,
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Figure 6.6: The non-cumulative UK14304-mediated responses in first order 
mesenteric arteries from 4-month old WT mice. A non-cumulative UK 
response curve alone (o, n = 12) and in the presence of L-NAME (1 x lO '^M,*, 
n = 6). Both data sets were expressed as a percentage of U46619-induced tone. 
Each point represents mean ± standard error.
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Figure 6.7:The non-cumulative UK14304-mediated responses in first order 
mesenteric arteries from 4-month old WT mice. A non-cumulative UK response 
curve alone (o, n = 12), and in the presence of rauwolscine (3 x lO'^M, □, n = 4). 
Both data sets were expressed as a percentage of U46619-induced tone. Each 
point represents mean ± standard enor.
relaxant responses obtained in control vessels were no different from those gained in 
vessels incubated with rauwolscine (p>0.05).
6.3.7 The non-cumulative UK143Q4 response in D79N arteries
Figure 6.8 shows the non-cumulative response to UK14304 in first order mesenteiic 
resistance arteries from four-month old D79N mice. UK14304 caused a concentration- 
related reduction in U46619-induced tone. At the highest agonist concentration tested 
(1 X lO'^^M), UK14304 caused a 67.6 ± 8.8 % reduction in U46619-induced tone. A 
pICso value was calculated in this instance, because the relaxation caused by UK14304 
exceeded 50 %, and was determined to be 4.8 ± 2.3.
6.3.7 Effect of L-NAME on the non-cumulative UK14304 response in the D79N 
Figure 6.8 also shows the effect of increasing concentrations of UK14304 alone, and in 
the presence of L-NAME (1 x lO'^^ M) on responses in first order mesenteric arteries 
from four-month old D79N mice. Incubation with L-NAME, prior to construction of a 
UK14304 curve, caused a significant reduction in the relaxant response obtained. 
Relaxations gained were significantly attenuated at 1 x 10'^, 1 x 10"^  and 1 x 10 "^ M. At 
the maximum UK14304 concentration (1 x lO'^^M), L-NAME significantly attenuated 
the relaxation responses. In the control curve, UK14304 at a concentration of 1 x lO'^ ^M 
caused a 67.6 ± 8.8 % reduction in tone, but in the presence of L-NAME the relaxation 
gained only reduced U46619-induced tone by 36 ± 2.1 % (p = 0.0001*'*''*').
6.3.8 Comparison of responses gained in WT and D79N arteries
Figure 6.9 shows the non-cumulative UK14304 response in WT and D79N arteries, to a 
UK14304 curve alone (figure 6.9 A), and in the presence of L-NAME (figure 6.9 B).
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Figure 6.8: The non-cumulative UK14304-mediated responses in first order 
mesenteric resistance arteries from 4-month old D79N mice. A non-cumulative 
UK response curve alone (o, n = 6) and in the presence of L-NAME (1 x 10"^M, 
• , n = 6). Both data sets were expressed as a percentage of U46619-induced 
tone. Each point represents mean ± standard eiTor.
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Figure 6.9: The non-cumulative UK14304-mediated responses in first order 
mesenteric resistance arteries from 4-month old WT and D79N mice. A A non- 
cumulative UK response curve in the WT (o, n = 12) and D79N (• , n = 6). B A  non- 
cumulative UK response curve in the presence of L-NAME in the WT ( o, n = 6 ) 
and D79N ( ■, n = 6 ). Data expressed as a percentage of U19-induced tone. Each 
point represents mean ± standard eiTor.
Comparison of the curves gained, showed that responses in the WT were shifted 
rightward in respect of the results gained in the D79N. At the highest UK14304 
concentration tested (1 x lO'^^M), there was no significant difference between relaxations 
in WT and D79N arteries (p = 0.328).
The most striking difference observed between UK14304-induced responses in 
mesenteric resistance arteries from WT and D79N mice occuiTed at higher UK14304 
concentration. L-NAME had a more significant effect on UK14304-mediated 
relaxations in D79N arteries, than it did in the WT. At the highest agonist concentration 
tested, relaxant responses were significantly smaller in the D79N (the inhibition of 
relaxation by L-NAME was greater in the D79N) than the WT in the presence of L- 
NAME (p = 0.025*). Yet in control curves, the responses at the same UK14304 
concentration were compai'able.
6.3.9 Effect of elevated K~*~ levels on UK14304-mediated relaxations 
Figure 6.10 A shows the response to a single concentration of UK14304 in the presence 
of elevated K^ levels (30mM). Following the elevation of extracellular K"^ , tone was 
elevated with U46619 (1 x lO'^M). Figure 6.10 B shows the response in the same artery 
after removal of 30mM KPSS from the sunounding bathing solution. In comparison to 
the response shown in figure 6.10 A, the relaxation caused by UK14304 (1 x 10‘^ M) 
when K^ levels were not elevated with KPSS are significantly greater.
In Figure 6.11 the results shown are similar to those in figure 6.10, but in this instance 
the concentration of KPSS used was lower (15mM). In the presence of elevated K^ the 
relaxant response to a single concentration of UK14304 (1 x lO'^M) was greater than
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Figure 6.10: A trace of the effect of UK at 1 x lO'^M, alone, and in the presence 
of 30niM KPSS. A The relaxant response to UK in the presence of U19-induced 
tone and 30mM KPSS. B The relaxant response to the same UK concentration in 
the presence of U19-induced tone, after KPSS has been removed from the 
myograph bath. Responses shown are in a single vessel.
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Figure 6.11: A trace of the effect of UK at 1 x lO'^M, alone, and in the presence of 
15mM KPSS. A The relaxant response to UK in the presence of U19-induced tone 
and 15mM KPSS. B The relaxant response to the same UK concentration in the 
presence of U19-induced tone, after KPSS has been removed from the myograph 
bath. Responses shown are in a single vessel.
when levels were enhanced. Figure 6.11 B illustrates that as in figure 6.10 B in the 
absence of elevated the relaxant response to UK14304 was greater.
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6.4 Discussion
In mouse mesenteric resistance arteries, UK14304 causes concentration-related 
relaxations of wire myograph-mounted first order mesenteric resistance arteries from 
the WT and D79N. Fortunately, the UK14304-mediated response in mesenteric 
resistance arteries is reproducible, and more easily studied than UK14304-induced 
contractions of the murine tail artery.
Stimulation of oci-adrenoceptors, located on endothelial cells of rat mesenteric 
resistance arteries, leads to vasodilatator responses of preconstricted isolated arteries. In 
porcine arteries, this has been attributed to activation of the ctiA/o-adrenoceptor (based 
on the rank order of potency of a number of selective agonists), which leads to 
alterations in cAMP levels [Bockman et al, 1993].
Cumulative UK14304 response in mesenteric resistance arteries 
Initially, the effect of UK14304 on U46619-induced tone was investigated by 
constructing cumulative response curves. The responses gained were variable. In 
addition, a number of vessels were unresponsive to agonist stimulation, even when an 
acetylcholine-induced relaxation had been confirmed during the wake-up protocol. 
Given this, and in light of the desensitisation of UK14304-mediated contractions in the 
tail and mesenteric resistance arteries, all further experiments investigating the effect of 
UK14304 on mesenteric arteries, were studied by constructing randomised, non- 
cumulative response curves.
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The non-cumulative UK14304-medi ated response
UK14304 causes concentration-related vasodilatation of U46619-induced tone in first 
order mesenteric aiteries from four-month old WT mice. The responses gained, tend to 
be greater in size than those observed in the cumulative response, and are less variable. 
This is shown by a measurable response being obtained in all arteries used, and a 
reduction in the standard error of the mean, which is indicative of a reduction in 
variability.
In D79N arteries, curves were only constructed non-cumulatively. UK14304 causes 
concentration-dependent reductions in U46619-induced tone, that are of comparable 
size to those gained in the WT, and at a UK14304 concentration of 1 x lO'^M, are 
significantly greater. The relaxant response to UK14304 in D79N arteries, suggests that 
in murine mesenteric vessels, the aiA/o-adrenoceptor is not the major subtype mediating 
agonist-induced relaxations or, that another receptor has been up-regulated to 
compensate for its loss.
Endothelial cells contribute to vasodilatation by regulating the delicate balance between 
endothelium derived relaxing and contracting factors. Vasodilator responses occur 
when nitric oxide, prostacyclin, and endothelium derived hyperpolarizing factor 
(EDHF) are liberated or released. Nitric oxide appears to be the major contributor to 
relaxant responses in large calibre aiteries, such as the aorta and carotid, while the 
relaxant effects of EDHF increases, the further you move down the vascular tree 
[Shimokawa et al, 1996].
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Effect of L-NAME on UK-mediated vasodilatations
At low agonist concentrations, incubating mesenteric arteries with L-NAME (1 x 10" 
prevents UK14304-induced relaxations in the WT and D79N. However, at high 
agonist concentrations, relaxations that are of comparable size to those gained in a 
control curve still occur. This suggests the involvement of additional relaxing factors, 
and uncovers a relaxant response that cannot be attributed solely to the release of nitric 
oxide.
At submaximal UK14304 (1 x lO'^M) concentrations, the relaxant response in the D79N 
is slightly, but significantly, greater than that of the WT. L-NAME abolishes the 
enhanced vasodilator response in the D79N, giving relaxations that are of comparable 
size to those produced in the WT. In the presence of L-NAME, UK14304-mediated 
relaxations at a concentration of 1 x lO'^^ M are significantly smaller in the WT than the 
D79N. This suggests that nitric oxide plays a more significant role in the regulation of 
vascular responses in the D79N than in the WT. Results gained in chapter three (figure 
3. 11) show that blocking nitric oxide release significantly potentiates contractile 
responses in the D79N tail artery but has little, if any, effect in the WT. Although the 
difference in relaxant responses is not as obvious as the effect on contractility, this still 
provides further evidence in support of the hypothesis, that in the absence of a fully 
functional a2A/D-adrenoceptor pool, regulation of nitric oxide release is affected (and 
may be increased).
In rat mesenteric resistance arteries, blockade of nitric oxide alone does not inhibit 
endothelium-mediated relaxations, because prostacyclin and EDHF participate in the 
vasodilator response. Furthermore, acetylcholine-induced vasodilatations of rat
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mesenteric resistance arteries are mediated, primarily by EDHF [Shimskawa et al,
1996]. However, when nitric oxide synthase is inhibited with L-NAME, and COX 
activity is blocked with indomethacin, NO scavengers can still significantly reduce 
acetylcholine-induced relaxations [Chauhan et al, 2003], refuting this hypothesis.
In the rat, EDHF is a major contributor to relaxant responses in mesenteric resistance 
arteries, but plays little, if any role in lai’ger calibre blood vessels [Hwa et al, 1994]. In 
mouse mesenteric arteries, L-NAME is not maximally effective in the WT or the D79N, 
suggesting the involvement of other, as yet unidentified relaxing factors. In preliminary 
studies, raising extracellulai' potassium levels inhibits UK14304-medi ated relaxations in 
a reversible manner. Reducing K^ levels allows relaxations to resume. This provides 
evidence, which suggests that EDHF is involved in UK14304-mediated vasodilatations 
of mouse mesenteric resistance arteries. Experimentally, when extracellular K^ influx is 
blocked, EDHE-induced relaxations are prevented [Chanhan et al, 2003].
In rat mesenteric and hepatic arteries, treatment with L-NAME and COX inhibition 
cause a significant reduction in acetylcholine-mediated vasodilatations. The remaining 
response has previously been attributed to EDHF, but in the presence of NO scavengers, 
a further inhibition of relaxations is observed [Chauhan et al, 2003]. Leading to the 
conclusion that nitric oxide, proposed to be stored in endothelial cells, can be released 
and mediate vasodilatations, by opening K^ channels [Chauhan et al, 2003]. This 
hypothesis is supported by experiments by Simonsen and co workers. They have shown 
that in the presence of submaximal concentrations of L-NAME, that microsensors can 
still detect nitric oxide release [Simonsen et al, 1999].
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The results presented here suggest that UK14304~mediated nitric oxide release 
contribute to relaxant responses of murine mesenteric resistance arteries. However, the 
surmountable effect of L-NAME, suggests the involvement of additional relaxing 
factors. Preliminary studies suggest the involvement of EDHF, but without COX 
inhibition and the use of NO scavengers, no clear conclusions as to the identity of 
additional relaxant mediators can be made.
Effect of rauwolscine on UK14304-mediated responses
Due to the high variability and lack of responsiveness when cumulative UK14304 
curves are constructed, and the additional complication of agonist-induced receptor 
desensitisation, the effect of rauwolscine was investigated against first, non-cumulative 
response curves. Rauwolscine, at a concentration of 3 x lO'^M, antagonises 
vasodilatations induced by low concentrations of UK14304. The antagonism produced 
by rauwolscine is surmountable, and at high UK14304 concentrations, relaxations, that 
are comparable to those gained in a control curve, proceed. The inhibitory effect of 
rauwolscine provides evidence that the UK14304-mediated response, results from 
selective stimulation of ai-adrenoceptors, which are probably endothelial in origin. The 
use of higher concentrations of rauwolscine was deemed unproductive since selectivity 
against ai-adrenoceptors could not be guaranteed. However, at high concentrations of 
UK14304, the lack of effect of rauwolscine suggests an effect that cannot be attributed 
to stimulation of (%2 -adrenoceptors.
Summarv and conclusions
To s u m m a r i s e ,  u n l i k e  t h e  r a t ,  t h e  ( % 2 A / D - a d r e n o c e p t o r  d o e s  n o t  a p p e a r  t o  b e  t h e  m a j o r  
0 ( 2 - a d r e n o c e p t o r - s u b t y p e  m e d i a t i n g  v a s o d i l a t a t i o n s  of m u r i n e  m e s e n t e r i c  r e s i s t a n c e
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arteries. This conclusion is made based on the results obtained in the D79N, where 
UK14304-mediated relaxations persist even in the absence of functional aiA/D- 
adrenoceptors. The inhibitory effect of rauwolscine confirms that UK14304-mediated 
effects are attributable to stimulation of az-adrenoceptors, but at high agonist 
concentrations may involve another receptor. Taken together, the results in the D79N, 
and responses in the WT with rauwolscine, lead to the conclusion that the UK14304 
response is mediated, in part, by the (%2 c and/or a 2 B subtype (s). We cannot exclude 
involvement of the ot2 A/D in the control mouse, but, if it is significant there, it must have 
been compensated for, or replaced by another subtype when it was suppressed in the 
D79N.
Activation of (%2 -adrenoceptors in mesenteric resistance arteries stimulates nitric oxide 
release, which acts to oppose U46619-induced contractions. In addition, other relaxing 
factors, which are not susceptible to L-NAME, contribute to vasodilatations. Their 
identity has yet to be determined, but these responses are presumed to involve EDHF. 
However, the possibility that stored nitric oxide, and/or prostacyclin are involved, 
cannot, at this point, be excluded.
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Chapter seven
The determination of pA% values for prazosin in the tail 
artery of young and old WT and aiB KO mice
201
7.1 Introduction
Experiments in knockout mice provide evidence that the aiB-adrenoceptor is involved 
in the regulation of pressor responses in the mouse [McCafferty et al, 1999]. In the 
pithed mouse, phenylephrine-induced pressor effects can be antagonised by the a i- 
selective antagonist terazosin, but were resistant to antagonism with rauwolscine. B-HT 
933, an az-selective agonist, also caused an increase in peripheral blood pressure, which 
was antagonised by rauwolscine, but unaffected by low doses of terazosin. This data 
confirmed that as in the rat, pressor responses were mediated by a mixed population of 
a i and (%2 -adrenoceptors in the mouse [McCafferty et al, 1999], and that in vitro 
analysis was required to claiify which arteries were major contributors to the control of 
blood pressure, and to delineate the role of each adrenoceptor subtype in situ,
aiB-adrenoceptors are expressed in a wide variety of arteries known to regulate blood 
pressure, yet the contractile responses mediated by this adrenoceptor subtype, are poorly 
defined. This is due in part to a lack of subtype selective ligands. In light of the cuirent 
advances in molecular biology, mice have been generated with gene-targeted 
disruptions of each adrenoceptor subtype. This procedure has been used successfully to 
‘knockout’ the ociB-adrenoceptor [Cavalli et al, 1997].
Studies that aimed to determine the changes in the expression levels of ai- 
adrenoceptors are often contradictory, and the changes that occurred in expression 
levels of adrenoceptors appear to depend on the species and vessel type studied. Data 
has been presented that proposes that age dependent alterations occur in the expression 
and function of the ocm receptor subtype in the rat vasculature [Ibana et al, 1997]. 
However, little if any information is available on what happens to responses mediated
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by a iB“adrenoceptors, partly because of the lack of subtype selective compounds for 
this adrenoceptor.
It has been suggested that the increase in systemic blood pressure occumng with age, 
may be the result of an elevation in peripheral nerve activity. Evidence in support of 
this hypothesis came from studies that showed circulating levels of catecholamines 
increased in humans with advancing age [Buchholz & Duckies, 1990]. Age related 
increases in sympathetic nerve activity are known to occur in peripheral blood vessels 
[Buchholz et al, 1995]. Whether a change occurs in the expression or function of the 
adrenoceptors exposed to high levels of neurotransmitters is uncleai’.
There were two main aims in canying out the experiments contained within this 
chapter. The first was to determine what, if any, role the aiB-adrenoceptor plays in 
phenylephrine-induced contractions of the murine tail artery. This aim was achieved by 
testing the effects of prazosin, in combination with studies where the subtype selective 
antagonists, 5MeU and BMY7378 were utilised [Daly et al, 2002]. Secondly to 
determine, if ai-adrenoceptor responses were altered with increasing age and, if so, 
what affect does a lack of functional aiB-adrenoceptors have on these responses?
Previous work has documented a change in catecholamine-induced contractions of the 
rat tail artery. With increasing age, contractile responses became significantly 
potentiated in maximum. In addition to an alteration in the size of the responses 
achieved, the sensitivity to exogenous agonists was also affected. The increase in tissue 
sensitivity has been attributed to an increase in oxidative stress with advancing age 
[Janero et al, 1990].
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7.2 Methods
Four and sixteen-month old WT (C57BL/6c/129Sv) and aiB KO (aie -/- 
C57BL/6c/129Sv, background) mice were killed by asphyxiation with CO2 .
Immediately after, tails were removed and immersed in fresh, cold Krebs until 
dissection. Tails arteries were dissected, and mounted in Mulvany/Halpern wire 
myograph baths, containing 5mls of fresh Krebs, gassed with a 95 % O2  5 % CO2  
mixture. Following an equilibration period a resting tension of 0.25gms Force was 
applied to each mounted arterial ring (Detailed description contained in chapter two).
7.2.1 Wake-up protocol
Each mounted, arterial ring was challenged with phenylephrine at a concentration of 1 x 
lO'^M. Once the contractile response reached a plateau, arteries were washed with fresh 
Ki^ebs four times over a fifteen minute period. This procedure was repeated twice, once 
with the same concentration of phenylephrine, and a second time with phenylephrine at 
a concentration of 1 x lO'^M. When the third, and final, phenylephrine response 
reached a plateau, acetylcholine (3 x lO'^M) was added to test the viability of the 
endothelium. After a series of washes over a fifteen minute period, arteries were 
allowed a 30-35 minute rest period before construction of the first phenylephrine curve.
7.2.2 Effect of nifedipine on phenvlephrine-induced contractions
Tail arteries from WT and ocm KO mice were incubated with nifedipine at a 
concentration of 1 x 10‘^ M (final bath concentration), for a minimum of twenty minutes 
prior to construction of a phenylephrine response curve. After construction of a control 
curve, to determine the effect nifedipine had on contractile responses, all subsequent 
experiments were carried out in the presence of nifedipine: this was done for two
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reasons. Firstly, experiments were carried out in the presence of nifedipine to 
complement an earlier study carried out in the laboratory [Daly et al, 2002]. Secondly, 
as in the earlier publication to prevent the development of rhythmic contractions that 
occur when exogenous agonists are applied in the tail artery.
7.2.3 Effect of prazosin on phenvlephrine-induced contractions 
The effect of increasing concentrations of prazosin has been determined against the 
phenylephrine-induced response in tail arteries from WT and aiB KO mice, at two age 
points. To permit the calculation of a pA% value, prazosin was used at three 
concentrations, ranging from 1 x 10'^ to 1 x 10‘^ M. Each mounted vessel was subjected 
to an initial phenylephrine curve, which was followed by a phenylephrine curve in the 
presence of nifedipine (1 x Where one vessel was then used as a time control,
receiving a curve in the absence of antagonists. The remaining three vessels were 
incubated with a single concentration of prazosin for a minimum of thirty minutes 
before construction of a further response curve. Therefore, each mounted vessel was 
subjected to two consecutive response curves.
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1 3  Results
7.3.1 Effect of nifedipine in arteries from 4-month old WT and arnKQ mice
Figure 7.1 shows the cumulative phenylephrine response alone, and in the presence of 
nifedipine; curves were constructed in tail aiteries from four-month old WT (figure 7.1 
A) and otig KO (figure 7.1 B) mice. In WT arteries, contractions to phenylephrine 
reached a maximum of 0.64 ± 0.06gms Force, while in the presence of nifedipine the 
maximum contraction was significantly reduced to 0.51 ± 0.05gms Force (p = 0.006*).
Nifedipine has a more pronounced effect on the phenylephrine-induced response in tail 
arteries from the aie KO. The maximum contraction in the phenylephrine control curve 
was 0.73 ± 0.09gms Force, while in the presence of nifedipine it was reduced 
significantly to 0.39 ± 0.05gms Force (p<0.001***).
Figure 7.2 shows the responses gained in WT and aiB KO tail arteries in a control curve 
(figure 7.2 A) and in the presence of nifedipine (figure 7.2 B), on the same graph for 
ease of comparison. In the control curve the maximum response in the (Xib KO was 
significantly greater than that of the WT. The WT maxima was 0.64 ± 0.06gms Force, 
compared to the maximum response gained in the aiB KO, that was 0.73 ± 0.09gms 
Force (p = 0.02*). This order is reversed after nifedipine; WT 0.51 ± 0.05gms Force,
(%iB KO significantly smaller at 0.39 ± 0.05gms Force (p = 0.0098**).
Nifedipine caused a greater reduction in the maximum phenylephrine-induced response 
in the KO than in the WT. The mean change in maximum in the WT was 0.13 ± O.lgms 
Force, while in the a is  KO the mean reduction in maximum was 0.42 ± 0.04gms Force.
206
A WT
0
1I
1.00
0.75
0.50
0.25
0.00
L_
9 ■48 7 ■6 5
Log M [Phenylephrine]
B KO
2
£iO)
1.00
0.75
0.50
0.25
0.00
L_
9
J L _
7 6 ■48 ■5
Log M [Phenylephrine]
Figure 7.1: Responses in tail arteries from 4-month old WT and KO mice. A 
A PE response curve alone (o, n = 9) and with nifedipine (1 x lO'^M, • ,  n = 6) in
the WT. B A PE response curve alone (O, n = 9) and with nifedipine ( • ,  n = 6) in 
the KO. Each point represents mean ± standard error.
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Figure 7.2: Responses in tail arteries from 4-month old WT and ct^gKO mice. A 
A PE control curve in the WT (o, n = 9) and aj^KO (•, n = 9). B A PE response 
curve in the presence of nifedipine ( 1 x lO'^M) in the WT (o, n = 6) and a^gKO 
(•, n = 6). Each point represents mean ± standard eiTor.
Statistical analysis of the reduction in the maximum between strains revealed that in the 
otiB KO, nifedipine caused a significantly greater reduction in maximal contractions
(p<0.0001***).
Comparison of responses gained in the presence of nifedipine revealed two things. 
Firstly, that nifedipine caused a significant reduction in phenylephrine-induced 
contractions in the WT and otiB KO tail artery. Secondly, that the reduction in the 
maximum response in the aiB KO was significantly greater than in the WT. In the 
control curve, the maximum agonist-induced contraction was greater in the aiB KO than 
in the WT. However, in the presence of nifedipine, contractile responses in the WT tail 
artery exceeded those of the aiB KO. This situation is unique amongst the vessels that 
our laboratory has compared in the WT and aiB KO. In aorta, carotid and first order 
mesenteric resistance arteries responses have been shown to be consistently larger in the 
aiB KO, but the study of responses in these arteries was not complicated by the 
development of rhythmic contractions, unlike the mouse tail artery.
Figure 7.3 shows the phenylephrine response in control curves, and in the presence of 
nifedipine in tail arteries from WT (figure 7.3 A) and ociB KO (figure 7.3 B) mice, 
expressed as a percentage of their own maximum. In WT arteries, the control curve had 
a pECso of 6.0 ± 0.01, which was significantly reduced in the presence of nifedipine to
5.7 ± 0.01 (p<0.0001***). Nifedipine had a similar effect on the pECso value gained in 
the aiB KO. The ctiB KO control curve yielded a pECso value of 6.0 ± 0.02, while in the 
presence of nifedipine the pECso value was significantly reduced to 5.5 ± 0.02 aiB KO 
(p<O.OOOF**).
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Figure 1.3: Responses in tail arteries from 4-month old WT and oCjg KO mice, 
expressed as percentage maximum. A A PE response curve alone (o, n = 9) and with 
nifedipine (1 x • , n = 6) in the WT. B A PE response curve alone (o, n = 9)
and with nifedipine (•, n = 6) in the KG. Each point represents mean ± standard
error.
7.3.2 Effect of prazosin in 4-month old WT and a i n KO tail arteries 
All of the response curves constracted to investigate the effect of prazosin on the 
phenylephrine-induced response were performed in the presence of nifedipine (1 x 10" 
^M). Prazosin caused a rightwai'd shift in the concentration response curve to 
phenylephrine in tail arteries from WT mice, and a significant reduction in the 
maximum response at a prazosin concentration of 1 x lO'^M. The WT control curve 
maximum was 0.51 ± O.OSgms Force, in the prazosin curve (1 x lO'^M) was 0.38 ± 
0.04gms Force, at 1 x lO'^M was 0.45 ± 0.05gms Force (no significant change at this 
concentration), and at 1 x lO'^M, prazosin caused a significant reduction to 0.29 ± 
0.03gms Force (p<0.01*'*') although a true maximum was not established even at 
phenylephrine concentrations of 3 x lO'^^ M. Additionally, the maximum response at 1 x 
lO'^M was also significantly smaller than the response gained in the presence of 
prazosin at a concentration of 1 x lO'^M (p <0.05*).
In tail arteries from the aiB KO, increasing concentrations of prazosin caused a 
rightward shift in the phenylephrine response curve, and at higher antagonist 
concentrations (1 x lO'^M) a significant reduction in the maximum response, though 
again this was not a true maximum. The otig control curve maximum was 0.39 ± 
0.05gms Force, with 1 x lO'^M prazosin was 0.27 ± 0.04gms Force, at 1 x lO'^M was 
0.36 ± 0.04gms Force (no significant change to this concentration), and at 1 x lO'^M 
prazosin the response was significantly reduced to 0.12 ± 0.05gms Force (p<0.05*). In 
addition to a reduction in contractility when compaied with the control curve, the 
maximum response in the presence of prazosin at 1 x lO’^ M was significant smaller than 
the response gained with prazosin at 1 x lO'^M (p<0.05*). As figure 7.4 (effect of 1 x
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10'^ and 1 X lO'^M prazosin) and 7.5 (effect of 1 x lO'^M prazosin) show the pattern of 
effects of prazosin was similai' in the two strains.
7.3.3 pA? values for prazosin in tail arteries from 4-month old mice 
Figure 7.6 shows the Schild regression plot for prazosin in tail arteries from four-month 
old WT (figure 7.6 A) and aie KO (figure 7.6 B) mice. To determine the pAz (detailed 
description contained in chapter two) value the log (dose ratio -  1) was calculated and 
plotted for each result gained from a sample size of six, in each strain. Where the line 
intercepts the x-axis deteimines the pA2  value. Arteries from WT mice had a pA% value 
of 8.8, and the regression line had a slope of 0.95 ± 0.13, indicative of competitive 
antagonism. The pA2  value calculated for prazosin in tail arteries from otiB KO mice 
appearred to be higher than that obtained for the WT at 9.2, with a slope of 0.99 ± 0.14, 
again the slope of the line was not significantly different from unity, again indicative of 
competitive antagonism.
WT otiB KO
Maximum (gms Force) Maximum (gms Force)
Control 0.64 ± 0.06, n = 9 0.73 ± 0.09, n = 9
Nifedipine 1 x lO'^M 0.51 ± 0.05, n = 6 0.39 ± 0.05, n = 6
Prazosin 1 x 10"^M 0.38±0 .04 ,n  = 6 0.27 ± 0.04, n = 6
Prazosin 1 x lO'^M 0.45 ± 0.05, n = 6 0.36 ± 0.04, n = 6
Prazosin 1 x lO^M 0.29 ± 0.03*, n = 6 0.12 ± 0.05*, n = 6
Table 7.1 Highest response attained in tail arteries from four-month old WT and otiB KO
209
0.75
O^
 0 .50£
IO ) 0.25
0.00
7 5 ■4■9 68
B
8V.£
E
Log M [Phenylephrine]
0.75
0.50
0.25
0.00
i_
■7 6 459 8
Log M [Phenylephrine]
Figure 7.4: Responses in tail arteries from 4-month old WT and a^gKO mice (with 
nifedipine). A A PE response curve in the WT (o, n = 6) and a^gKO (•, n = 6) 
with prazosin at 1 x 10‘^ M. B A PE response curve in the WT (o, n = 6) and 
a^gKO (•, n = 6) with prazosin at 1 x lO'^M. Each point represents mean ± 
standard eiTor.
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Figure 7.5: Responses in tail aiteries from 4-month old WT and KO mice 
(with nifedipine). A PE control curve (o, n = 6), and with prazosin (1 x lO'^M, 
• , n = 6)) in the WT. B PE control curve (o, n = 6), and with prazosin (1 x 10' 
^M, • , n = 6)) in the KG. Each point represents mean ± standaid error.
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Figure 7.6; Schild regression plots for prazosin in tail arteries from 4-month old 
WT and ot^jKO mice. A In WT arteries (■, n = 6), yielding a pAg value of 8.8 
with a slope of 0.95. B In a^^KO arteries (■, n = 6), yielding a pA2  value of 9.2 
with a slope of 0.99. Each point shows a single results for a given antagonist 
concentration.
Figure 7.7 illustrates the effect of nifedipine (1 x lO'^M) on phenylephrine-induced 
contractions of tail arteries from four (figure 7.7 A) and sixteen-month old WT (figure
7.3.4 Effect of nifedipine in tail arteries from 16month old WT and am KO mice
7.7 B) and four (figure 7.7 C) and sixteen-month old aiB KO (figure 7.7 D) mice. At 
sixteen-months in the WT, the maximum response gained was 0.81 ± 0.07gms Force.
In the presence of nifedipine, the maximum was reduced to 0.67 ± 0.04gms Force (p = 
0.075), which is not significantly different from the control curve. However in the aiB 
KG, the nifedipine-induced reduction in the maximum response was significant, with 
the control maximum being reduced from 0.86 ± 0.07gms Force, to 0.60 ± 0.08gms 
Force (p = 0.038*). Figure 7.7 A and figure 7.7 C are replicates of the graphs shown in
figure 7.1, but were presented here for easy of comparison with the responses gained at 
sixteen-months.
Figure 7.8 compares the responses gained in a phenylephrine control curve at four 
(figure 7.8 A) and sixteen-months (figure 7.8 B), and the effect of nifedipine at four 
(figure 7.8 C) and sixteen-months (figure 7.8 D) on the phenylephrine-induced 
responses in the WT and ocib KG. At sixteen-months in the WT control curve, 
phenylephrine produced a maximum response of 0.81 ± 0.07gms Force in WT arteries, 
compared with 0.86 ± 0.07gms Force for the KG, which were not significantly 
different (p>0,05). In the presence of nifedipine, contractions were generally smaller, 
but of comparable size in both strains. WT arteries gave a maximum contraction of 
0.67 ± 0.04gms Force, compared with 0.60 ± O.OSgms Force in the sixteen-month old 
aiB KG mice (p>0.05). Again, figures 7,8 A, and figure 7.8 C have already been shown 
in figure 7.2, but appear again for comparison with the responses at sixteen-months.
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Figure 7.7: Responses in tail arteries from 4 and 16-month old WT and ot^gKO mice. 
Figures A and C are a copy of figure 7.1 (4-month data). B A PE response curve 
alone (°, n = 10) and with nifedipine (1 x lO'^M,®, n = 9) in the WT at 16-months.
D A PE response curve alone (o, n = 10) and with nifedipine (•, n = 9) in the a^gKO
at 16-months. Each point represents mean ± standard error.
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Figure 7.8: Responses in tail arteries from 4 and 16-month old WT and ajgKO 
mice. Figures A and C are a copy of figure 7.2 (4-month data). B A PE control 
curve in the WT (o, n = 10) and a^gKO (• , n = 10) at 16-months. D A PE 
response curve with nifedipine in the WT (o, n = 9) and a^jKO (•, n = 9) at 16- 
months. Each point represents mean ± standard eiTor.
The phenylephrine control curve in tail arteries from sixteen-month old mice, and the 
response gained in the presence of nifedipine (1 x lO’^ M), were expressed as a 
percentage of the maximum for the WT at four (figure 7.9 A) and sixteen-months 
(figure 7.9 B) and aie  KO at four (figure 7.9 B) and sixteen-months (figure 7.9 D), and 
have been shown in figure 7.9. Figure 7.9 A, and figure 7.9 C are duplicates of the 
four-month data but have been shown again for ease of compaiison with the responses 
gained at sixteen-months. At sixteen-months, nifedipine had no effect on tissue 
sensitivity in the WT. The pECgo value in the WT control curve was 5.7 ± 0.01, which 
was no different to the pECso gained in the presence of nifedipine of 5.7 ± 0.005 
(p>0.05). In aiteries from (Xm KO mice the control curve pECso value was 5.7 ± 0.004, 
while in the presence of nifedipine the pECso value was slightly lower, at 5.5 ± 0.01 
(p>0.05).
7.3.5 Effect of prazosin in tail arteries from 16month old WT and am  KG mice 
In the WT at sixteen-months, prazosin caused a rightward shift in the concentration 
response curve at all antagonist concentrations. FurtheiTnore, prazosin also caused a 
progressive reduction in the maximum phenylephrine-mediated response in WT arteries, 
although this was significant only at the highest prazosin concentration tested and where 
no true maximum was attained. The control curve maximum was 0.67 ± 0.04gms 
Force, compared with 0.54 ± 0.07gms Force for 1 x lO'^M (p = 0.21), 0.45 ± 0.06gms 
Force for 1 x lO'^M (p = 0.73), and 0.23 ± 0.06 with prazosin at 1 x lO'^M (p = 0.02*).
In tail arteries from sixteen-month old am  KO mice, prazosin caused a rightward shift 
in the phenylephrine response curve, but did not reduce the maximum response, unlike 
the WT. The maximum contraction in the control curve was 0.60 ± O.OSgms Force,
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Figure 7.9: Responses in tail arteries from 4 and 16-month old WT and KO 
mice, expressed as percentage maximum. A and C are a copy of figure 7.3 (4- 
month data). B A PE response curve alone (o, n = 10) and with nifedipine (1 x 10' 
^M, • , n = 9) in the WT. D A PE response curve alone (o, n = 10) and with 
nifedipine (•, n = 9) in the KG both at 16-months. Each point represents mean 
± standard eiTor.
compared with 0.49 ± O.lgms Force for 1 x lO'^M, 0.58 ± 0.09gms Force for 1 x lO'^M, 
and 0.52 ± O.lgms Force for 1 x 10‘^ M prazosin.
Figure 7.10 shows the comparison of responses in the WT and ocib KO, and at both age 
points with prazosin at a concentration of 1 x 10'^ and 1 x 10‘^ M. Figure 7.10 A 
compares the response in the WT and aiB KO with prazosin at 1 x lO'^M at four- 
months, while figure 7.10 C compares the responses between WT and aiB KO with 
prazosin at 1 x lO'^M at four-months. Figure 7.10 B shows the response with prazosin 
at 1 X lO'^M in the WT and cxib KO at sixteen-months, while figure 7.10 D compares 
the responses in the WT and aiB KO with prazosin at 1 x lO'^M, at sixteen-months.
At four-months, the lowest prazosin concentration tested (1 x 10‘^ M) shifted the 
response in the aiB KO further to the right than in the WT. At a concentration of 1 x 10' 
prazosin, the maximum response in the WT was 0.45 ± O.OSgms Force, which was 
significantly greater than the maximum in the aiB KO of 0.27 ± 0.04gms Force (p = 
0.037*).
Figure 7.10 also shows the comparison between responses gained in WT and aiB KO at 
16-months with two concentrations of prazosin, those gained at 1 x lO'^M (figure 7.10 
B), and those at a concentration of 1 x lO'^M (figure 7.10 D). The responses gained at 
both antagonist concentrations were compai'able in size and sensitivity in the WT and 
otiB KO.
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Figure 7.10; Responses in tail arteries from 4 and 16-month old WT and a^gKO 
mice. Figures A and C show responses at 4-months in WT and ajg KO arteries. B 
A PE response curve in the WT (o, n = 6) and aj^KG (• , n = 6) with prazosin at 1 
X lO'^M, at 16-months. D A PE response curve in the WT(o, n = 6) and a^gKO 
(•, n = 6) with prazosin at 1 x lO'^M, at 16-months. Each point represents mean ± 
standard error.
Figure 7.11 shows the phenylephrine-mediated response in tail arteries from four-month 
old WT (figure 7.11 A) and aiB KO (figure 7.11 C) mice in the presence of prazosin at 
a concentration of 1 x 10‘^ M. At this concentration, prazosin caused a significant 
reduction in the maximum response in both strains. In the WT, the control curve 
maximum was reduced from 0.51 ± 0.06gms Force, to 0.29 ± 0.03gms Force in the 
presence of prazosin (p<0.02*). Responses in the KO were reduced from 0.39 ± 
O.OSgms Force in a control curve, to 0.12 ± O.OSgms Force in the presence of prazosin
(p<0.012*).
Figure 7.11 also shows the phenylephrine-induced control response, and the response 
gained in the presence of prazosin at a concentration of 1 x 10‘^ M in tail arteries from 
sixteen-month old WT (figure 7.11 B) and aie KO (figure 7.11 D) mice. The prazosin- 
induced reduction in the control curve maximum was obvious in WT arteries. In 
contrast, contractile responses, although shifted rightward retain their maximum in 
arteries from the am  KO. Statistical analysis of the contractile responses in the 
presence of prazosin confirmed that contractile responses in the WT were significantly 
smaller than those of the am  KO (p = 0.02"^).
213
A 4-month WT B 16-month WT
0.75
0.50
O)O) 0.25
0.00
6 5 ■4■9 ■8 7
0.75
0.50
0.25
0.00
49 8 ■6■7 •5
Log M [Phenylephrine] Log M [Phenylephrine]
C 4-month KO D 16-month KO
0.75
0.50
O)u> 0.25
0.00
L_9 x_■8 ■6•7 5 ■4
0.75
0.50
0.25
0.00
■6 ■5 ■4 39 ■8 7
Log M [Phenylephrine] Log M [Phenylephrine]
Figure 7.11: Responses in tail arteries from 4 and 16-month old WT and a^g KO 
mice. Figures A and C show responses at 4-months in WT and ajg KO. B PE 
response in the WT control (o, n = 9) and with prazosin at 1 x lO'^M (•, n = 6) at 16- 
months. D PE response in the a^g KO control (o, n = 9) and with prazosin at 1 x 10" 
(•, n = 6) at 16-months. Each point represents mean ± standard error.
WT aiB KO
Maximum (gms Force) Maximum (gms Force)
Control curve 0.81 ± 0.07, n =  10 0.86 ± 0.07, n = 10
Nifedipine 1 x lO'^M 0.67 ± 0.04, n = 9 0.60 ± 0.08, n = 9
Prazosin 1 x lO'^M 0.54 ± 0.07, n = 6 0.49 ± 0.10, n = 6
Prazosin 1 x lO'^M 0.45 ± 0.06, n = 6 0.58 ± 0.09, n = 6
Prazosin 1 x lO'^M 0.23 ±0.06*, n = 6 0.52±0.10*,n  = 6
Table 7.2 Highest response attained in tail arteries at sixteen-months in WT and aiB 
KO.
7.3.6 pA? values for prazosin in tail arteries from 16month old WT and ocm KO mice 
Figure 7.12 shows Schild regression plots for prazosin in tail arteries from four (figure 
7.12 A) and sixteen-month old (figure 7.12 B) WT mice and four (figure 7.12 C) and 
sixteen-month old (figure 7.12 D) KO mice. In WT arteries, the intercept of the 
regression line with the x-axis gave a pA% value of 8.8, with a slope of 0.84 ± 0.13 at 
16-months. While in the (%iB KO the pÀ2  value was slightly higher than the WT at 9.0, 
with a slope of 0.72 ± 0.12 at 16-months. In both strains the regression lines had a slope 
that was significantly different from unity, indicative of non-competitive antagonism.
tail artery (4-month old) tail ai'tery (16-month old)
pAz Slope pAz Slope
WT 8.8 0.95 8.8 0.84
ociB KO 9.2 0.99 9.0 0.72
Table 7.3 pA% values for prazosin at both age points in tail arteries from WT and aiB 
KO mice.
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Figure 7.12: Schild regression plots for prazosin in tail arteries from 16-month old 
WT and a^gKO mice. Figures A and C are a copy of figure of the 4-months in the 
WT and a^g KO. B Schild plot for WT arteries (■, n = 6) at 16-months, prazosin has 
a pA2  of 8.8 with a slope of 0.84. D Schild plot for a^gKO arteries (■, n = 6) at 16- 
months, prazosin yields a pÀ2  of 9.0 with a slope of 0.72. Each point shows a single 
results for a given antagonist concentration.
7.3.7 Compaiison of results gained in arteries from 4 and 16month old mice 
Figure 7.13 compares the phenylephrine control curves from four and sixteen-month old 
WT (figure 7.13 A) and a ^ K O  mice (figure 7.13 B). In arteries from WT mice, 
contractile responses reached a greater maximum at sixteen-months than at four. At 
four-months the maximum response gained in the control curve was 0.64 ± 0.06gms 
Force, compared with 0.81 ± 0.07gms Force obtained in arteries from sixteen-month old 
WT mice (p = 0.02*).
In the ttiB KO, contractile responses tended to be greater at sixteen-months, but were not 
significantly different from those gained at four-months. At sixteen-months the 
maximum response was 0.86 ± 0.07gms Force, compared with a maximum of 0.73 ± 
0.09gms Force in tail arteries from four-month old aiB KO mice (p = 0.50).
The phenylephrine control curves for the WT (figure 7.14 A) and a%B KO (figure 7.14 
B) at each age point were expressed as a percentage of their own maximum and are 
shown in Figure 7.14. In WT arteries, the pECso value at 4-months was 6.0 ± 0.01, 
compared with a value of 5.7 ± 0.01 for curves constructed in arteries from sixteen- 
month old mice (p = 0.0007***). The significant shift in pECso values, suggested that 
arteries are slightly less sensitive to phenylephrine with increasing age. A similar result 
was obtained in the aiB KO, with a pEC^o of 6.0 ± 0.01 at four-months, compared with a 
pECso of 5.7 ± 0.004 in the response curve from sixteen-month old mice (p<0.0001***).
At both age points, and in both strains, nifedipine reduced the contractile maximum, but 
had only a slight effect on tissue sensitivity. Figure 7.15 shows phenylephrine response 
curves in the presence of nifedipine (1 x 10"^M) constructed in arteries from four-month
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Figure 7.13: Responses in tail aiteries from 4 and 16-month old WT and 
KO mice. A A PE control curve at 4 (o, n = 9) and 16-months (•, n = 10) in 
the WT. B A PE control curve at 4 (o, n = 9) and 16-months (• , n = 10) in the 
a^gKO. Each point represents mean ± standard enor.
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Figure 7.14: The phenylephrine response in tail arteries from 4 and 16-month old 
WT and a^gKO mice, expressed as a percentage of the maximum response. A In 
WT controls at 4 (o, n ~ 9) and 16months (• , n = 10). B In KO controls at 4 
(o, n ~ 9) and 16months (•, n = 10). Each point represents mean ± standard enor.
old and sixteen-month old WT (figure 7.15 A) and aiB KO (figure 7.15 B) mice. In WT 
arteries, the contractile maximum at four-months was 0.51 ± 0.05gms Force, which was 
significantly lower than the maximum response at sixteen-months of 0.67 ± 0.04gms 
Force (p = 0.009**). In am  KO mice, the maximum phenylephrine-induced response at 
four-months was 0.39 ± 0.05gms Force, which was significantly smaller than the 
response at sixteen-months, which was 0.60 ± O.OSgms Force (p = 0.014*).
Figure 7.16 shows a comparison of the phenylephrine-induced contractions in tail 
arteries from four (figure 7.16 A) and sixteen-month (figure 7.16 B) old WT and am 
KO mice in the presence of the highest concentration of prazosin tested ( 1x10  ^M). At 
four-months the phenylephrine-induced response was small in tail arteries from the WT 
and am  KO, but in the am  KO the maximum response gained was significantly smaller 
than that of the WT (p = 0.02*). At sixteen-months the converse was true. The 
phenylephrine-induced contraction in the WT was significantly smaller than that of the 
am  KO (p = 0.017*)
In the WT, the size of contractile responses tended to increase at sixteen-months, but 
comparison with responses gained at four-months has shown no significant difference. 
However, comparison of the response curves gained in the am  KO at both age points 
revealed that in the presence of all three concentrations of prazosin, the contractile 
responses were significantly greater at sixteen-months (at 1 x 10 ^M, p = 0.048*, 1 x 10 
^M, p = 0.04*, and 1 x lO '^M, p = 0.004**)
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Figure 7.15: The phenylephrine response in the presence of nifedipine in tail 
arteries from 4 and 16-month old WT and A A PE response curve at 4 (o,
n = 6) and 16-months (•, n = 9) in the WT. B A PE response curve at 4 (o, n = 6)
and 16-months (•, n = 9) in the oc^gKO. Each point represents mean ± standard
eiTor.
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Figure 7.16: Responses in tail arteries from 4 and 16-month old WT and ajgKO 
mice (with nifedipine). A PE response at 4-months in the WT (o, n = 6) and 
aigKO (•, n = 6) with prazosin at 1 x 10‘'^ M B PE response at 16-months in the 
WT (o, n = 6) and ot^gKO (• , n ~ 6), with prazosin at 1 x lO'^M. Each point 
represents mean ± standard eiT or.
7.4 Discussion
Work presented in this thesis provides evidence that the murine tail artery contracts in 
response to activation of a mixed population of a i and a 2 -adrenoceptors. However, to 
date the role of each adrenoceptor subtype in mediating contractile responses is poorly 
defined, in particular, the role of the aiB-adrenoceptor. It has previously been proposed 
that the aiB-adrenoceptor plays only a minor role in the control of peripheral blood 
pressure [Piascik et al, 1993]. The work shown here in combination with studies using 
subtype selective antagonists from our laboratory has been used to argue in support of 
this hypothesis [Daly et al, 2002]. Given that prazosin has been used widely as a 
pharmacological tool to assign receptor functions, I have assessed the effects of this 
drug in the mouse tail artery.
Prazosin is an (%i-selective antagonist, that causes potent inhibition of phenylephrine- 
induced contractions in a number of murine blood vessels, including the tail artery, 
mesenteric, carotid and aorta [Daly et al, 2002]. The data shown here confions that 
prazosin antagonises phenylephrine-induced contractions of the murine tail artery and, 
at the highest drug concentrations used, causes a significant reduction in the contractile 
maximum in arteries from WT and KO mice, at four and sixteen-months.
The data presented in this chapter foims part of a recent publication by Daly et al, where 
the effect of prazosin, and a number of selective antagonists were used to determine the 
major «i-adrenoceptor subtype causing contraction of the mouse tail aitery, aorta, 
carotid, and first order mesenteric resistance arteries. The effects of prazosin alone, 
provide little information on the adrenoceptor subtypes involved in mediating 
contractions of the murine tail artery, but combined with the complimentary infomriation
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provided by the other antagonists helps to determine the major (%radrenoceptor subtype 
causing contraction. Thus providing clarification on the role of the aiB-adrenoceptor in 
the murine tail artery.
The responses shown in chapter three and four, where az-adrenoceptor-mediated 
contractions of the tail artery were investigated, are complicated by the development of 
rhythmic contractions of the murine tail artery. In a similai' way, stimulation of cxi- 
adrenoceptors also leads of the development of unwanted rhythmic contractility in the 
mouse tail artery. Low concentration of nifedipine prevents rhythmic contractions from 
developing, and causes a reduction in the absolute size of the contractile response.
Nifedipine is a dihydropyridine calcium channel blocker, known to cause a significant 
reduction in noradrenaline-induced contractions of rabbit veins [Dunn et al, 1991]. The 
effect of nifedipine on contractions of the murine tail aitery is similar, and predictable, 
because the influx of extracellular calcium is retarded. Although contractions are 
reduced in size, they are still substantial in both strains, providing evidence that aj- 
adrenoceptor-mediated contraction of the tail artery depends on both extra and 
intracellular calcium. Extracellular calcium enters the cell via nifedipine sensitive 
channels, while intracellular calcium probably originates from the sarcoplasmic 
reticulum. Nifedipine significantly reduces the magnitude of the phenylephrine-induced 
response in the a is  KO at both age points, and in the WT at sixteen-months, but 
sensitivity remains similar.
In complementary studies caiiied out in our laboratory on mesenteric resistance arteries, 
5MeU has been shown to competitively antagonise the phenylephrine-induced response
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in WT and aiB KO arteries. In the KO, the pAa value for 5MeU (8.5) is higher than that 
of the WT (8.3). This is a very small difference, but there was also a change in the 
slope of the Schild plot from the WT (1.4) to KO (1.1) [Daly et al, 2002]. Taken 
together, this is consistent with a minor contractile role for the aiB-adrenoceptor- 
subtype. Furthermore, increasing concentrations of BMY7378, ranging from 1 x 10"^  to 
1 X lO'^M, have no effect on phenylephrine-induced contractions of the murine tail 
artery [Daly et al, 2002]. This provides evidence that the aio-adrenoceptor does not 
contribute to contractile responses in the murine tail artery, unlike first order mesenteric 
resistance arteries where a small, but significant contractile function has been uncovered 
(Chapter eight).
In the aiB KO, nifedipine causes a reduction in contractility that is of greater magnitude 
than the reduction observed in the WT. This represents an unexplained phenotype. It 
may reflect a gieater dependency of the remaining adrenoceptor subtypes on 
extracellulai’ calcium, or could be attributable to compensatory mechanisms that result 
in this phenotype because of the germline disruption of the aiB-adrenoceptor.
Effect of prazosin on PE-induced contractions in the WT and KO tail arterv 
Agonist-induced contractions of the rat tail artery appear to result from the activation of 
more than one ai-adrenoceptor subtype [Lachnit et al, 1997]. The combined use of 
CEC and RS17053, respectively considered to be am  and aiA-selective antagonists, has 
been taken to demonstrate the existence of functional am and ai a-adrenoceptors in the 
rat tail. In the presence of RS 17053 alone, phenylephrine curves are biphasic. However 
preincubation with CEC gives a monophasic response curve. The data gained from 
functional studies in the rat indicates that the major ai-subtype leading to contraction of
219
insurmountable reduction in agonist-induced contractions, a phenomenon that also 
occurs in mesenteric resistance arteries in the presence of the aiA-selective antagonist 
5MeU (Chapter eight).
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the rat tail artery is the aiA-subtype, with a small, but significant contractile function 
being mediated by the am-adrenoceptor [Lachnit et al, 1997]. The data presented here, 
combined with the effect of 5MeU on the phenylephrine response [Daly et al, 2002] 
provides evidence that indicates that responses in the mouse tail artery are similar to
those of the rat.
The study of responses in the mouse tail artery have shown that prazosin shifts the 
phenylephrine-induced response curve to the right in the WT and am  KO at four and 
sixteen-months. At high antagonist concentrations, prazosin causes a significant 
reduction in phenylephrine-induced contractions of the WT tail artery at four and 
sixteen-months, and at four-months in the am KO, despite the agonist concentration 
being increased to 3 x lO '^M. High concentration of ai-antagonists can cause an
I
I
The effect of increasing age
In young rats, ligands that selectively inhibit aiA-adrenoceptor-mediated pressor 
responses in the pithed rat are more effective antagonists than those that block am  and 
or am-adrenoceptor-mediated responses [Ibaixa et al, 1997]. However, in old rats the 
aiD and am selective antagonists BMY7378 and CEC, antagonise agonist-induced 
increases in diastolic blood pressure, while blockade of a%A-adrenoceptors is ineffective 
[Ibarra et al, 1997]. This suggests that am  and or am-adrenoceptors play a more 
significant role in contraction of the rat vasculature with increasing age. Studies where
the expression levels of ai-adrenoceptors have been studied often provide contradictory 
results. In the rat expression of the Œm-adrenoceptor is proposed to decrease with age, 
while expression of the am-adrenoceptor is unchanged [Gurdal et al, 1995 a, b]. Yet, in 
the rat aorta, the expression of a i A-adrenoceptors increases with age, while the 
expression of the otm decreases [Ibarra et al, 1997]. Although informative, data 
presenting a change in expression levels of a given receptor does not clarify whether the 
responses of the existing receptor population change with increasing age, so 
investigating the functional response is imperative, as is determining the outcome of 
responses in vivo.
Increases in blood pressure occur with age. This has been proposed to result from an 
alteration in sympathetic nerve activity. For example, in the rat tail artery, stimulation 
evoked release of noradrenaline increases significantly with advancing age [Buchholz et 
al, 1998]. An alternative hypothesis to an altered sympathetic nerve response, leading 
to changes in blood pressure regulation with age, is that increased blood pressure may 
result from altered sensitivity of adrenoceptors to endogenous catecholamines. If 
receptors become supersensitive to endogenous agonists, then contractions mediated by 
vascular smooth muscle cells will ultimately be increased, leading to a decrease in 
vessel lumen and an elevation in resting pressure.
Data from the WT suggests that the sensitivity of the tail artery to antagonism with 
prazosin is unaffected by increasing age. In the am KG the decrease in potency of 
prazosin suggests that the remaining receptor population may be slightly more resistant 
to the effects of prazosin. Whether this reflects a true phenotypic change in the function 
of the aiA and am-adrenoceptors with increasing age, or is the result of an unexplained
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phenotype that arises from deletion of germline am-adrenoceptors, requires 
claiification.
Catecholamine-induced contractions of rodent arteries have been shown to increase with 
advancing age [Buchholz et al, 1998]. In the tail artery, contractile responses to 
phenylephrine are not significantly affected by age. The obvious assumption may then 
be to hypothesise that the potentiation of catecholamine-induced responses may be 
attributable to enhanced responsiveness of vascular az-adrenoceptors. However, the 
data presented in chapter three of this thesis refutes this hypothesis. In the D79N tail 
artery from young and old mice, UK14304-mediated contractions are of comparable 
size and sensitivity. This data suggests, that at least in the D79N mouse, a 2 - 
adrenoceptor-mediated contractions do not increase with age.
The one significant change that does occur at sixteen-months, is a potentiation of 
phenylephrine-induced contractile responses in the presence of prazosin in the am  KO. 
At sixteen-months the control curve in WT arteries is significantly greater in maximum 
than at four-months, but is not enhanced in the presence of nifedipine and/or prazosin. 
The results in arteries from sixteen-month am  KO mice present an unexplained 
phenotype, as a similar alteration in contractility does not occur in the WT. Whether 
this represents enhanced contractility of the major a%-adrenoceptor-subtype, the ttiA 
receptor, or reflects the involvement of the aio-adrenoceptor in contractile responses in 
arteries from older animals, cannot be clarified here without the use of subtype selective 
antagonists.
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Although potentiated in size, tail arteries from the am KO are slightly less sensitive to 
phenylephrine at sixteen-months, evidenced by a reduction in the pECso value. A 
similar decrease in sensitivity to phenylephrine occurs in the WT at sixteen-months. 
This data suggest that although agonist-induced contractions can be potentiated with 
age, higher concentrations of agonist are required to produce a measurable response. 
This may represent a protective mechanism whereby the concentration of agonist 
required to produce a response is elevated when responses become potentiated in size 
with increasing age.
The expression levels of ai-adrenoceptor subtypes have been shown to change with 
increasing age, and expression of the am-adrenoceptor has been proposed to increase 
[Ibarra et al, 1997]. The data presented here indicates that ai-adrenoceptor-mediated 
contractions have a tendency to increase in size with age, a phenomenon that is 
accompanied by a slight reduction in sensitivity. Whether the increase in size of 
responses is attributable to the am-adrenoceptor remains to be determined.
Summarv and conclusions 
In summary, phenylephrine causes concentration-dependent contractions of the murine
:
tail artery from four and sixteen-month old mice, contractions that are potently inhibited 
by prazosin, a non-selective ai-adrenoceptor antagonist. In the WT, although responses 
in a control curve tend to be greater in maximum, they are relatively unaffected by 
advancing age. However, in the am  KO an unexplained potentiation of contractile 
responses in the presence of all three concentrations of prazosin occurs. Prazosin 
provides slightly lower pA% values for arteries from KO mice than for the WT. Alone, 
this provides little information on the subtypes involved in responses, but combined
-h:—
with the data published by Daly et al with 5MeU, data points toward the aiA- 
adrenoceptor as the major contractile oti-adrenoceptor-subtype. It appears that, like the 
rat tail artery [Lachnit et al, 1997], the am-adrenoceptor plays only a minor role in 
contraction of the mouse tail artery.
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Chapter eight
The «iD-adrenoceptor mediates a small but significant 
contractile response in mouse mesenteric resistance
arteries
225
8.1 Introduction
Preliminary studies have suggested that phenylephrine-induced contractions of
mesenteric resistance arteries from WT and am  knockout mice are, in part, resistant to 
antagonism with the a%A-selective antagonist 5MeU. The following experiments were 
earned out to determine whether a 5MeU resistant contractile component does exists, 
and if so, what adrenoceptor subtype was responsible for the ‘minor’ contractile 
response?
I
To answer these questions, 5MeU was administered at a concentration known to
.
antagonise aiA-adrenoceptor-mediated contractile responses. These experiments were 
earned out in WT, am  and am  KO mice. In addition to the use of transgenic mice, the 
aiD“Selective antagonist BMY7378 was used to determine if the am-adrenoceptor 
mediates contractile responses in mesenteric resistance arteries of the mouse.
,|
Identification of the major adrenoceptor subtype leading to vascular contraction is often 
complicated by the presence of multiple receptor subtypes, ai-adrenoceptors are 
coexpressed in a variety of different blood vessels. Regardless of this, it appears to be a 
single subtype that is the major receptor leading to contraction of a given artery or tissue 
[Hrometz et al, 1999]. Mesenteric resistance arteries are no exception to this. The major 
a%-adrenoceptor subtype causing contraction of first order mesenteric resistance arteries 
from the mouse is the am-adrenoceptor (based on selectivity of subtype selective 
ligands) [Daly et al 2002]. So what functions do the remaining adrenoceptors perform? 
The work contained within this chapter goes some way to uncovering a secondary 
contractile response that was not attributable to the am-adrenoceptor.
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8.2 Methods
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IWT controls (C57BL/6c/129Sv), am  and am  knockout mice (C57BL/6c/129Sv 
background) aged four and fourteen-sixteen months were used for these studies. All the 
mice used were euthanised by asphyxiation with CO2 . Immediately after death, the 
mesentery of each mouse was removed and placed in fresh, cold Krebs. The mesenteric 
ai'cade was then pinned out on a petri dish containing Krebs solution. The main 
mesenteric arcade was located and several first order arteries were identified, dissected, 
cleared of any excess fat and connective tissue and rings of approximately 2mm in 
length were mounted in 5ml stainless steel Mulvany/Halpem myograph baths (detailed 
description in Chapter two). Following a 30-35 minute resting period, vessels were 
stretched to give a resting tension of 0.17gms Force (determined as a suitable resting 
tension, unpublished observation).
8.2.1 Wake-up protocol
Each arterial segment was stimulated with phenylephrine at an initial concentration of 1 
X lO'^M. Once the contraction reached a plateau, each bath was washed four times over 
a fifteen minute period, before repeating the entire procedure. Then arteries were 
administered a lower phenylephrine concentration, of 1 x lO'^M, following which, 
acetylcholine (3 x lO' '^M) was used to test the viability of the endothelium.
8.2.3 Effect of 5-methvluranadil and BMY7378 on arterial contractions 
5MeU and BMY7378 were made up according to the manufacturers’ guidelines 
(described in Chapter two). Both of the drugs were used at a concentration of 1 x lO'^M 
known to be subtype selective [Daly et al, 2002]. Each drug was administered a 
minimum of thirty minutes before construction of a phenylephrine concentration
.±:_
response curve. When two antagonists were added to a single artery, the drugs were 
administered five-ten minutes apart, and the thirty minute equilibration period began 
after the last antagonist has been added to the bath.
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Cumulative response curves to phenylephrine alone, and with the aio-selective 
antagonist BMY7378, were constructed in first order mesenteric resistance arteries from
8.3 Results
8.3.3 Time controls in mesenteric arteries from four-month old mice
In figure 8.1 the time controls for 5MeU, and 5MeU with BMY7378 curves in four- 
month old WT mice have been shown. Unlike vessels treated with antagonists, second, 
and third, consecutive curves showed no reduction in maximum (figure 8.1 A). The 
maximum in the first curve was 0.32 ± 0.04gms Force, compared with that of the 
second 0.33 ± 0.06gms Force, and third of 0.30 ± 0.06gms Force. When this data was 
expressed as a percentage of the control curve, the responses gained were relatively 
consistent, but showed a slight reduction in sensitivity in the third curve (figure 8.1 B). 
The pECso values for the first, second, and third curves were 5.6 ± 0.04, 5.5 ± 0.04, and
5.1 ± 0.04 respectively.
In figure 8.2, the time controls for the drug treatments tested in mesenteric arteries from 
aiB (figure 8.2 A) and Œm KO (figure 8.2 B) mice have been shown. In arteries from 
aiB and am  KO mice the maximum response to phenylephrine was unchanged in 
consecutive response curves. The maximum responses gained in a first, second, and 
third curve, constructed in arteries from am  KO mice were as follows, 0.65 ± 0.05, 0.63 
± 0.06, 0.64 ± 0.05gms Force. In am  KO the first curve maximum was 0.53 ± 
0.035gms Force, compared with those of the second and third curves, which were 0.55 
± 0.02, 0.58 ± 0.05gms Force respectively.
8.3.4 Effect of BMY7378 on phenvlephrine-induced contractions in 4-month old WT 
mice
;
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Figure 8.1: Consecutive time controls in mesenteric aiteries from 4-month old WT 
mice. A PE-induced responses in a first (o, n = 11), second (•, n = 11), and third 
( □, n = 12) cumulative curve. B PE curves, expressed as percentage of the 
maximum in a first, second, and third response curve. Each point represents mean 
± standard error.
A  a jg K O
0.75
0.50
0> 0.25
0.00
L.
9 ■48 ■67 5
Log M [Phenylephrine]
B a jp K O
0.75
0.50
D) 0.25
0.00 JL_8 4569 7
Log M [Phenylephrine]
Figure 8.2: Consecutive time controls in mesenteric arteries from 4-month old 
and ajjj KO mice. A A first (o, n = 12), second (• , n = 6), and third (□, n = 6) PE 
curve in KG arteries. B A first (o, n = 10), second (•, n = 7), and third (□, n = 7) 
PE curve in a^g, KO aiteries. Each point represents mean ± standard error.
four-month old WT mice. The effect of BMY7378 was studied at three concentrations, 
ranging from 1 x lO'^M to 1 x lO^M.
In figure 8.3, the effect of BMY7378 (1 x 10' M) on phenylephrine-induced 
contractions is shown. In the control curve the maximum response was 0.41 ± 0.03gms 
Force, compared with a maximum of 0.41 ± 0.09gms Force in the presence of 
BMY7378 (figure 8.3 A). In figure 8.3 B, responses to phenylephrine, have been 
expressed as a percentage of the control maximum for calculation of pECso values. In 
the control curve a pECso value of 5.5 ± 0.02 is gained, while in the presence of the 1 x 
lO'^M BMY7378, the pECso was slightly lower at 5.06 ± 0.03.
Figure 8.4, shows phenylephrine response curves alone, and with BMY7378 (1 x 10"
^M) in mesenteric arteries from four-month old WT mice. BMY7378 caused a slight 
reduction in the maximum response. The control curve maximum was 0.41 ± 0.03gms 
Force, compared with 0.30 ± 0.03gms Force, in the presence of BMY7378 (figure 8.4 
A). Statistical analysis of the maximum contractions to phenylephrine alone, and with 
BMY7378 at 1 x lO'^M has shown that although contractions tend to be lower, they 
failed to reach statistical significance (p = 0.07). A pECso value of 5.0 ± 0.03 was 
determined in the presence of 1 x lO'^M BMY7378, which was significantly lower than 
the control value of 5.5 ± 0.02 (p<0.0001***, figure 8.4 B)
Figure 8.5 shows the effect of the highest concentration of BMY7378 (1 x lO '^M) on 
the size (figure 8.5 A) and sensitivity (figure 8.5 B) of phenylephrine-induced 
contractions of mesenteric resistance arteries. At the highest agonist concentration 
tested, the size of the maximum response was no different from that gained in the
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Figure 8.3; Responses in mesenteric arteries from 4-month old WT mice. A PE 
response curves alone (o, n = 12), and with BMY7378 at 1 x lO'^M (•, n = 3). B 
PE response curves, expressed as a percentage of the control curve maximum. 
Each point represents mean ± standard enor.
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Figure 8.4; Responses in mesenteric arteries from 4-month old WT mice. A A PE 
curve alone (o, n = 12), and with BMY7378 at 1 x lO'^M ( □, n = 4). B PE 
response curves, expressed as a percentage of control maximum. Each point 
represents mean ± standard error.
8I
0.75
0.50
0.25
0.00
6 ■4 38 7 59
B
II
I
Log M [Phenylephrine]
100
75
50
25
0
■4 2-36 59 8 7
Log M [Phenylephrine]
Figure 8.5: Responses in mesenteric arteries from 4-month old WT mice. A A 
PE curve alone (o, n = 12) and with BMY7378 at 1 x lO'^ ^M (■, n = 4). B PE 
response curves, expressed as a percentage of control maximum. Each point 
represents mean ± standard error.
control curve (1 x lO'^M BMY7378 maximum 0.43 ± O.Olgms Force, control maximum 
0.41 ± 0.03gms Force (p>0.05)). The pECso value was shifted from 5.5 ± 0.02 in the 
control curve, to 4.6 ± 0.02 in the presence of BMY7378.
At the lowest antagonist concentration tested (1 x lO'^M) a shift in the response curve 
could not be calculated, because of the small sample size, and the variability within the 
results. Due to this a pA% value was not calculated, because a minimum of three 
antagonist concentrations are necessary to construct a Schild regression plot. Therefore, 
a pKfi value was calculated for the two remaining antagonist concentrations. At a 
concentration of 1 x lO'^M a pKg value of 7.0 ± 0.37 was determined, which was not 
dissimilar from the value gained at 1 x 10‘‘"M, found to be 6.9 ± 0.08.
8.3.1 Effect of 5MeU in mesenteric resistance arteries
Figure 8.6 shows the phenylephrine response in first order mesenteric resistance arteries 
from four-month old WT (figure 8.6 A) and otm KO mice (figure 8.6 B) in the presence 
of increasing concentrations of 5MeU. In both strains, 5MeU caused a rightward shift 
in the concentration response curve. In the WT, at the highest antagonist concentration 
(1 X lO'^M) a 5MeU resistant component of the contraction was uncovered. In the aiB 
KG this appears at a lower antagonist concentration of 1 x lO'^M. The results shown 
provided evidence that a receptor other than the aiA-adrenoceptor-subtype was 
responsible for the 5MeU resistant component of the phenylephrine-induced 
contraction.
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Figure 8.6: Phenylephrine response in first order mesenteric resistance arteries from
4-month old WT and KO mice in the presence of 5MeU. A PE response in the 
WT alone (o, n= 13) and with 5MeU at 1 x 10'^ (•, n =4) 1 x 10"^  (d, n = 5), and 1 x 
lO'^M (■, n = 6). B In the KG, alone (o, n = 3), and with 5MeU at 1 x 10'® ( o, n 
= 3), and 1 x lO'^M (■, n = 2) 5MeU. Each point represents mean ± standard eiTor.
8.3.2 Effect of 5MeU and BMY7378 in mesenteric arteries from 4-month old mice 
Figure 8.7 shows responses to consecutive, cumulative phenylephrine curves 
constructed in first order mesenteric resistance arteries from four-month old WT mice, 
alone, and in the presence of 5MeU (1 x lO'^M), and 5MeU with BMY7378 (Both at 1 x 
10"^M). Data has been shown in two ways. Firstly, the absolute size of contractile 
responses has been shown in figure 8.7 A. Data was then expressed as a percentage of 
the control maximum, and is depicted in figure 8.7 B. In the control curve, the 
maximum response was 0.44 ± 0.06gms Force. In the presence of 5MeU the maximum 
contraction obtained was significantly smaller at 0.23 ± 0.04gms Force (p = 0.001 **), 
even in the presence of a higher agonist concentration. In addition to antagonism 
produced by 5MeU, BMY7378 shifted responses further to the right, and the largest 
response obtained was 0.22 ± 0.03gms Force in size (p>0.05, not significantly different 
from the effect of 5MeU).
When expressed as a percentage of the first control curve, the reduction in 
phenylephrine-induced responses was shown more easily (figure 8.7 B). In the 
presence of 5MeU alone, the largest response gained at the highest agonist 
concentration was 51.9 ± 4.8 % of the control maximum. In the presence of 5MeU and 
BMY7378, the maximum was 53.6 ±6.1 % of the control curve maxima.
Contractile responses to consecutive, cumulative phenylephrine curves constructed in 
first order mesenteric resistance arteries from four-month old aiB KO mice, alone, in the 
presence of an Œia, and aiD-selective antagonists have been shown in figure 8.8. Figure 
8.8 A, shows the size of contraetile responses in the three response curves. In the 
control curve, responses reached a maximum of 0.65 ± 0.05gms Force. In the presence
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Figure 8.7: Responses in mesenteric arteries from 4-month old WT mice. A PE 
curve alone (o, n = 10), with 5MeU (1 x • , n = 10), and 5MeU and
BMY7378 (Both 1 x lO'^M, ^ , n  = 10). B PE response curves, expressed as a
percentage of control curve maximum. Each point represents mean ± standard
enor.
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of 5MeU a maximum was obtained that was significantly reduced to 0.30 ± 0.07gms 
Force (p = 0.0005 ***). When arteries were incubated with 5MeU and BMY7378 
before construction of a response curve the maximum (0.42 ± O.llgms Force) was 
smaller than in controls but was no different than that obtained with 5MeU alone.
Responses to phenylephrine in aiB KO arteries, have been expressed as a percentage of 
the control curve maximum, and are shown in figure 8.8 B. 5MeU caused a rightward 
shift in the concentration response curve, and a significant reduction in maximum. In 
the presence of 5MeU contractile responses reached 55.1 ± 10.2 % of those gained in 
the control curve. With 5MeU and BMY7378, the maximum contraction achieved was
76.6 ± 14.7 % of the control curve maximum. So BMY7378 caused no further 
reduction in the maximum response obtained.
Phenylephrine-induced response curves, constructed in mesenteric resistance arteries 
from four-month old am  KO mice, alone, and in the presence of the antagonists 5MeU 
and 5MeU with BMY7378, have been shown in figure 8.9. Figure 8.9 A shows the size 
of contractile responses. In a first control curve, the maximum contraction obtained was 
0.53 ± 0.03gms Force. In the presence of 5MeU, contractile responses were shifted 
rightward, and had a maximum of 0.45 ± 0.04gms Force, which was not significantly 
different from that obtained in the control curve (p = 0.14). BMY7378, an am-selective 
antagonist, had no further effect on contractile responses, on either size, with a 
maximum of 0.46 ± 0.04gms Force, or sensitivity. In figure 8.9 B phenylephrine- 
induced contractions alone, with 5MeU, and 5MeU with BMY7378 in am  KO arteries, 
were expressed as a percentage of the control curve. The control pECgo was 5.3 ± 0.02,
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Figure 8.8: Responses in mesenteric arteries from 4-month old KO mice. A PE 
curve alone (o, n = 7), with 5MeU (1 x • , n = 7), and 5MeU and BMY7378
(Both at 1 X n = 7). B PE response curves, expressed as a percentage of
control curve maximum. Each point represents mean ± standard error.
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Figure 8.9: Responses in mesenteric arteries from 4-month old oCj^KO mice. A PE- 
induced responses alone (o, n = 10), with 5MeU (1 x lO'^M, • ,  n = 10), and 5MeU 
and BMY7378 (Both at 1 x lO '^ M, □, n = 10). B PE response curves, expressed as a 
percentage of control curve maximum. Each point represents mean ± standard error.
in the presence of 5MeU. The maximum response was reduced to 69.05 ± 4.3 % of the 
control maximum, and when 5MeU and BMY7378 was present, responses were 68.2 ±
7.6 % of the maximum response gained for the control curve.
8.3.7 Time controls for 14-16month old mice
Figure 8.10, shows the time controls for 5MeU, and 5MeU with BMY7378 in 
mesenteric arteries from fourteen-sixteen-month old WT mice. Responses to a first, 
second, and third curve were of comparable size, with maximum responses of 0.31± 
0.02, 0.34 ± 0.02, and 0.32 ± 0.05gms Force, respectively (figure 8.10 A). 
Phenylephrine-induced contractions in consecutive time controls were expressed as a 
percentage of the maximum response, and have been depicted in figure 8.10 B. The 
sensitivity of the second response curve was slightly lower than that of the first, and 
third, were the first curve had a pECso value of 5.6 ± 0.06, the second a pECso of 5.2 ± 
0.06, and the third curve had a pECso value of 5.6 ± 0.05.
Figure 8.11, shows the responses gained in time controls for 5MeU alone, and 5MeU 
with BMY7378, constructed in mesenteric arteries from 14-16-month old aiB (figure 
8.11 A) and am  KO (figure 8.11 B) mice. In arteries from both strains neither the 
maximum gained, or the sensitivity to phenylephrine were changed in a second or third 
consecutive response curve. In the a ^  KO the first, second and third curve maximums 
were 0.45 ± 0.07, 0.47 ± 0.1, and 0.43 ± 0.1 gms Force, respectively. The time control 
curves were then expressed as a percentage of their maximum to permit calculation of 
pECso values. The pECgo values for KO time controls were 5.7 ± 0.01 for a first,
5.5 ± 0.02 for a second, and 5.5 ± 0.04 for the third response curve (not shown 
graphically).
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Figure 8.10: Consecutive time controls in mesenteric arteries from 14-16-month old 
WT mice. A First (o, n = 11), second (• , n = 10), and third ( □, n = 10) PE 
response curves. B First, second, and third PE response curves, expressed as a 
percentage of the maximum response. Each point represents mean ± standard error.
A  a ,g K O
8
£
E
0.75
0.50
0.25
0.00
89 7 6 ■5 4
Log M [Phenylephrine]
8
I
0.75
0.50
0.25
0.00
58 ■49 7 6
Log M [Phenylephrine]
Figure 8.11: Consecutive time controls in mesenteric arteries from 14-16-month old 
otjB and a^pKO mice. A Responses to a first (o, n = 12), second (•, = 6) and third 
(□, = 6) PE time control in KO arteries. B Responses to a first (o, n = 10), 
second (• , = 8) and third (d, = 8) PE time control in a^j^KG arteries. Each point 
represents mean ± standard eiTor.
Similarly, the maximum contractions gained in the time controls for mesenteric arteries 
from aiD KO mice were unchanged. In the first, second and third consecutive response 
curves the maximum contractions gained were as follows, 0.61 ± 0.07, 0.60 ± 0.08, and 
0.54 ± 0.06. The responses gained were then expressed as a percentage of the control 
curve maxima for calculation of pECgo values. The pECso values for the first, second 
and third curves were as follows 5.2 ± 0.02, 4.5 ± 0.03 and 4.7 ± 0.02 (not shown 
graphically).
8.3.5 Contractions in arteries from 14-16-month old transgenic mice 
Cumulative, consecutive response curves to phenylephrine alone, in the presence of 
5MeU, and with 5MeU and BMY7378 (both at concentrations of 1 x lO'^M) were 
constructed in first order mesenteric resistance arteries from fourteen-sixteen-month old 
WT (figure 8.12 A) and otmKO (figure 8.12 B) mice, the responses gained are shown in 
figure 8.12. The contractions obtained in WT arteries were generally smaller than those 
of the transgenics, with the control curve reaching a maximum of 0.36 ± 0.04gms Force. 
5MeU caused a rightward shift of the response curve, and a reduction in the maximum 
response in the WT to 0.23 ± 0.04gms Force. The reduction in the maximum response 
caused by 5MeU was significant (p = 0.036'*'). The addition of BMY7378 produced a 
slight rightward shift without reducing the contractile maximum, which was 0.23 ± 
0.05gms Force.
Phenylephrine-induced contractions of mesenteric arteries from fourteen-sixteen-month 
old aiD KO mice were greater in size than that those obtained in age matched WT 
arteries. In the am  KO the maximum phenylephrine response in a control curve was
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Figure 8.12: Responses in mesenteric arteries from 14-16-month old WT and 
KO mice. PE curve alone (o), with 5MeU (1 x 10"^M, •), and 5MeU/BMY7378 
(Both 1 X 10"^M, °), respectively. A In WT arteries, (o, n = 11), (• , n = 11), (□, n 
= 11). B In aj^KG aiteries, (o, n = 10), (♦, n = 10), (°, n = 10). Each point 
represents mean ± standard error.
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0.61 ± O.OTgms Force, which was significantly greater than the WT maximum of 0.36 ± 
0.04gms Force (p<0.01**). In aiteries from am  KO mice, 5MeU caused a rightward
shift of the concentration response curve, and a small, but significant reduction in
maximum response from 0.61 ± 0.07gms Force to 0.43 ± 0.05gms Force (p = 0.025*). 
BMY7378 had no effect on the size or sensitivity of the remaining contractile response, 
with a maximum contraction of 0.43 ± 0.04gms Force being achieved in the third, and 
final response curve.
8.3.6 5MeU resistant contraction in mesenteric arteries from amKO mice 
Figure 8.13 shows the responses to consecutive, cumulative phenylephrine response 
curves alone, with 5MeU, and in the presence of 5MeU and BMY7378 in mesenteric 
resistance arteries from am  KO mice. In the control curve, the maximum response 
gained was 0.45 ± 0.02gms Force. The presence of the aiA-selective antagonist 5MeU 
caused a rightward shift in the concentration curve, but at lower agonist concentrations, 
a component of the contraction that was resistant to 5MeU antagonism, was obvious. 
The maximum response obtained in the presence of 5MeU was 0.43 ± 0.12gms Force. 
The addition of BMY7378 (1 x 10"^M) removed the resistant phase of the phenylephrine 
contraction, shifting the curve further to the right (at low agonist concentrations).
When compared to a control curve, the presence of 5MeU with BMY7378 tended to 
reduce the size of contractile responses from 0.45 ± 0.02gms Force in the control curve 
to 0.32 ± O.OSgms Force, with both antagonists. However, statistical analysis of the 
responses gained in the control curve, compared with that of the curve constructed in 
the presence of 5MeU and BMY7378 showed that responses were not significantly 
smaller in size (p = 0.76).
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Figure 8.13: Responses in mesenteric arteries from 14-16-month old mice.
Responses to PE alone (o, n = 12), with 5MeU (1 x lO'^M, •, n = 12) and with 
5MeU and BMY7378 (Both 1 x lO^M, a, n = 12) in cC]g KO arteries. Each point 
represents mean ± standard error.
The following three figures (8.14 to 8.16, inclusive) compare the responses gained in 
aiB KO arteries to the other strains studied. Figure 8.14 shows phenylephrine-induced 
response curves, constructed in the presence of 5MeU in mesenteric arteries from aiB 
and aiD KO mice (figure 8.14 A). The curve produced in the am  KO was clearly 
shifted further to the right, than that of the am  KO. The addition of BMY7378 on top of 
5MeU (figure 8.14 B) shifted responses in am  KO aiteries, leaving a response that was 
comparable in shape and size, to that gained in the am  KO.
Figure 8.15 shows the contractile effect of cumulative phenylephrine response curves in 
mesenteric resistance arteries from all three murine strains, expressed as a percentage of 
their control curve maximum. In figure 8.15 A, the responses to phenylephrine in the 
presence of 5MeU are shown for WT, am  and am  KO arteries. Mesenteric arteries 
from am  KO mice are the least sensitive to phenylephrine, while responses in WT 
arteries, although smaller in size, were more sensitive to phenylephrine. Although 
responses obtained in arteries from am  KO mice lie somewhere between the two strains, 
a clear ‘bump’ in the curve was observed between 10-25% of the contractile maximum. 
When BMY7378 was present the 5MeU resistant phase of contraction was removed 
(figure 8.15 B). In the presence of 5MeU alone a PEC2 5  value of 6 . 6  ± 0.3 had been 
calculated for the am  KO, in the presence of 5MeU and BMY7378 the PEC2 5  was 
shifted to 4.8 ±0.1 (p<0.0001^^'^).
Figure 8.16 shows the comparison between the size (figure 8.16 A) and sensitivity 
(figure 8.16 B) of control curves to phenylephrine in mesenteric resistance arteries from
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Figure 8.14: Responses in mesenteric arteries from 14-16-month old mice, in 
(•) and a^^KO (n), respectively. A PE curves with 5MeU at 1 x lO'^ ^M, (• , 
n = 12), ( o, n = 10). B PE curves with 5MeU and BMY7378 both at 1 x lO'^M, 
( • , n = 1 2 ) , ( n , n = 1 0 ) .  Each point represents mean ± standard error.
I
o0
100
75
50
25
0
4 ■3■9 8 6 5■7
B
100
I .  0!
£  25
50
Log M [Phenylephrine]
□ □
-9 -8 -7 -6 “5 -4 -3
Log M [Phenylephrine]
Figure 8.15: Responses in mesenteric arteries from 14-16-month old mice, expressed 
as a percentage of control maximum for WT (o), ajg (•)  and (□),
respectively. A With 5MeU at 1 x lO'^M, (°, n = 11), (• , n = 12), ( □, n = 10). B 
With 5MeU and BMY7378, both at 1 x lO'^M, (o, n = 11), (• , n = 12), ( □, n = 10) 
arteries. Each point represents mean ± standard error.
0.75
0.50
LL
O ) 0.25
0.00
JL.
8 49 7 6 5
B
*Ea>f
Log M [Phenylephrine]
100
75
50
25
0
9 8 7 6 5 4 3
Log M [Phenylephrine]
Figure 8.16: The PE response in mesenteric arteries from 14-16-month old WT 
mice. A First curves to PE in WT (o, n = 11), (• , n = 12) and ( o,
n = 10) arteries. B First curves to PE in the WT, and aj^KO arteries, 
expressed as a percentage of their own maximum. Each point represents mean ± 
standard eiTor.
fourteen-sixteen-month old WT, ocm and aipK O  mice. Arteries from aioK O  mice 
gave the greatest contractile responses, and had a maximum of 0.61 ± 0.07gms Force. 
The smallest contractile response was obtained in arteries from WT mice, with a 
maximum response of 0.36 ± 0.04gms Force. Contractions in a%B KO arteries were 
between those gained in WT and am  KO mesenteric arteries; having a maximum of 
0.45 ± 0.02gms Force. Statistical analysis confirmed that contractile responses in 
arteries from am  KO mice were significantly greater in maximum than those obtained 
in age matched WT (p< 0.01**), and am KO arteries (p<0.01**). While the maximum 
contractions produced in WT and am  KO arteries was not significantly different 
(p>0.05)
In figure 8.16 B, phenylephrine-induced contractions in control curves from WT, am, 
and am  KO mice, have been expressed as a percentage of their own maximum 
response. Arteries from WT and am  KO mice had comparable sensitivity, with a pECso 
value of 5.7 ± 0.02 for WT, and a pECso of 5.7 ± 0.02 for the am  KO. While am  
arteries were least sensitive to phenylephrine, yielding a pEC^o value of 5.3± 0.02.
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Figure 8.17 shows the absolute size of contractions to phenylephrine in the presence of 
5MeU alone (figure 8.17 A), and 5MeU with BMY7378 (figure 8.17 B) in the three 
murine strains studied. Contractions gained in the presence of 5MeU were of 
comparable size in arteries from knockout mice, with an am  maximum of 0.43 ±
0.12gms Force, and an am  maximum of 0.43 ± 0.05gms Force arteries. However
;
contractile responses in WT arteries were significantly smaller than both the am 
(p<0.01 **) and am  KO (p<0.01 **), having a maximum of 0.23 ± 0.04gms Force.
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Figure 8.17: The PE response in mesenteric aiteries from 14-16-month old mice. A 
PE curves with 5MeU, in WT (o, n = 11), (• , n = 12), and ( □, n = 10)
arteries. B PE curves with 5MeU and BMY7378, in WT (o, n = 11), (• , n = 12),
and a^gjKO ( °, n = 10) arteries. Each point represents mean ± standard error.
Comparison of the maximum responses gained in ctiB and am  KO arteries confirmed 
that there was no significant difference in the maximum response between these two 
strains (p>0.05).
Figure 8.17 B shows the effect of BMY7378 (in addition to 5MeU) on phenylephrine- 
induced contractions in mesenteric arteries from WT, am, and am  KO mice at 14-16- 
months. Again responses in am and am  KO arteries were of comparable size and 
sensitivity. The contractile responses in arteries from the am  KO were significantly 
greater in size, than those obtained in WT mesenteric arteries (p = 0.027*). The 
contractile responses gained in am  KO arteries were also significantly greater than 
those of the WT (p<0.01**).
8.3.8 Comparison of responses gained in arteries from 4 and 14-16-month old mice 
Figure 8.18, shows the responses gained in four-month (figure 8.18 A) and fourteen- 
sixteen-month (figure 8.18 B) old mesenteric arteries from WT mice. Contractile 
responses were not significantly different at the age points studied. The maximum 
response in arteries from four-month old WT mice was 0.44 ± 0.06gms Force, 
compared with that at fourteen-sixteen-months, which was 0.36 ± 0.04gms Force (p = 
0.20). Flowever, the first phenylephrine-induced response curve constructed in 
mesenteric arteries from four-month old WT mice, failed to reach a contractile plateau. 
5MeU at a concentration of 1 x lO^M caused a rightward shift in the concentration 
response curves at both age points, and a reduction in maximum. The addition of 
BMY7378 in the third response curve caused a slightly greater shift, again, at both age 
points.
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Figure 8.18; The PE response in mesenteric arteries from 4 and 14-16-month old 
WT mice. A PE curve alone (o, n = 10), with 5MeU (1 x lO'^M, • , n = 10), and 
5MeU/BMY7378 (Both 1 x lO^M, o, n = 10) at 4-months. B PE curve alone (o, n 
= 11), with 5MeU (1 x lO'^M, • , n = 11), and 5MeU/BMY7378 (Both 1 x lO'^M, 
□, n = 11) at 14-16-month. Each point represents mean ± standard eiTor.
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Consecutive, cumulative phenylephrine response curves constructed in mesenteric 
arteries from four (figure 8.19 A) and fourteen-sixteen-month (figure 8.19 B) old « ib 
KO mice, are shown in figure 8.19. Responses obtained in arteries from four-month old 
mice were significantly greater in size than those obtained in older mice. With the 
maximum response gained in the control curve from four-month old mice being 0.65 ±
O.OSgms Force, compared with 0.45 ± 0.02gms Force in mesenteric arteries from
-■fourteen-sixteen-month old mice (p = 0.02*). The major difference between the 
responses gained in four and 14-16months old aiB KO arteries, was that at four-months 
the 5MeU resistant component of contraction was not as obvious. However, at 14- 
16months, it could clearly be seen.
Figure 8.20 shows the results gained for am  KG mice at four (figure 8.20 A) and 
fourteen-sixteen-months (figure 8.20 B) In the control curves, the size of responses in 
arteries from fourteen-sixteen-month old mice appeared to be greater than the maximum
..."
-".fachieved at four-months. The maximum contractile effect of phenylephrine in fouiteen- 
sixteen-month arteries was 0.61 ± O.OVgms Force, compared with 0.53 ± 0.03gms Force 
at four-months. However, statistical analysis showed that responses at four-months 
were not significantly smaller than those at fourteen-sixteen-months (p = 0.27). 5MeU 
caused a significant rightward shift in the response curves to phenylephrine in arteries 
from am  KO mice, at both age points. BMY7378 had little, if any, effect on 
phenylephrine-induced contractions, at either age point.
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Figure 8.19: The PE response in mesenteric arteries from 4 and 14-16-month old oCjg 
KO mice. A PE curve alone (o, n = 7), with 5MeU (1 x lO'^M, • , n = 7), and 
5MeU/BMY7378 (Both 1 x lO'^M, o, n = 7) at 4-months. B PE curve alone (o, n = 
12), with 5MeU (1 x lO'^M, • , n = 12), and 5MeU/BMY7378 (Both 1 x lO'^M, □, n 
= 12) at 14-16-months. Each point represents mean ± standard error.
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Figure 8.20: The PE response in mesenteric arteries from 4 and 14-16-month old 
a^^KO mice. A PE curve alone (o, n = 5), with 5MeU (1 x lO^M, • , n = 5) and 
5MeU/BMY7378 (Both at 1 x lO'^M, n = 5) at 4-months. B PE curve alone (o, n 
= 10), with 5MeU (1 x lO ^M, • , n = 5) and 5MeU/BMY7378 (Both at 1 x lO ^M, 
o, n = 10) at 14-16-months. Each point represents mean ± standard error.
8.4 Discussion
The major a i^ -adrenoceptor leading to contraction
The aiA-adrenoceptor has previously been shown to be the major (%i-adrenoceptor 
subtype leading to contraction of first order mesenteric resistance arteries in WT and 
aiB KO mice [Daly et al, 2002]. The data presented here provides further evidence in 
support of this hypothesis. 5MeU (1 x lO'^M) causes potent, insurmountable 
antagonism of phenylephrine-induced contractions in mesenteric resistance arteries 
from WT, aie and aio KG mice, at four and fourteen-sixteen months.
Having established the major ai-adrenoceptor responsible for mediating contractile 
responses, the main aim was to determine, what, if any contractile function the 
remaining ai-adrenoceptor subtypes perform. In order to negate the use of multiple a i- 
adrenoceptor antagonists, 5MeU and BMY7378 (at concentrations known to be subtype 
selective) were used in combination with three murine strains.
Time controls
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Time control experiments were carried out in mesenteric arteries from WT, a is, and aio 
KG mice aged four and fourteen-sixteen months of age. At both age points, and in all 
strains studied, phenylephrine-induced contractions showed no reduction in the 
maximal response gained, and little if any change in tissue sensitivity. The data gained 
from the time control experiments confirms that the actions of 5MeU and BMY7378 are 
drug-induced, and are not due to a generalised reduction in responsiveness.
  .
'j:
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Effect of increasing concentrations of BMY7378 in WT mesenteric resistance arteries 
BMY7378 causes a small, but significant rightward shift in phenylephrine-induced 
concentration response curves. At a concentration of 1 x lO'^M, the small sample size, 
and variability of the data prevented calculation of a dose ratio. Therefore, this 
prevented the calculation of a pA% value for BMY7378 in this blood vessel. However, 
at higher antagonist concentrations dose ratio values could be determined, permitting 
calculation of a pKs. At 1 x 10‘^ M a pKg of 7.0 ± 3.7 was determined, and at 1 x lO'^M 
the value was 6.9 ± 0.08. Therefore, at a concentration of approximately 1 x 10"^M,
BMY7378 occupies fifty percent of the available receptor binding sites. Although this 
antagonist concentration is relatively high, when compaied with the values gained for 
drugs such as 5MeU and prazosin, it does provide evidence that the aio-receptor is 
involved, in part, in contractile responses of mesenteric resistance arteries from WT 
mice.
ISize of responses and tissue sensitivitv at both age points
A high degree of vaiiability exists between the size of responses gained between strains 
at both age points, and across the species. These might be simply explained by 
differences between batches and biological variability; or, may reflect altered 
responsiveness of the remaining population of ai-adrenoceptors in the absence of one of 
the other subtypes.
Arteries from four-month old mice ocm KO mice give the greatest maximal contractions, 
while WT arteries produce the lowest response. At fourteen-sixteen-months, the ccm 
KG gives the greatest contraction but, again contractile responses are smallest in arteries
:
from WT mice. What becomes clear is that contractile responses in arteries from WT
:
3
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mice consistently produce responses that have a smaller maximum response than either 
knockout species.
The tissue sensitivity of the first cumulative curve to phenylephrine has been compai'ed
in mesenteric arteries from all three strains, and at both age points. WT arteries have
,
the greatest sensitivity to phenylephrine at four and fourteen-sixteen months, which may 
be explained by the existence of all three ai-adrenoceptor subtypes. Mesenteric arteries 
from aiD KO mice, at both age points, show the lowest sensitivity to phenylephrine in 
their control curves. This provides further evidence that the aio-adrenoceptor
'?
contributes to contractile responses, mediated by ai-selective ligands in mesenteric 
resistance arteries.
J':
T h e g j n-adrenoceptor p lavs a m inor contractile role in  m esenteric  resistance arteries 
5MeU cau ses potent antagonism  o f  phenylephrine-indu ced  contractions in first order 
m esenteric  resistance a iteries from  four and fourteen-sixteen-m on th  o ld  WT, am, and  
aiD KO m ice. 5MeU is  a subtype se lec tiv e  antagonist at aiA -adrenoceptors [H ieb le et 
al, 1995], and is  proposed  to inh ib it contractions m ediated  b y  the aiA -receptor subtype  
in a co m p etitive  manner. H o w ev er  in  the data sh ow n  here, 5MeU cau ses a sign ificant 
reduction in the m axim al response, in d icative  o f  n on -com p etitive  antagonism .
At four-months, the addition of the am-selective antagonist BMY7378 causes a further 
rightward shift in arteries from the WT and am KO, without causing a reduction in the 
size of responses obtained. BMY7378 has no effect on phenylephrine-induced 
contractions of mesenteric arteries from four-month old am  KO mice, which lack 
functional am  receptors. This suggests that in the WT and am  KO the shift produced
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by BMY7378 indicates the presence of the am-adrenoceptor, and therefore that it plays 7
a small, but significant role in mediating contractile responses of mesenteric resistance 
arteries in WT and ccib KO mice.
At fourteen-sixteen months the role of the am-adrenoceptor in mediating contractile 
responses becomes even clearer. In arteries from WT mice, BMY7378 produces a 
biphasic curve, by inhibiting phenylephrine-induced contractions at high agonist 
concentrations. As at four-months and fourteen-sixteen months BMY7378 has no effect 
on phenylephrine-induced contraction of mesenteric resistance arteries from am  KO
'mice. The compelling evidence in support of a am  contractile component comes from 
data gained in the am  KO. 5MeU causes a rightward shift of the phenylephrine 
response curve without reducing maximal responses. At lower agonist concentrations a 
5MeU resistant contractile response is evident. This gives rise to a biphasic response 
curve, which is indicative of receptor heterogeneity. BMY7378 completely abolishes 
the secondary contractile response, and shifts the response curve further to the right.
Given that BMY7378 is a selective am-adrenoceptor antagonist [Saussy et al, 1994], :
this provides strong evidence that the am  receptor contributes to contractile responses 
in first order mesenteric resistance arteries from the mouse.
The am-adrenoceptor is the major contractile receptor that leads to contractions of large 
calibre murine blood vessels, such as the aorta and caiotid [Piascik et al, 1997]. In 
studies carried out in the rat, a number of smaller downstream arteries have been shown 
to contract following stimulation of am-adrenoceptors; these include femoral, iliac, and 
superior mesenteric arteries [Hrometz et al, 1999]. The work shown here presents
another contractile response that can be attributed to stimulation of vasculai' am- 
adrenoceptors.
In summary, the pKe values calculated and the inhibitory effect of BMY7378 on 5MeU 
resistant contractions provide evidence that the am-adrenoceptor mediates contractile 
responses in mesenteric resistance arteries, and plays a secondary role to the dominant 
aiA receptor subtype. Data gained from WT mice is often complex because of the 
presence of all three a%-adrenoceptor subtypes, because of this, a combination of 
transgenic mice and subtype selective antagonists simplify responses. In the presence 
of aiA antagonism, and when functional am-adrenoceptors are absent, a am  contractile 
component is unmasked.
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Responses mediated by postjunctional ^-adrenoceptors are difficult to study because 
the experimental conditions provided in vitro do not mimic conditions in vivo. To 
overcome this, I used published literature on the rat tail artery [Templeton et al, 1989], 
to develop a number of complex protocols intended to permit the study of responses 
mediated by postjunctional az-adrenoceptors in the mouse tail artery.
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General discussion
The main aim of this study was to determine the effects of stimulation of az and ai- 
adrenoceptors on two murine blood vessels, the tail artery and first order mesenteric 
resistance arteries. These aims have been achieved by using a combination of 
transgenic mice and classical phaimacological techniques. The recent advances in 
molecular biology have provided us with mice harbouring gene directed deletions or 
mutations of given receptor subtypes. Because of this, the mouse has now become the 
main focus of research in many laboratories. Transgenic technology combined with the 
use of subtype selective ligands has provided data, not only in this thesis but also in a 
wealth of recent publications, which clarifies the function of postjunctional a i and « 2 - 
adrenoceptors.
Elevation of vascular tone with the synergist U46619, to levels comparable to fifty 
percent of the noradrenaline response, provides conditions where a clear (%2 - 
adrenoceptor-mediated contractile response can be observed. This shows that, as in the 
rat tail artery, elevated vascular tone is advantageous for the study of ct2 -adrenoceptor- 
mediated responses. Having established that the ^-selective agonist UK14304 causes a 
contraction of the murine tail artery, the use of subtype-selective antagonists was 
applied to confirm that the contractile response to UK14304 is the result of stimulation
_
I
of receptors belonging to the a 2 -subfamily, and cannot be attributed to non-selective 
stimulation of oci-adrenoceptors at high agonist concentrations. A further complication 
of studying a 2 -adrenoceptor-mediated responses was also uncovered during this work. 
Once activated, a 2 -adrenoceptor-mediated responses are susceptible to profound 
agonist-induced desensitisation, which can, in part, be delayed by limiting the length of 
time receptors are exposed to the agonist UK14304.
To overcome the lack of subtype selective antagonists for the three 0 C2 -adrenoceptor 
subtypes, the D79N mouse has been used to clarify the role of the a z A / D  receptor 
subtype in responses of the tail and first order mesenteric resistance arteries. The D79N 
mouse canies a point mutation of the a2A/D-adrenoceptor, which prevents activation of 
K*^  channels, and has therefore been proposed to act as a functional ‘knockout’ 
[MacMillan et al, 1996].
In a protocol designed to give the most suitable conditions for the investigation of the 
UK14304-mediated response in the tail artery, the contractile effect of UK14304 was 
significantly smaller in the D79N than in the WT. This leads to the conclusion that the 
ct2A/D-adrenoceptor plays a role in a2-adrenoceptor-mediated contractions of the murine 
tail artery. However, given that consecutive response curves were impossible due to 
profound desensitisation of postjunctional (%2 -adrenoceptors, response curves thereafter, 
were constructed non-cumulatively. Under these conditions, the contractile response in 
the D79N is of comparable size to that of the WT. This data indicates that it is not 
necessarily a lack of functional (%2A/D-adrenoceptors that leads to a reduction in the 
UK14304-mediated response, but some consequence of the method in which the agonist 
is administered in the mutant mouse. These findings present an unusual phenotype in
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the mutant mouse, where the remaining « 2 -adrenoceptor subtypes (and possibly some 
functional otiA/D-adrenoceptors) are more sensitive to the desensitising effect of 
stimulation with UK14304.
Physiologically, the tail is an important thermoregulatory organ in rodent species [Rand 
et al, 1965]. In the perfused rat tail, there is an increase in surface temperature in 
response to a 2 -adrenoceptor antagonists, providing evidence that a 2 -adrenoceptors are 
involved in contraction of the rat tail artery [Redfern et al, 1995]. Furthermore, 
contractile responses in distal segments of the murine tail artery appear to be enhanced 
by a reduction in temperature (from 37 to 28^C), which has been attributed to activation 
of quiescent a 2 c-adrenoceptors [Chotani et al, 2000]. The data presented in this thesis 
in chapter five contradicts the findings presented by Chotani and co workers, I have 
found that a reduction in temperature, alone, is insufficient to alter UK14304-mediated 
contractions of wire myograph mounted vessels. However, prior exposure to the a i- 
selective agonist, phenylephrine, does lead to a significant potentiation of UK14304- 
mediated contractions at 22^0.
Tail arteries from D79N mice respond in the same way to those of the WT. This 
suggests that the elevation in contractility, induced by cold temperatures, is probably 
not due to the a 2 A/D-adi'enoceptor, a hypothesis that is supported by the Chotani et al 
publication. Therefore the data presented here, yet again, presents a response that is 
mediated by « 2 -adrenoceptors, which is only detectable under specific experimental 
conditions. Enhanced contractility of cutaneous blood vessels in cold temperatures 
would reduce the blood flow and hence maintain a low surface temperature of the tail, 
or in the case of humans, the surface temperature of the skin of the hands. Therefore,
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these protective mechanisms reduce the amount of heat lost from the tail and digits 
respectively. The findings that I have shown indicate that enhanced a 2 -adrenoceptor 
mediated contractions do not act in isolation, and are only significantly potentiated 
when stimulation of closely associated vascular ai-adrenoceptors precedes the 
UK14304-mediated response. Given the location of the mouse tail artery, it is 
reasonable to assume that the physiological temperature of the tail is lower than core 
body temperature. In light of this, I propose that the a 2 c-adrenoceptor, known to be 
involved in enhanced contractility at cold temperature [Chotani et al, 2000], will not be 
quiescent under “normal” conditions, but actively involved in the development of 
contractions of the mouse tail artery. This also leads me to ask the question “Should all 
experiments on the tail artery be canied out at lower experimental temperature?”
In first order m esenteric resistance arteries, stim ulation o f  (%2-adrenoceptors, m ost 
probably located  on  endothelia l c e lls , leads to relaxant responses, w hich  are due, in part, 
to stim ulation  o f  the a 2A/D-adrenoceptor-subtype. T he relaxant e ffec t o f  activating Œ2- 
adrenoceptors leads to a response that is quite d istinct from  the contractile e ffect in the 
m urine tail artery. T he p h y sio lo g ica l s ign ifican ce  o f  the differential e ffects  o f  
stim ulating a i-ad ren ocep tors in the tail and m esenteric arteries are com p lex . It w ou ld  
appear that the ability  o f  these receptors to m ediate quite d istinct resp on ses is  critically  
dependent o f  the loca tion  and the p h y sio lo g ica l function  o f  the artery studied.
The physiological function of the tail artery is such that under conditions of stress, 
which includes extremes of cold, additional contractile ability is required for the 
maintenance of a homeostatic balance. In the mouse, there is strong evidence that this 
function is fulfilled by activation of quiescent adrenoceptors [Chotani et al, 2000].
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Mesenteric arteries supply the intestine with a rich blood supply and nutrients, and 
given the size and location of these arteries it is reasonable to assume that they may be 
involved in the maintenance of peripheral blood pressure. In this instance the role of the 
otz-adrenoceptor is quite distinct from that of the tail artery. The differential responses 
in the tail and mesenteric arteries highlight the intricate balance between contractile and 
relaxant responses in peripheral arteries. The relaxant responses to UK14304 are 
antagonised by rauwolscine and L-NAME, but are not abolished be either. Preliminary 
studies in which the [K^] is elevated, suggest the involvement of EDHF in mediating 
relaxant responses in first order mesenteric resistance arteries, in addition to nitric 
oxide.
In the tail artery stimulation of ai-adrenoceptors causes contractile responses that are 
more sensitive and significantly greater in maximum than responses mediated by %- 
adrenoceptors. The pAg values determined for prazosin and the subtype selective 
antagonists 5MeU and BMY7378, proposed to be selective for the aiA and am- 
adrenoceptors respectively, provide little evidence that the aiB-adrenoceptor is a major 
contributor of phenylephrine-induced contractions of the tail artery from WT and aiB 
KO mice.
Adrenoceptor-mediated contractile responses can be enhanced with increasing age 
[Docherty, 1988]. However, most of the studies providing evidence in support of this 
hypothesis have been carried out in the rat, while the effects of age on contractile 
responses are poorly defined in the mouse. Contractions that result from stimulation of 
ai-adrenoceptors, with the selective ligand phenylephrine, are similar in tail arteries 
from young and old WT mice. However in the am  KO, contractile responses are
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significantly greater in size in the presence of all three concentrations of prazosin tested 
against phenylephrine-induced contractions at sixteen-months when compared with the 
response in young animals. This represents a phenotype that is unexplained and which 
cannot be attributed solely to increasing age, since a similar potentiation in the size of 
responses does not occur in the WT. Whether this response is a manifestation of a 
compensatory mechanism that results from the germline deletion of the am- 
adrenoceptor, or reflects an increase in the responsiveness of one of the remaining a i- 
adrenoceptor subtypes is interesting, but unresolved, and merits further investigation!
The murine tail artery and first order mesenteric resistance arteries contract when 
vascular aiA-adrenoceptors are stimulated with selective agonists [Daly et al, 2002]. In 
mesenteric resistance arteries from young and old mice the am-selective antagonist 
5MeU, causes a significant shift in the phenylephrine-induced response curve, and like 
prazosin in the tail artery, tends to reduce the maximum response. Agonist-induced 
responses and the effects of antagonist drugs are simplified in aileries from older 
animals. In the presence of 5MeU a component of contraction that cannot be attributed 
to the aiA-adrenoceptor is obvious in the am  KO mouse. Yet this resistant phase of 
contraction is notably absent in the am  KO. The addition of BMY7378, an am- 
selective antagonist, removes the 5MeU resistant contraction in the am  KO. This 
finding confirms that the am-adrenoceptor mediates a small, but significant contractile 
response in first order mesenteric resistance arteries of the am  knockout mouse.
In this instance, the use of transgenic mice combined with subtype selective ligands has 
provided strong evidence that the am-adrenoceptor contributes to contractile responses 
in murine mesenteric resistance arteries. If the transgenic mice, or the subtype selective
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ligands had been used in isolation, a clear conclusion as to the function of the am- 
adrenoceptor in this blood vessel would have been impossible.
I have no doubt the future of cardiovascular research has been, and will continue to 
advance with the aid of transgenic technology. Future work will undoubtedly focus 
heavily on the use of transgenic animals, and given the success of germline 
manipulation in the mouse, may be applied to other species. The most significant 
advantage of molecular technology is that it will help provide clarification on responses 
mediated not only by adrenoceptors, but also by a plethora of other G-protein coupled 
receptors and enzymes. Yet caution is still required, as it has been highlighted here that 
transgenic mice, alone, cannot provide all of the answers. However, when experimental 
conditions and the method in which drugs are applied are questioned, our understanding 
of complex physiological responses can be greatly increased.
In sum m ary, the w ork presented  in  this thesis has ach ieved  several things. In the tail 
artery, suitable con d ition s for the investigation  o f  contractile resp on ses m ediated  by Œ2- 
adrenoceptors have b een  d ev ised , a llow in g  so m e analysis o f  their responses and a 
partial subtyping o f  the receptors in vo lved . A t 37*^ C, and w hen  UK14304 curves are 
constructed  cum u latively  the aiA /o-receptor subtype appears to m ediate p a il o f  the  
contractile response in the m ou se  tail aitery. H ow ever, at 22^C, and w hen curves are 
constructed non -cu m u latively , the ro le  o f  the a2A/D-adrenoceptor in  contractility  
d eclin es. Furtherm ore the e ffec t o f  in creasin g  age on responses m ed iated  b y  a i -  and 
adrenoceptors has been  in vestiga ted  in  the tail artery. T he data presented has sh ow n  
that contractility , m ediated  b y  the a i  and a 2-adrenoceptor su b fam ilies is not 
sign ifican tly  enhanced  b y  advancing age up to sixteen-m onths.
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Stimulation of (%2 -adrenoceptors in murine mesenteric resistance arteries produces a 
vasodilator response that is quite distinct from the contractile effect in the tail. 
Relaxations of mesenteric resistance arteries are receptor specific, and appear to depend 
on both the release of nitric oxide, and the endothelial derived relaxing factor, EDHF. 
Furthermore, a novel role for the am-adrenoceptor, which is contractile in nature, has 
been described in mesenteric resistance arteries. The identification of several of the 
novel receptor-mediated responses, determined here, would have been considered 
impossible just ten years ago.
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